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Abstract 
 
The fatty acid amides, a structurally diverse endogenous congener of molecules active in 
cell signaling, may prove to have diverse activity due to their interface with a number of 
receptor systems, including, but not limited to cannabinoid receptor 2 (CB2) and PPARγ. 
Select extracts of Echinacea spp. contain the fatty acid amides known as alkylamides. 
These extracts were a previously popular remedy relied on by U.S. physicians, one of the 
top sellers in the natural products industry and are currently a frequently physician 
prescribed remedy in Germany. In the series of experiments contained within, Galenic 
ethanolic extracts of Echinacea spp. root were used for the quantification, identification, 
degradation and bioactivity studies. On extraction, depending on the ratio of plant to 
solvent and fresh or dry, the data indicate that there is variability in the alkylamide classes 
extracted. For example the acetylene alkylamides appear to extract under different 
concentrations, as well as degrade faster than the olefinic alkylamides. In addition, the 
alkylamides are found to degrade significantly in both cut/sift and powdered forms of 
echinacea root. Human liver microsome oxidation of the major alkylamide dodeca-
2E,4E,8Z,10Z-tetraenoic acid isobutylamide generate hydroxylated, caboxylated and 
epoxidized metabolites. The carboxylated metabolite has, thus far, shown different 
immune activity than the native tetraene isobutylamide. Bioactivity studies, based on 
cytokine modulation of the alkylamides have been assumed to be due to a classic CB2 
response. However, the results of experiments contained herein suggest that IL-2 inhibition 
by the alkylamide undeca-2E-ene-8,10-diynoic acid isobutylamide, which does not bind to 
CB2, is due to PPARγ activation. These data, combined with data generated by other 
groups, suggest that the alkylamides of Echinacea spp. are polyvalent in effect, in that they 
modulate multiple biochemical pathways. 
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Chapter 1 
 
Research on herbal medicine and review of the 
alkylamides of Echinacea spp. 
 
 
Introduction 
 
A History of Research on Medicinal Drugs 
 
The hunt for active constituents in plants— the so called ―silver bullets‖ that 
characterize modern –single chemical entity drugs—is just over two centuries old. With 
multidrug resistance becoming a leading obstacle to curing infectious disease, resistance of 
chemotherapy in oncology, and adverse events in medicine becoming a leading killer of 
U.S. population, and the current research suggesting that multiple constituents may have 
even greater efficacy than single isolates (Borisy et al., 2003), it is foundational for 
medicinal plant researchers to understand single why isolated plant constituents were 
chosen over complex mixtures of phytochemicals as the preferred therapeutic choice.  
As chemistry was maturing in the 19
th
 century, the developing field of analytical 
chemistry, with its ability to isolate and purify the active ingredients of plants, was 
foundational in early drug research and thus, medicine (Drews, 2000). Alkaloids, as a 
widely diverse group of constituents, were some of the first principals isolated from plants. 
The historical record suggests Derosne was the first to extract plant alkali; he extracted a 
mixture of two alkaloids from opium in 1803 (Bruneton, 1995). During the same time 
period Sertürner was purifying constituents from opium and in 1817 succeeded in isolating 
morphine. (Bruneton, 1995; Huxtable and Schwarz, 2001) In the next five years, Pelletier 
Chapter 1  Introduction to the Literature 
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and Caventou, two French pharmacist-chemists at the Ecole de Pharmacie of Paris, 
isolated a number of noticeably active compounds including; caffeine, emetine from ipecac 
(Cephaelis ipecacuanha, Rubiaceae) and strychnine from Strychnos nux-vomica 
(Loganiaceae) (Bruneton, 1995). One of these alkaloids, the anti-malarial quinine, was to 
be a drug that would change the political and economic landscape of Africa and other 
tropical areas (Bruneton, 1995; Jarcho and Torti, 1993; Yarnell and Abascal, 2004). 
In the same period, Francois Magendie, known as the father of experimental 
pharmacology and the teacher of the renowned French physiologist Claude Bernard, began 
experimenting with Javanese arrow-poisons and eventually found that the active 
constituent was strychinine, elucidating much of its biochemical activity along the way. 
Some years later, working on the mechanisms of vomiting and ipecac, Magendie and 
Pelletier demonstrated that emetine was the primary active substance. Rather intriguingly, 
they were unable to isolate a pure substance. It was later shown that that their emetine was 
a mixture of at least three alkaloids (Singer and Underwood, 1962).  
Nevertheless, perhaps due to Sertürner establishing the belief that isolation of a 
particular constituent could capture the therapeutic activity of a medicinal plant (Huxtable 
and Schwarz, 2001), Magendie took pharmacology further into a reductionist direction by 
promoting the use of isolated principles from plants. In 1821 he published a pocket 
formulary for practicing physicians entitled (translated from the French) ―Formulary for 
the preparation and use of several new drugs, such as nux vomica, morphine, prussic acid, 
strychinine, veratrine, the chinchona alkaloids, emetine, iodine‖(Singer and Underwood, 
1962). This work was essentially a guide to using isolated alkaloids in clinical medicine. 
The silver bullets of modern pharmacology had arrived. 
Chapter 1  Introduction to the Literature 
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Half a century later the physician Thomas MacLagan, successfully used salicylic 
acid, a metabolite of salicin, in a clinical trial on patients with rheumatism (Sneader, 2000). 
By the late 19
th
 century, clinical trials such as MacLagan‘s and the groundbreaking 
experiments in physiology of Claude Bernard and François Magendie had fertilized the 
medical sciences to the point that pharmacology, which had been seen as having limited 
relevance to the medical sciences, was elevated to a respectable ranking among the medical 
disciplines.  During this period, Oswald Schmiedeberg and his students at the University of 
Strasbourg laid many of the intellectual and experimental foundations of pharmacology 
(Drews, 2000; Koch-Weser and Schechter, 1978). Friedrich Bayer (Sneader, 2000) and 
Charles Frederic Gerhardt (Lafont, 1996) produced acetylsalicylic acid and laid the 
foundation for the synthetic processing practices of what became the pharmaceutical 
industry.  
As a result of the combination of analytical chemistry‘s reductionistic influence, 
Schmiedeberg‘s group, and Sertürner‘s and Magendie‘s work, one of the foundations of 
pharmacology came to be the isolation and purification of constituents from plant 
medicines that were already being used in various non-purified forms (Drews, 2000; Koch-
Weser and Schechter, 1978). About half of the United States Pharmacopoeia (USP) at the 
beginning of the 20
th
 century were still ―impure‖ multi-constituent plant medicines 
(Vickers, 2002). Many of the 19
th
 century and early 20
th
 century medical journals 
documented case studies substantiating the effectiveness of plant medicines in their crude 
form.  
Early efforts in the development of pharmacological agents were based on the 
observations of living systems. In other words the outcomes were observed and 
conclusions were developed from observations. This strategy provided us with such drugs 
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as aspirin, as well as the Chinese and Ayurvedic pharmacopoeias, both of which are 
currently being mined for therapeutics to life-threatening diseases. As our understanding of 
pathogenesis advanced, research strategies moved to in vivo animal models, followed by in 
vitro cellular models, producing such drugs as penicillin and cisplatin (Lansbury, 2004). 
However, with increasing technology came sharper focus on single etiological agents; 
currently most drug discovery is confined to single protein targets. Medicinal chemists 
insist on single target-based screens because the alternative, studying multiple interactions, 
was, until recently, not technologically possible and was considered too complex 
(Nussbaum and Ellis, 2003). 
Thus the medical sciences have drastically changed their focus over the last 200 
years. Not only have we moved from complex molecular mixtures to single molecules, we 
have also shifted our focus from disease models of decreasing complexity, from the living 
to the inanimate (Lansbury, 2004). Lansbury (2004) suggest that despite the evidence that 
the leap from cellular models to a single protein is an uncertain strategy, it is considered 
intellectually superior. A similar attitude has been adopted for single molecules versus 
multi-constituent extracts which are often called ―dirty‖ denoting a lack of selectivity. 
Williamson points out that when complex extracts were simplified to one molecule 
scientists did not realize until much later that the specific mode of activity and the adverse 
side effects were altered, sometimes producing more serious adverse effects.  
Critics of medicinal plants argue that the low concentration of any one 
phytochemical in a plant creates a mixture of compounds too dilute to have an effect. 
However, Rajapakse et al.(2002) have demonstrated that very low concentrations of any 
one chemical will contribute to a chemical mixture‘s activity, even if that chemical does 
not show activity when isolated. This particularly challenges the research on herbal 
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medicine that has suggested that some herbal medicines are void of activity because of 
failure to find a single active constituent. This also challenges the research on medicinal 
plants that equate activity of a plant with a single isolated chemical contained within a 
plant or plant part.  
The general conclusion drawn from a century of research on isolating actives from 
medicinal plants, is that the occurrence of only one bioactive constituent is rare. Rather, 
medicinal plants commonly contain numerous active constituents (Bruneton, 1995; Singer 
and Underwood, 1962) and as a result may modulate numerous cellular pathways (Martin, 
2006). Attempts as early as 1928 demonstrated that the pharmacological activity of 
combinations of constituents often had different activity that could not be predicted by the 
activity of the isolated constituents (Borisy et al., 2003).  In other words, the efficacy of 
medicinal plants often cannot be reduced to a single constituent. More recently, Borisy et 
al. (2003) in screening combinations of active compounds found that unexpected activity 
arose from chemical combinations that could not have been predicted by the constituent 
properties. Thus much of the research on medicinal plants that seeks a pharmaceutical gem 
from a jungle of phytochemistry is incomplete as it neglects the possibility of synergic, 
additive or antagonist activity of multi-constituent remedies (Cech, 2003). Yet 
pharmacological modeling has used isolation as a fundamental tenant of inducing 
physiological change in humans.  
The chemical complexity of matrices of constituents is not without disadvantages. 
Medicinal plants/multi-component remedies represent a particular challenge to understand 
in regard to molecular modes of activity. That this is a particular complex issue is 
demonstrated by the attempts to use information theory to cope with the complexity of the 
multi-component nature of herbal remedies (Gong et al., 2003; Liang et al., 2004). This 
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issue still remains to be solved and will continue to delay meaningful pharmacological 
research on medicinal plants. Until modes of activity are clearly elucidated, however, 
outcome studies can still provide meaningful data.   
Unfortunately, modern pharmaceutics severed the connection between plants, foods 
and medicines during their 20
th
 century journey in search for disease curing silver bullets. 
At the same time, the abandonment of searching natural products for drug leads is 
accompanied by an inexorable rise in the cost of generating new drugs. Such methods as 
high-throughput screening, have been reported to have not had a significant impact on the 
derivation of new drugs (Proudfoot, 2002). Random search through combinatorial libraries, 
according to one estimate, leads to hits at a rate of 1:10,000 (Jansen, 2003). Unfortunately, 
combinatorial libraries are not generally based on biologically relevant properties but on 
the basis of chemical accessibility and maximum achievable size (Martin and Critchlow, 
1999). Conversely, combinatorial libraries based on natural products, many compounds 
that, by default, have been selected for biological activity through the high-throughput 
screening of the evolutionary process, increase the likelihood of finding active compounds 
(Brohm et al., 2002). Similarly, ethnobotanical leads, which can be viewed as rudimentary 
small-scale, but long-standing, clinical trials, have yielded positive activity in the order of 
2 to 5 times higher than random screening (Lewis and Elvin-Lewis, 1994). Butler (2004) 
rhetorically asks, is it from lack of natural products screening or from an increase in the 
difficulty of drug discovery that is the key issue in the hunt for silver bullets? If the 
problem lies in the rejection of natural products screening, a likely part of the issue, then an 
obvious source of new drug discovery lies in natural products. It seems quite likely that the 
increasing cost of generating new-to-nature molecules will generate a gap in medical care 
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that will reconnect plants and human health at a new level of technological sophistication 
(Ray et al., 2006).  
Comprehensive evaluations of medicinal plants are urgently needed before more 
plant species are lost and knowledge of specific traditional medicines becomes 
irretrievable. While the study of a medicinal plant and its many components -- some of 
them unidentified or having unknown properties -- is theoretically, economically and 
technically challenging, it should not be abandoned for the sake of investigative 
expediency. Research into the multi-component nature of medicinal plant remedies offers a 
segue way into more complex therapeutics. Thus, the issue of using herbal remedies to 
alleviate human suffering is not one of merely assessing efficacy and safety (Vickers, 
2002; Willcox et al., 2001), but a matter of the medical community‘s struggle to 
understand a pharmacological paradigm that embraces the complexity of bio-molecular 
networks interfacing with multi component remedies. 
Jansen (2003) points out that pharmacological research based on multiple 
perturbations of biological networks is likely to be more informative, and possibly 
economical, than those in which biological systems are studied by varying one 
environmental factor or gene at a time. Csermely et al. (2005) proposes that  drug-design 
directed at multiple targets will likely result in the development of more efficient 
therapeutics than currently offered by single-target agents. These perspectives coupled 
with the latest pharmacological models based on systems biology, build a paradigm in 
which multicomponent remedies, such as medicinal plants, are recognized as sophisticated 
pharmacological agents. Additionally these multi-component remedies may offer improved 
efficacy and safety over isolated silver bullets (Ágoston et al., 2005; Wagner and Ulrich-
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Merzenich, 2009). Yet current Food and Drug Administration regulations, limited by 
economic politics, have generated obstacles to the development of multicomponent drugs.  
 
An Example of a Medicinal Plant, Echinacea spp. 
 
The current body of scientific literature on echinacea can be confusing due to the 
multiple species in use – namely E. purpurea (L.) Moench, E. pallida (Nutt.) Nutt. and E. 
angustifolia DC. (Asteraceae) - which have phytochemical similarities, but also have 
notable differences, particularly around the identity and concentration of key constituents 
(Bauer, 1996; Chen et al., 2005; Hudson et al., 2005). Even though 80% of the echinacea 
products sold to consumers are made from E. purpurea (Li, 1998), all three 
1
Echinacea 
species are often used interchangeably for the treatment of cold, flu, respiratory infection, 
and inflammation (Bauer and Foster, 1991). Multiple species, plant parts, and preparations 
are also used, each of which may have a different constituent profile (Williamson, 2006). 
―Echinacea‖ may refer to the roots, aerial parts, whole plant or a combination of the above; 
echinacea products can be made from fresh or dried plant parts, and may be prepared by 
juicing, alcohol extraction, infusion, decoction, or consumed as tablets or capsules (Mills 
and Bone, 2000).  Most preparations are derived from the aerial parts of E. purpurea and 
underground parts of E. purpurea, E. angustifolia, or E. pallida.  Preparations from 
Echinacea spp. plants have been used for more than a century by physicians for treatment 
of a variety of infections (Couch and Giltner, 1920) and considerably longer if use by 
indigenous people is considered (Moerman, 1998).  
                                                          
1
 Echinacea is used as both a common name and a Genus. Therefore both non-italicized and italicized 
nomenclature is used throughout this dissertation. 
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Echinacea is also one of the most frequently used medicinal plants in clinical 
settings. For example, of the most prescribed drugs in Germany, echinacea preparations 
have been in the top 200 for many years (Der Marderosian, 1991). There are more than 800 
Echinacea products on the market (Sun et al., 2002). Despite the reluctance to use 
echinacea products clinically in the U.S., German physicians write over 3 million 
prescriptions annually for echinacea products for the treatment of upper respiratory tract 
infections (Keller, 1991; Tyler, 1994). Research suggests that Echinacea species have 
immunological effects, as well as anti-viral, antibacterial, antifungal, insecticidal and anti-
inflammatory properties (Kim et al., 2000). 
Physiological effects of Echinacea include immunomodulatory and other activities, 
such as stimulation of phagocytosis, induction of cytokines from macrophages and 
antioxidant activity (Bauer, 1999a; Hashemi et al., 2008; Hudec et al., 2007). The 
immunostimulating properties of extracts from Echinacea appear to be well established 
(Burger et al., 1997; Maass et al., 2005; Melchart et al., 1995; Morazzoni et al., 2005; See 
et al., 1997; Sun et al., 1999). Studies have reported that echinacea extracts have the ability 
to activate human phagocytic function both in vitro and in vivo (Burger et al., 1997; 
Melchart et al., 1995; Morazzoni et al., 2005; Percival, 2000; Roesler et al., 1991). 
Although some studies have failed to find immunostimulatory activity in vivo (Schwarz et 
al., 2002), other researchers have noted up-regulation of immune function in ex vivo 
models in human immunodeficiency disorders (See et al., 1997).   
A recent clinical trial by Turner et al. (2005) demonstrated no effect of  echinacea 
on the reduction of symptoms or duration of a cold. Conversely, recent Cochrane reviews 
reach different conclusions; some echinacea preparations may be better than placebo 
(Melchart et al., 2000), inconsistent evidence suggest that preparations based on the aerial 
Chapter 1  Introduction to the Literature 
16 
 
parts of E. purpurea may be effective for the early treatment of colds in adults (Linde et 
al., 2006), in children E. purpurea was found to reduce the incidence of a second acute 
respiratory tract infection (Del-Rio-Navarro et al., 2006).  
A recent double-blind placebo-controlled trial failed to find immune stimulation 
(Schwarz et al., 2002). However, Schoop et al. (2006) in a meta-analysis, reports that 
standardized extracts of Echinacea were effective in the prevention of symptoms of the 
common cold after clinical inoculation, as compared with placebo. Islam and Carter (2005) 
after reviewing the evidence suggest that there is a beneficial effect, but like others suggest 
that differences in products and doses make evaluation challenging (Melchart et al., 2000). 
Finally, the most recent meta-analysis finds that the evidence supports Echinacea‘s benefit 
in decreasing the incidence and duration of the common cold (Shah et al., 2007). 
In spite of all of the aforementioned studies, there is still uncertainty as to which 
constituents primarily contribute to the purported immunomodulatory action of Echinacea 
species. The constituents of E. purpurea cover a wide range of polarity, from polar 
polysaccharides and glycoproteins, to moderately polar caffeic acid derivatives, to the 
rather lipophilic alkylamides (otherwise known as alkamides). Besides the alkylamides, 
which are the focus of this dissertation, three other constituent groups may have 
immunomodulatory activity; the phenylpropanoids (caftaric acid, caffeic acid, chlorogenic 
acid, cichoric acid, cinnamic acid, cynarin, echinacoside etc.), polysaccharides and 
glycoproteins (Bauer 1996; Bauer 1998). However, in extractions with ethanol 
concentrations above 40%, only very low levels of polysaccharides are left in suspension, 
and denaturing of proteins is expected (Brinker, 1999; Dalby-Brown et al., 2005). Thus, 
the major constituents of ethanolic echinacea extracts are phenylpropanoids and 
alkylamides. As a result of the ethanolic extracts that are used in the experiments herein the 
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following review of constituents of Echinacea spp. will be limited to the phenylpropanoids 
and the alkylamides. The emphasis will be on the alkylamides as these are the subject of 
the experiments contained herein. 
Bauer and Wagner (1999b) have suggested that the lipophilic fraction, e.g., 
alkylamides, is mainly responsible for the immunological activity of alcoholic Echinacea 
extracts. In addition there are claims of synergistic and polyvalent activity between 
constituents in Echinacea and while intriguing, they are nevertheless largely 
unsubstantiated (Wagner, 1999; Wills et al., 2000). They do, however, provide an 
opportunity to explore the features of interaction between the diverse constituents of this 
plant with various biochemical pathways and targets with reproducible and appropriate in 
vitro models.   
 
The phenylpropanoids 
 
The phenylpropanoids, present in all Echinacea spp., are predominantly caffeic 
acid derivatives (McCann et al., 2007). However the molecular species of these 
compounds is dependent on which plant taxa are being analyzed; caftaric acid (2-O-
caffeoyltartaric acid; monocaffeoyltartaric acid), chlorogenic acid [3-O-(3,4-
Dihydroxycinnamoyl)-D-quinic Acid], cinnamic acid, cynarin (5-O-dicaffeoylquinic acid), 
2-O-feruloyltartaric acid  and 2-O-caffeoyl-3-O-coumaroyltartaric acid are found in all 
Echinacea spp. (Bergeron et al., 2002). In E. purpurea, cichoric acid (2R,3R-O-
dicaffeoyltartaric acid)  is found ca 1% of herb of E. purpurea  and there are only traces in 
angustifolia and pallida (Becker and Hsieh, 1985). Conversely, echinacoside and cynarin 
are found in angustifolia and pallida only (Barnes et al., 2005). 
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Caffeic acid derivatives have been found to have antioxidant, antiviral, 
phagocytosis stimulating and hylauronidase inhibitory activity. Specifically, cichoric acid 
has demonstrated an inhibitory effect on hyaluronidase in the range of 50% inhibition 
(IC50) at concentrations of 0.42 mM. In addition, the hyalurinadase IC50 of cynarine and 
chlorogenic acid were found to be 1.85 and 2.25 mM (Facino et al., 1993).  
The antimicrobial activity of the phenylpropanoids has been investigated due to the 
antiviral activity of bee propolis and the subsequent finding that part of this activity was 
due to caffeic acid derivatives (Hudson and Towers, 1999), as well as the finding that 
caffeic acid is the main anti-HIV compound of Hyssop officinalis leaves (Kreis et al., 
1990). In addition, several esters of cinnamic acids, have been found to inhibit influenza 
virus infection in chicken eggs (Serkedjieva et al., 1992). It should be noted that the 
cichoric acid in Echinacea spp. is the levorotary isomer, while the dextrorotary isomer is 
found in chicory (Cichorium intybus) and lettuce (Lactuca sativa). In the case of echinacea 
antiviral activity has been observed on rhinovirus (RV) (Hudson et al., 2005), influenza 
virus (FV) (Hudson et al., 2005), vesicular stomatitis virus (VSV) (Cheminat et al., 1988),  
herpes simplex virus (HSV) (Binns et al., 2002; Hudson et al., 2005), human 
immunodeficiency virus (HIV) (McDougall et al., 1998a; Neamati et al., 1997; Reinke et 
al., 2004; Robinson, 1998; Robinson et al., 1996). L-cichoric acid has recently been found 
to selectively inhibit HIV-1 integrase (McDougall et al., 1998a; Neamati et al., 1997; 
Robinson, 1998; Robinson et al., 1996). In addition, the toxic concentration of cichoric 
acid was found to be a 100 fold greater suggesting a reasonable therapeutic index (Reinke 
et al., 2004). However, none of these models suggest notable antiviral activity except the 
HIV syncitia cell-based assays which suggested that L-cichoric acid shows promise as an 
anti-HIV lead with an EC50 (HIV-1 replication) of 2 μg/mL (McDougall et al., 1998b). An 
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E. purpurea HSV antiviral model, which combined UV-A light with echinacea extracts or 
isolated constituents,  found that both the lipophilic constituents (i.e. alkylamides, 
ketoalken/ynes) as well as the more polar compounds (phenylpropanoids) were antiviral 
suggesting multiple constituents may be responsible for echinacea‘s antiviral activity 
(Binns et al., 2002).   
Antibacterial activity has also been observed for echinacoside (Stall et al., 1950). 
Bauer and Wagner (1991) found activity against Staphylococcus aureus, Corynebacterium 
diphtheria and Proteus vulgaris. Of particular interest to the earlier argument of multiple 
constituents offering promise as drug agents, Hudson and Towers (1999) suggest that 
crude plant extracts are often more potent viral inhibitors than single pure compounds. 
Although many have mistaken the use of echinacea extracts in colds and flus as an 
interpretation that there must be antimicrobial activity, it should be kept in mind, however, 
that thus far, the bulk of echinacea‘s activity against infections does not appear to be 
related to its antimicrobial activity. Research suggests that immune modulation is the 
primary activity responsible for the observed decrease in colds and flu symptoms 
(Woelkart et al., 2008).  
There has also been in vitro antioxidant/radical scavenging activity by the 
phenylpropanoids demonstrated for E. purpurea and E. angustifolia extracts (Dalby-Brown 
et al., 2005; Facino et al., 1995; Thygesen et al., 2007). Phenylpropanoids, especially 
cichoric acid and caffeic acid, are some of the most efficient antioxidants from natural 
sources (Hudec, Burdova, Kobida, Komora, Macho, Kogan, Turianica, Kochanova, Lozek, 
Haban, and Chlebo 2007). Cichoric acid is also found in the aerial parts of E. pallida. 
Other caffeic acid derivatives are found in the three main Echinacea species, especially in 
the aerial parts (Bauer and Wagner, 1991).  
Chapter 1  Introduction to the Literature 
20 
 
While the activity of the phenylpropanoids is potentially interesting, it should not 
be confused as being responsible for the main activity of echinacea extracts. Unfortunately, 
in the haste to produce products appealing to the public and supported by scientific 
evidence (although weak evidence), manufacturers have generated products standardized 
to phenolic acids or echinacoside (in the case of  E. angustifolia). These products have 
been found to be inactive as immunostimulatory agents, although cichoric acid has been 
found in vitro to stimulate phagocytosis (Bauer and Wagner, 1991) and modulate NF-κB, 
TNF-α and NO levels (Aktan et al., 2003; Goel et al., 2002a). However, products 
standardized to phenolic acids or echinacoside are able to maintain their anti-inflammatory 
and antioxidant properties (Wilasrusmee et al. 2002).  
Finally, it should be mentioned in regard to the phenylpropanoids that their stability 
in extracts is an issue. Some, but not all, of the phenylpropanoids in Echinacea spp. are 
heat sensitive. For instance, echinacoside concentrations in E. angustifolia are greatly 
reduced with the addition of heat to the drying regime of the plant (Kabganian et al., 2002). 
In addition, many of the caffeic acid derivatives are known to degrade rapidly in ethanolic 
solution (Livesey et al., 1999). While in pressed juice products of E. purpurea, cichoric 
acid is thought to be substantially reduced by enzymatic degradation via the polyphenol 
oxidases (Nüsslein et al., 2000). However, 2-O-feruloyltartaric acid appears to be stable 
(Bergeron et al., 2002). While the activities of the phenylpropanoids is interesting, they do 
not appear to cross the gut membrane (Matthias et al., 2004). 
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The alkylamides 
 
The widespread occurrence, metabolism and physiological significance in plants of 
the fatty acid amides have only recently begun to be appreciated. The primary fatty acid 
amides, the alkamides, even though restricted in distribution, are known to occur in 10 
plant families, namely, Aristolochiaceae, Brassicaceae, Convolvulaceae, Euphorbiaceae, 
Menispermaceae, Piperaceae, Poaceae, Rutaceae, and Solanaceae. In the above-listed 
families, these metabolites may play a protective role (Molina-Torres et al., 2004). Plants 
containing greater than > 0.5% of alkylamides include Echinacea spp. (Asteraceae), 
Chrysanthemum spp. (Asteraceae), Anacyclus pyrethrum (L., Asteraceae), Spilanthes spp. 
(Asteraceae), Piper spp. (Piperaceae), Zanthoxylum spp. (Rutaceae). In the Asteraceae 
alkylamides are particularly prevalent, characteristically in the Heliantheae and the 
Anthemideae tribes, in such plants as Achillea spp., Echinacea spp. and Spilanthes spp. 
(Greger, 1984). Currently over 300 fatty acid amides have been characterized to date 
(Gertsch, 2008). 
The alkylamides are fatty acid derivatives whose general structure derives from the 
condensation of an unsaturated fatty acid and an amine (Hofer et al., 1986). This class of 
compounds is known to be bioactive in microbes, plants and animals. Farrell and Merkler 
(2008) point out that an emerging theme arriving from research laboratories is that fatty 
acid amides are common in numerous plant and animal species. Longer chain alkylamides, 
specifically N-acylethanolamines, in low concentration are known to regulate animal 
physiology, while low concentrations of medium chain alkylamides have been shown to 
modulate plant physiology. In both plants and animals, the N-acylethanolamines (NAEs) 
16:0, 18:1, and 18:2 acylethanolamides are common. However, plants appear to be 
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particularly responsive to low concentrations of medium chain NAEs, whereas, animal 
physiology is largely regulated by low concentrations of long chain polyunsaturated NAEs 
(e.g., NAE20:4), both of which constitute a relatively minor fraction of the NAE pool in 
their respective systems. Because of their significant role in cell signaling, these molecules, 
and their analogs, appear to have diverse activity due to their interface with a number of 
receptor systems, including, but not limited to CB2 and PPARγ (Farrell and Merkler, 
2008).  
 
 
N
H
O
 
 
 
N
H
O
  
Figure 1.1.  Structure of common alkylamides in various Echinacea spp. 
The alkylamides are fatty acid derivatives formed through the condensation of a fatty acid with an amine.  
A. An olefinic alkylamide, dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide.  
B. An acetylenic alkylamide, undeca-2E-ene-8,10-diynoic acid isobutylamide.  
 
Of relevance to this discussion, are the unsaturated alkylamides; acetylenic 
alkylamides and the olefinc alkylamides (Figure 1.1). While both members of the 
unsaturated class of alkylamides occur in the Asteraceae, the acetylenic alkylamides are 
A 
B 
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characterized as having an acetylenic tail (Figure 1.1B), with over 250 compounds 
occurring in over 100 genera in the Heliantheae tribe alone (Christensen and Lam, 1991). 
This is opposed to the purely olefinic alkylamides (contain double-bonded fatty tails) 
identified in 6 genera in 5 subtribes: Ecliptinae (Wedelia): Galinsoginae (Acmella); 
Helianthinae (Echinacea); Verbesininae (Salmea); Zinnininae (Heliopsis and Sanvitalia).  
However, in the previous listed genera not all species contain alkylamides (Molinatorres et 
al., 1996). Both class of alkylamides commonly occur with various degrees of 
unsaturation. For example, Figure 1.1A illustrates one of the isomeric polyunsaturated 
tetraenes, the most prominent alkylamides contained in E. angustifolia and E. purpurea 
and Figure 1.1B shows the polyacetylene alkylamide undeca-2E-ene-8,10-diynoic acid. 
Initial studies reported that the olefinic alkylamides, the class of alkylamides of 
research interest in Echinacea spp., were found to be insecticidal (Crombie and Harper, 
1949; Jacobson, 1948, 1954; Jacobson, 1967). This was later suggested to be due to effects 
at the voltage-gated sodium channels (Ottea et al., 1989; Ottea et al., 1990). Like 
veratridine, the N-alkylamides are reported to have greater activity with resistant strains of 
insects than do the pyrethroids (Amanda et al., 1990). As would be expected for 
allelochemicals, the plant signaling molecule methyl jasmonate has been found to 
upregulate alkylamide production in young plants (Binns et al., 2001). Later work 
demonstrated that the alkylamides promote growth and alter root development in 
Arabidopsis seedlings (Ramirez-Chavez et al., 2004). 
While the insecticidal properties of echinacea and other alkylamide containing 
plants are indicative of biological activity and were likely exploited by native Americans, 
the ethnobotanical documentation list uses such as anesthetic, antiseptic, alterative and 
sialogogue for Echinacea spp. (Duke, 2009; Moerman, 1998). Other plants that were rich 
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in alkylamides were used similarly (Ekanem et al., 2007). For example, Spilanthes spp. are 
also known as ‗toothache plant‘ due to traditional cultures exploitation of the anesthetic 
properties of the alkylamides. 
Continued research on alkylamides elucidated an oncolytic effect from the 
alkylamides (Voaden and Jacobson, 1972). In vitro studies have shown various modes of 
anticancer activity for complex extracts of echinacea (Mazzio and Soliman, 2008). Other in 
vitro research has demonstrated inhibition of angiogenesis induced by lung and kidney 
cancers by an alkylamide containing extract (Rogala et al., 2008). Past studies on structure 
activity relationships of alkylamides have suggested that particular of the alkylamides 
promote differentiation of leukemia to a benign state (Harpalani et al., 1993).  In addition, 
in a study of patients suffering from metastasizing advanced colorectal cancers, 7 of 15 
patients showed no further progression of the cancer after using Madaus Echinacin (60 
mg/m2 i.m. x 7 d). One patient had partial tumor regression (Lersch et al., 1992). In vitro 
work using hexane extracts, which are rich in alkylamides due to the lipophilic nature of 
these fatty acid derivatives, have demonstrated that a juice of E. angustifolia and E. 
purpurea herba reduce the cell viability of a human colon cancer cell line (COLO320) and 
a human pancreatic cancer cell line (MIA PaCa-2) (Chicca et al., 2007). Although the basis 
of activity for the oncolytic activity has thus far not been clearly elucidated, stimulation of 
natural killer (NK) cell numbers and activity appear to be a possible explanation. Mice 
injected with leukemic cells followed by a daily dose of E. purpurea (Phyto Adrien 
Gagnon, Santé Naturelle [A.G.] Ltée, La Prairie QC, Canada 0.45 mg/d) showed an 
elevation of NK cells as compared to the control group. After a month of echinacea dosing 
the untreated mice had died. By 3 months, 1/3 of the echinacea treated group were still 
alive and went on to live full life spans with 2x the normal NK cell count as normal mice 
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(Currier and Miller, 2001). In a similar study, mice that were immunized against leukemia 
5 weeks prior to injection with live leukemic cells, again had a survival rate of about 30%. 
When echinacea was combined with the immunization, the survival rate went up to 60% 
group (same dose and preparation). In this case the echinacea treated group had NK levels 
3x the immunized mice. Other murine models have shown increases in NK cells (Sun et 
al., 1999). In vivo research has shown in humans that the number of NK cells (CD16+ and 
CD56+) increases after dosing with an echinacea product. These previously mentioned 
studies utilizing various model systems is a step forward in validating the clinical 
experience of the Ecletics who claimed that Echinacea angustifolia was useful in breast 
and other cancers (Ellingwood and Lloyd, 1919). Unfortunately, the majority of these 
studies do not provide clear evidence as to the specific activity of alkylamides due to the 
use of multicomponent extracts. 
However, specific immunological activity of the alkylamides has been researched 
in vitro. Earlier studies by Bauer and Wagner (1985) showed that the chloroform fraction 
of the root of E. purpurea, which concentrates the alkylamides, enhanced the phagocytic 
activity of monocytes. In other studies murine macrophages, when exposed to select 
alkylamides or a mixture of alkylamides exhibited a significant down-regulation of  LPS-
mediated activation as demonstrated by a reduction in nitric oxide (NO) production at 
ID50s of the majority of the alkylamides at 3-6 μg/mL (Chen et al., 2005). However, 
Stevenson et al. (2005) demonstrated no effect on NO production by the acetylenic 
isobutylamide undeca-2E-ene-8,10-diynoic acid (UDA, Figure 1.1B) and the olefinic 
isobutylamide dodeca-2E,4E,8Z,10Z-tetraenoic acid (Z-tetraene, Figure 1.1A ≤ 2.0 
μg/mL), but did show a significant reduction of NO by the mixture of alkylamides found in 
E. purpurea and E. angustifolia root. Matthias et al. (2007) showed that a mixture of 
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alkylamides or UDA inhibited LPS induced production of NO, although only the mixture 
was statistically significant. This group also showed that the Z-tetraene (2.0 ng/mL) 
reduced levels of NFκB, while UDA had no effect (≤ 2.0 ng/mL). However, UDA (2.0 
ng/mL) significantly increased TNF-α levels as compared to controls (Stevenson et al., 
2005).  
Other in vitro studies have shown that in macrophages that are not primed for an 
immune response only UDA has an effect. NFκB expression levels are reduced by UDA (2 
ng/mL), although the Z-tetraene shows a trend towards reduction (Matthias et al., 2007). If 
the macrophages are primed with LPS, NFκB expression is significantly reduced by Z-
tetraene or a mixture of alkylamides, while UDA shows a trend towards reduction. In this 
same series of experiments, Matthias et al. (2007), showed that in macrophages that are 
primed with phorbol myristate (PMA), TNF-α levels are reduced by cichoric acid (0.8 
ng/mL) and Z-tetraene (2 ng/mL),  but increased by a mixture of alkylamides. In 
experiments with Jurkat cells (transformed T lymphocytes), when Jurkats are unstimulated 
a mixture of alkylamides and UDA (both at 2.0 μg/mL) show a trend in the reduction of 
NFκB expression, while the Z-tetraene showed a trend towards an increase in NFκB 
expression levels. In LPS stimulated Jurkats the mixture of alkylamides and the Z-tetraene 
(both at 2 μg/mL) showed a significant increase of NFκB. In PMA stimulated Jurkats there 
were no effects by alkylamides except a strongly significant effect by UDA down-
regulating NFκB expression. The only other work to date that has utilized Jurkats with 
isolated alkylamides is the study by Sasagawa et al (2006). They found that IL-2 
production was inhibited by the isomeric mixture of the tetraenes (≥1.25 μg/mL), as well 
as dodeca-2E,4E-dienoic acid isobutylamide (≥0.625 μg/mL).     
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Ex vivo studies show that the oral administration of the alkylamide fraction of E. 
angustifolia and E. purpurea to mice improved phagocytic carbon clearance by factors of 
1.5 and 1.7 respectively (Bauer et al., 1989; Bauer et al., 1988). Other studies show that the 
alkylamides at a dose level of 12 mg/kg/day, had a significant influence on the phagocytic 
activity of alveolar macrophages. In addition, the alkylamides caused a dose-dependent 
increase in NO release from the alveolar macrophages on stimulation with LPS (Goel et 
al., 2002b).   
Most recently, a great deal of interest in the alkylamides has been generated on two 
fronts: The recent reports that the alkylamides, unlike the phenylpropanoids, demonstrate 
bioavailability in humans (Matthias et al., 2005) and the discovery that the alkylamides 
function as cannabinoid ligands (Raduner et al., 2006; Woelkart et al., 2005). This is 
significant because the endocannabinoid network, which consist of lipid messenger 
molecules and their associated receptors, is now known to modulate such systems as the 
nervous system, the endocrine network, the immune system, the gastrointestinal tract and 
the reproductive system, as well as playing a key role in pathological conditions. As a 
result, since the discovery of the cannabinoid receptor 1 (CB1) (Matsuda et al., 1990) and 
cannabinoid receptor 2 (CB2) (Munro et al., 1993), G protein-coupled receptors found 
predominantly in the CNS and the periphery, respectively, lipids such as (-)-Δ9 
tetrahydrocannabinol and fatty acid derivatives have been scrutinized more intensely as 
molecular messengers. Other CB ligands include the arachidonic derivatives such as 
dihomo-γ-linolenylethanolamide, docosatetraenolylethanolamide, oleamide, and N-
oleolydopamine (Hanus, 2007; Kogan and Mechoulam, 2006; Pertwee, 2005). However, 
the only endogenous ligands that thus far demonstrate cannabinoid binding at 
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physiological relevant concentrations are anandamide and 2-arachidonoyl glycerol 
(Pertwee and Ross, 2002).  
In reference to immunomodulation, CB2 is found in the spleen and on leukocytes 
(monocytes/macrophages, dendritic cells and osteoclasts) and is well established to 
modulate immune function (Berdyshev, 2000; Klein et al., 2000).  Of particular relevance 
to the immunological effects of Echinacea spp. is that specific alkylamides bind with 
similar affinities to CB2 as the endocannabinoids (≈57 nM)  (Matovic et al., 2007). Two 
laboratories have confirmed binding to CB2 by select alkylamides (Raduner et al., 2006; 
Woelkart et al., 2005). Using radioligand binding assays, Raduner et al. (2006) 
demonstrated that the radioligand binding to CB2 of dodeca-2E,4E,8Z,10Z-tetraenoic acid 
isobutylamide gave a 53% inhibition with a Ki of 57 nM. In the same series of experiments 
dodeca-2E,4E-dienoic acid isobutylamide gave an inhibition of 52% to CB2 with a Ki of 
60 nM. However, Woelkart and colleagues (2005) showed CB2 Ki‘s much higher. They 
report Ki‘s for the isobutylamides dodeca-2E,4E-dienoic acid and dodeca-2E,4E,8Z,10E/Z-
tetraenoic acid of 5.5 and 9.7 μM respectively. Docking studies also indicate that the Z-
tetraene and dodeca-2E,4E-dienoic acid isobutylamide fit into the putative binding pocket 
of CB2 (Raduner et al., 2006). Later work showed that of the three tetraene isobutylamide 
isomers which make up the bulk of alkylamides in E. purpurea and E. angustifolia, 
dodeca-2E,4E,8Z,10Z-tetraenoic acid (Z-tetraene) had the highest affinity (57 nM) as 
opposed to dodeca-2E,4E,8Z,10E-tetraenoic acid (4500 nM) and dodeca-2E,4E,8E,10Z-
tetraenoic acid (9000 nM). The Z-tetraene makes up 32% of the tetraene isomers in E. 
purpurea and 10% in E. angustifolia.   
Besides binding assays, CB activity has been demonstrated in vitro. Gertsch et al. 
(2004) showed that the isobutylamides dodeca-2E,4E-dienoic acid and dodeca-
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2E,4E,8Z,10Z-tetraenoic acid (Z-tetraene) were able to significantly increase the induction 
(5-12 fold) of tumor necrosis factor-α mRNA in macrophages. This effect was blocked by 
the CB2 antagonist WR144528. Further studies demonstrated a significant up-regulation 
(130-160%) of IL-6 in CB2 positive HL60 cells by the Z-tetraene and dodeca-2E,4E-
dienoic acid isobutylamide, but no effect by undeca-2E-ene-diynoic acid isobutylamide. 
CB2 antagonist SR144528 (500 nM) was able to inhibit the up-regulation of IL-6.  In the 
same series of experiments an up-regulation of IL-8 expression by dodeca-2E,4E-dienoic 
acid isobutylamide was shown, but no effect by the tetraenes or UDA isobutylamide on IL-
8 expression (Raduner et al., 2006).  
While the CB2 activity of select alkylamides is a novel discovery, it has caused 
some to suggest that the basis of activity for echinacea has finally been discovered 
(Woelkart et al., 2005). Considering the previously discussed activity of the 
polysaccharides and the phenylpropanoids, this is quite likely an overstatement. In 
addition, it is important to recognize that the numerous effects of the endocannabinoids 
may be mediated by other targets. For example, a CB3 receptor has been proposed (Ryberg 
et al., 2007) and recent results also demonstrate that the endocannabinoids, anandamide 
and 2-AG, bind to PPARγ (Rockwell and Kaminski, 2004; Rockwell et al., 2006; Sun and 
Bennett, 2007).  
 
Is PPARγ a target of alkylamides? 
 
The peroxisome proliferator-activated receptors (PPAR) constitute a set of three 
receptor sub-types which are members of the nuclear receptor superfamily of ligand-
activated transcription factors, which includes steroid hormone receptors. They are 
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encoded by distinct genes that function as lipid sensors that regulate gene expression in 
many metabolically active tissues (Bishop-Bailey and Wray, 2003). The PPARs, so named 
because the stimulation of PPARδ results in the increase of peroxisomes, have a significant 
role in cellular energy balance, fuel utilization, the metabolism of fatty acids and other 
lipids, the generation and remodeling of adipose tissue and fibrotic and hypertrophic 
responses in the heart and vascular wall. Many of these actions are via interactions with 
nuclear factors such as NF-κB and activator protein 1 (AP-1), thus modulating expression 
of pro-inflammatory cytokines and adhesion molecules, and altering cell signaling 
pathways (Touyz and Schifffrin, 2006). Thus, PPARs, in response to stressors, play a role 
in the complex orchestration of adaptive cellular physiology working in a concerted mode 
with the vitamin D receptor and the retinoic acid receptor (RXR). Thus, many 
pharmaceutical companies are involved in PPAR research in areas such as diabetes, 
obesity, cardiovascular disease and immunology with drug development in mind. 
The endogenous ligands to the PPAR sites were originally unknown, earning the 
PPARs the name ―orphan nuclear receptors‖. However, many ligands are now known: 
PPARα is known to bind polyunsaturated fatty acids such as docosahexanoic acid (DHA) 
and eicosapentaenoic acid (EPA), oxidized phospholipids, lipoprotein lipolytic products as 
well as the lipid lowering fibrates (fenofibrate and gemfibrozil) (Desvergne and Wahli, 
1999; Touyz and Schifffrin, 2006). PPARδ ligands include polyunsaturated fatty acids and 
prostaglandins and its activity is postulated to be biochemically related to lipid levels, 
wound healing and colon cancer, but the evidence for a connection to all of these pathways 
is limited (Weindl et al., 2005). PPARγ binds fatty acid derivatives, such as 
hydroxyoctadecadienoic acid (HODEs), prostaglandin derivatives, such as 15-deoxy-δ-
(12,14)-prostaglandin J2 (15d-PgJ2), and thiazolidinedione (TZDs) drugs, such as 
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pioglitazone and rosiglitazone (Touyz and Schifffrin, 2006). Nevertheless, the ―true‖ 
endogenous ligands are still debated due to these receptors demonstrating a significant 
amount of promiscuity in ligand binding.  
 
PPARγ is linked to immune function 
 
A variety of types of immune cells contain the PPAR subtypes, α, δ, and γ. PPARs 
are noted to generate transrepression via molecular association with, and the resulting 
inhibition of, nuclear factor of the κ-enhancer in B cells (NFκB), nuclear factor of 
activated T cells (NFAT), activator protein 1 (AP-1 – a heterogeneous dimer of c-fos and 
c-jun) and other transcription factors (Blanquart et al., 2003; Chung et al., 2003; Yang et 
al., 2000).  
Specifically, PPARγ produces a variety of different immune effects, which 
generally involves leukocyte down-regulation (Daynes and Jones, 2002). This results in the 
inhibition of cytokine production, suppressed proliferation and circumstance dependent 
modulation of apoptosis (Appel et al., 2005; Wang et al., 2002). PPARγ is known to affect 
recruitment of monocytes in vascular endothelial cells and quench inflammation in a 
number of disorders (Neve, 2000). Storer et al. (2005) observed inhibition of nitric oxide, 
TNF, IL-1β and IL-6, as well as the chemokines MCP-1 from microglia and astrocytes by 
the thiazolidinedione drugs, but noted that the endogenous ligand 15d-PgJ2 had stronger 
anti-inflammatory activity than the TZDs. Other research demonstrates PPARγ mediated 
protection from experimentally induced encephalitis (Iruretagoyena et al., 2006; Storer et 
al., 2005) as well as significant anti-inflammatory effects on ex-vivo T cells from multiple 
sclerosis patients (Schmidt et al., 2004). In addition, a 12 week human trial with Type 2 
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diabetic patients given troglitazone (a PPARγ agonist) lowered 2sCD40L resulting in a 
novel finding of a mode of anti-inflammatory activity that may limit diabetes associated 
arterial disease. Other groups have found similar activity in coronary artery disease (Marx 
et al., 2003).  
The above evidence suggests that PPARγ is involved in the signal transduction of 
immune dynamics, and that activation of PPARγ is likely important in ameloriating 
immune dysregulation. Thus agonists, inverse agonists and antagonist of PPARγ (and 
possible PPARα & PPARδ ) likely offer insights into immune allostasis. 
 
PPARγ binds fatty acid derivatives  
 
An obstacle in molecular biology has been the determination of the endogenous 
ligands of PPARs. It seems a number of naturally occurring compounds have been found 
to activate PPARs. However, as of yet, none of the ligands of PPARs have been 
completely accepted as endogenous ligands (Bishop-Bailey and Wray, 2003). This has 
resulted in the speculation that PPARs may function as general lipid sensors. As previously 
discussed polyunsaturated fatty acids and archidonate derivates – eicosanoids, have been 
found to be endogenous ligands of PPARs (Burstein, 2005). PPARγ is currently known to 
be tripped by prostaglandin derivatives such as 15-deoxy-Δ(12,14)-prostaglandin J2, 
hydroxyoctadecadienoic acid and the exogenous pharmaceuticals known as the TZDs 
(Touyz and Schifffrin, 2006). 
 
                                                          
2
 Diabetic patients have elevated plasma levels of soluble CD40 ligand (sCD40L), which is proinflammatory. 
This is independent of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein 
cholesterol, triglycerides, blood pressure, body mass index, gender, C-reactive protein, and soluble ICAM-1. 
Thus, CD40L is emerging to be a ―nontraditional‖ risk factor implicated in atherosclerosis. 
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PPARγ is linked to IL-2 and other cytokines 
 
Although cytokine inhibition by leukocytes is speculated to be transduced by CB 
receptors, non-cannabinoid modes of activity appear to also be involved (Klein, 2005; 
Pertwee and Ross, 2002). IL-2 secretion is a characteristic response of T cell activation. 
This cytokine is vital in adaptive immune response due to essential roles in T cell 
proliferation, differentiation and cell survival. Rather conveniently, there is very little basal 
expression of IL-2 but rapid secretion on T cell perturbation. This makes IL-2 a marker of 
T cell activation. Central to the experiments contained in the PPARγ chapter, both 
anandamide and 2-AG, in a number of models, demonstrate concentration dependent 
inhibition of IL-2 (Rockwell et al., 2006). Moreover, anandamide induces a concentration-
dependent inhibition of interleukin-2 in primary splenocytes which is unaffected by 
SR141716A and SR144528. In the same model arachidonic acid shows similar activity as 
anandamide which is attenuated by pretreatment with nonspecific COX inhibitors as well 
as COX-2 specific inhibitors.  Pretreatment with the PPARγ antagonist T0070907 also 
attenuated anandamide mediated suppression of IL-2 secretion (Rockwell and Kaminski, 
2004).  
Following the line of reasoning that IL-2 activity is at least partially mediated by 
PPARγ, Yang et al. (2000) observed that PPARγ free Jurkat cells did not respond to 
PPARγ ligands troglitazone and 15d-PgJ2, but PPARγ expressing Jurkats did exhibit IL-2 
inhibition in response to PPARγ agonists. Of significance in regard to structural leads, the 
PPARγ agonist Wy14643 did not show any IL-2 activity. Clark et al. (2000) and Rockwell 
et al. (2006) also found PPARγ inhibitory activity on IL-2 secretion by the PPARγ agonists 
ciglitazone and 15d-PgJ2. Rockwell et al. (2006) also ruled out CB1 and CB2 activity on 
Chapter 1  Introduction to the Literature 
34 
 
inhibition of IL-2 in their model of Jurkat cells and 2-AG ligand by demonstrating the 
inhibition of transcriptional activity of the crucial IL-2 transcriptional factors, NFAT and 
NFκB. Thus in the absence, but not the presence, of T0070907 IL-2 secretion was 
inhibited. Finally, Rockwell et al. (2006) reported that 2-AG treatment doubled the 
PPARγ/ PPAR response elements (PPRE) and suppressed mRNA levels for IFN-γ and IL-
4 in Jurkats. 
 
Structural similarities between alkylamides and PPAR-γ agonist 
 
As has been previously stated, PPARs are believed to be lipid sensors. Thus, select 
fatty acids and many of their derivatives are recognized as PPAR ligands (Nakamura et al., 
2004; Rodriguez-Cruz et al., 2005). A structural lead to the PPARγ ligands comes from the 
observation that saturated fatty acids do not appear to act as agonist for the PPARs 
(Nakamura et al., 2004). As previously discussed, the alkylamides are fatty acid derivatives 
formed by the condensation of a fatty acid with an amine (Hofer et al., 1986). In the case 
of Echinacea spp. the alkylamides reported to be CB2 ligands are unsaturated: the Z-
tetraene as well as other isobutylamides such as dodeca-2E,4E-dienoic acid, dodeca-
2E,4E,8Z-trienoic acid are all reported to bind with similar Ki‘s making them viable 
pharmacological ligands for CB2.   
Of interest is that with few exceptions, the alkylamides that are reported to have 
physiologically relevant Ki‘s for the CB2 are of the olefinic class of alkylamides. The 
polyacetylenic alkylamides appear to be active in cell culture studies, but are reported to 
have Ki‘s for CB2 that are too high for pharmacological activity in vivo. For example, 
UDA contained in E. angustifolia (although mistakenly reported to occur in E. purpurea – 
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see Chapter 2), binds CB2 with negligible affinity (40-66 μM) (Raduner et al., 2006; 
Woelkart et al., 2005).  In addition, Chen et al. (2005) demonstrated that the 
isobutylamides that have acytelenic tails reduced NO production and had lower ID50s than 
the established CB2 ligands Z-tetraene and dodeca-2E,4E-dienoic acid (3 μg/mL vs. 6 
μg/mL). PPARγ activation has shown to result in reduction in NO (Varga and Nagy, 
2008). 
Other discrepancies concerning CB2 being the sole target for alkylamides are 
suggested by Raduner et al. (2006) who report that in CB2 negative HL-60 cells, IL-8 
expression is inhibited by the isobutylamides Z-tetraene, dodeca-2E,4E-dienoic acid and 
undeca-2E-ene-diynoic acid. Notably, PPARγ has been reported as a target for IL-8 
inhibition (Chinetti et al., 2000; Tesse et al., 2008). Thus, the numerous effects reported for 
the alkylamides raises the question, whether the plethora of effects merely reflect 
alkylamide action on CB2 or whether there are unknown targets playing a role. 
 
Research plan  
 
Considering the proposed activity of alkylamides discussed above, the research 
described in this thesis had the following aims: 
 
1. Characterization, extraction and degradation of the alkylamides in E. purpurea. 
The characterization and extraction of the alkylamides contained within E. purpurea will 
provide details as to the availability of these compounds in ethanolic extracts. These 
extracts, as well as alkylamide isolates, will then be utilized in subsequent metabolism and 
bioactivity investigations. Degradation studies will also provide information on the 
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stability of the alkylamides. The quantification of various alkylamides occurring in the 
extracts at different time points will also be useful data for the natural products industry. 
2. Metabolism of the alkylamide isomers, dodeca-2,4,8,10-tetraenoic acid 
isobutylamide.  
The enzymatic transformation of the isomeric tetraenes will also provide meaningful data 
on the bioavailability of the alkylamides during and after absorption. 
 
3. Bioactivity of the alkylamides. 
 
Specifically, the bioactivity of the isobutylamide undeca-2E-ene-8,10-diynoic acid will be 
explored using an ELISA assay to measure IL-2 response in Jurkat cells. In addition, a 
fibroblast adipocyte differentiation model utilizing 3T3-L1 cells will be explored. 
 
Hypothesis  
 
This thesis will investigate two hypotheses:  First,   that the alkylamides present in 
Echinacea spp. are preserved during traditional preparative methods.  Second, that specific 
alkylamides from traditional preparations of Echinacea inhibit the release of  IL-2 and 
affect expression of key genes involved in the immune response, via the PPARy signalling 
system. 
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Chapter 2 
 
Alkylamide characterization and yield in fresh versus dry 
ethanolic extracts of Echinacea purpurea utilizing  
HPLC-ESI-MS  
 
Introduction 
 
The analysis of medicinal plant extracts presents a number of analytical challenges. 
Although many products have been shown to contain active constituents, they are 
commonly obscured in biological matrices that generate confounding variables. 
Unfortunately, such technical challenges may generate obstacles to chemical analysis 
resulting in ambiguity of product content. Fortunately, hyphenated chromatographic 
approaches such as gas chromatography mass spectrometry (GC-MS), liquid 
chromatography mass spectrometry (LC-MS) and capillary electrophoresis mass 
spectrometry (CE-MS) allow for analysis of challenging mixtures through enhanced 
selectivity, chromatographic separation and measurement precision, as well as chemical 
fingerprinting (Hansen, 2001; Li et al., 2007).  In particular, electrospray ionization mass 
spectrometry (ESI-MS), with its exceptional specificity, speed and sensitivity (Cech and 
Enke, 2001; Xing et al., 2007) and its ability to ionize non-volatile molecules, is an ideal 
first choice for characterization of chemically complex plant extracts.   
The investigations described herein employ high performance liquid 
chromatography coupled to electrospray ionization mass spectrometry (HPLC-ESI-MS) 
for the comprehensive characterization of several extracts from the medicinal plant 
Echinacea purpurea (L.) Moench.  Echinacea is widely used for the treatment of upper 
respiratory infections, and is a global top seller. Three main species of echinacea are used 
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clinically and available to consumers, Echinacea pallida, E. purpurea and E. angustifolia.  
Of these, E. purpurea represents 80% of commercial production (Li, 1998).  E. purpurea 
products range from the injectables prepared to rigorous European pharmaceutical 
manufacturing standards, to the low tech ethanolic extractions or “tinctures” that follow 
general manufacturing practices (GMPs) of the United States dietary supplements industry. 
Although in Germany the aerial parts are preferred, ethanolic extracts of echinacea root 
make up a large source of sales and clinical use in the United States. Manufacturing 
practices generally dictate whether the starting plant material should be fresh or dry, but in 
the case of echinacea species, both fresh and dry root extracts are commercially available. 
To further complicate matters, these extracts are prepared with varying ratios of 
plant:solvent depending on the manufacturer.  Currently, there are few investigations 
comparing the efficiency of extracting active constituents under these various extraction 
conditions. There is currently a lack of information regarding differences in chemical 
composition among extracts prepared using fresh versus dried Echinacea.  One of the 
goals of the studies conducted herein was to provide such information. 
Of the four constituent groups currently believed to be the source of activity in the 
echinacea genus; alkylamides (alkamides), phenylpropanoids (caffeic acid derivatives), 
polysaccharides, and glycoproteins (Bauer, 1996, 1998), to date, human pharmacokinetic 
studies of Echinacea spp. suggest that the alkylamides are the major constituent group 
circulated in plasma (Matthias et al., 2005a; Woelkart et al., 2006).  
Alkylamides, found in other medicinal plants besides Echinacea spp., have been of 
pharmacological interest since the tingling and numbing effect from chewing plants rich in 
these compounds were noted (Greger, 1984). This anesthetic property was utilized by 
Native Americans (Moerman, 1998) and eventually by physicians in the early 20
th
 century 
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for a variety of purposes including as a sialogogue, antitussive and for toothache. 
Alkylamides were later recognized as insecticidal (Greger, 1984; Jacobson, 1948; 
Jacobson, 1967; Jondiko, 1986; Meisters and Wailes, 1966; Towers and Champagne, 
1988) and oncolytic (Voaden and Jacobson, 1972). Recent investigations have 
demonstrated immunomodulatory activity of alkylamides in vitro (Dalby-Brown et al., 
2005; Matthias et al., 2007; Merali et al., 2003; Muller-Jakic et al., 1994; Raduner et al., 
2006; Sasagawa et al., 2006; Sharma et al., 2006) and in vivo (Goel et al., 2002), as well as 
direct antiviral activity (Hudson et al., 2005; Vimalanathan et al., 2005). Of late, these fatty 
acid derivatives have become a subject of renewed interest due to their recent identification 
as cannabinoid receptor 2 (CB2) ligands (Gertsch et al., 2006; Gertsch et al., 2004; 
Raduner et al., 2006; Woelkart et al., 2005b) and most recently, PPARγ activity has been 
demonstrated (Christensen et al., 2009; Spelman et al., 2009). 
Even though there is a renewal of pharmacological investigations in the 
alkylamides, there is a paucity of research on the extraction of alkylamides (Gafner and 
Bergeron, 2005; Stuart and Wills, 2000; Stuart et al., 2004), especially of the abundant 
ethanolic extractions that make up a significant share of the echinacea products purchased 
by consumers. These galenicals are prepared by maceration or percolation of the starting 
plant material in a variable ratio of ethanol and water dependent on plant species, plant part 
and manufacturing customs.  The few studies investigating the extraction of alkylamides 
have generally utilized dried root, while alkylamide extraction of fresh roots has scarcely 
been studied (Sun et al., 2002). Notably, the Germans prefer E. purpurea aerial parts, 
where most phytotherapists in the United States prefer preparations from the root. 
Regardless, traditional preparation of echinacea tincture is often from fresh plant material 
(Moore, 2003).   
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Given that the alkylamides appear to be one of the key constituent classes 
responsible for pharmacological activity of E. purpurea, the studies described herein 
focused on this class of constituents. Due to the convenient chromophoric nature of the 
secondary amide groups and olefinic double bounds of the alkylamides, much of the past 
characterization of alkylamides has been generated with LC-UV (Bauer et al., 1988a; 
Bauer and Remiger, 1989; Bauer et al., 1988b; Bauer et al., 1988c, 1989; Bauer et al., 
1988d). LC with gradient elution provides reproducibility, good linear range and, key to 
the complex environments presented by phytochemical matrices, allows for analyzes of 
multiple constituents from plant extractions (Ong, 2004). While initial reports had used 
longer analysis times (Bauer and Remiger, 1989), Bergner demonstrated that the use of a 
short C18 reverse phase column with small particle size (75 x 4.5 mm i.d.; 3μm) allows for 
improvement of the separation and shortens the time of analysis of alkylamides (Bergeron 
et al., 2000).  
However, comprehensive profiling of echinacea alkylamide content using LC-UV 
alone has been challenging. These compounds are present at widely different 
concentrations, and many of them are isomeric. Consequently, co-elution of structurally 
similar alkylamides is common, and UV detectors may not detect minor alkylamide 
constituents because of low concentrations and/or co-elution with other compounds. Mass 
spectrometry (MS) provides a distinct advantage over UV detectors due to its sensitivity 
and the ability to select by mass the ions corresponding to the compounds of interest (He et 
al., 1998; Hudaib et al., 2002; Matovic et al., 2007). As the data presented here will 
demonstrate, this advantage makes HPLC-ESI-MS an ideal technique for the 
comprehensive analysis of the isomeric alkylamide content in Echinacea purpurea.  
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LC-ESI-MS provides further advantages such as greater sensitivity and resolution 
and as a result less need for separation of chromophores. Additionally, LC-MS/MS 
fragmentation has also been used to identify the characteristic fragmentation pattern of 
alkylamides (Bauer et al., 1988b; Cech et al., 2006a; Cech et al., 2006b). Although several 
investigators have previously employed HPLC-ESI-MS to the analysis of Echinacea (Cech 
et al., 2006a; He et al., 1998; Luo et al., 2003; Sloley et al., 2001; Woelkart et al., 2005a; 
Woelkart et al., 2006) many of these previous investigations have not been quantitative 
(He et al., 1998; Luo et al., 2003; Sloley et al., 2001).  Furthermore, because of the 
abundance of isomeric alkylamides, even with the use of MS detectors, mis-identification 
or incomplete identification of alkylamides has been common (Bauer et al., 1987; He et al., 
1998; Jacobson, 1967; Wills and Stuart, 1999).   
The investigations described here employ HPLC-ESI-MS with an ion trap mass 
spectrometer for the quantitative and qualitative analysis of alkylamide content in various 
Echinacea purpurea extracts, filling a gap in the current literature.  The objective of these 
studies is to employ comprehensive analysis with HPLC-ESI-MS to compare the 
alkylamide content of various fresh and dry Echinacea purpurea extracts.  In contrast to 
previous reports (Bauer and Wagner, 1991; Hudaib et al., 2002; Luo et al., 2003; Perry et 
al., 1997; Wills and Stuart, 1999), we report that the species Echinacea purpurea contains 
at least 15 different alkylamides that are detectable in ethanolic extractions of the root. 
Utilizing the capability of the ion trap mass analyzer to generate MS-MS fragments, we are 
able to report what is, to date, the most comprehensive list of alkylamides present in 
traditionally prepared ethanolic extractions of E. purpurea root.  In addition, our results 
demonstrate the optimal length of maceration time for extracting alkylamides in ethanol, 
and demonstrate differences in alkylamide yield in extracts prepared using various 
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plant:solvent ratios, and with fresh and dry plant roots.  The results presented here are 
relevant to researchers engaged in the chemical characterization of plant extracts in that 
they demonstrate the power of MS-MS characterization for distinguishing structurally 
similar constituents. More broadly, these results are relevant to the dietary supplements 
industry because they demonstrate methods that can be employed to yield extracts with 
significant content of active constituents, in this case alkylamides.  Using novel 
pharmaceutical and biomedical analysis we were able to identify new alkylamides and a 
correction of a previously published error. Thus, using LC-ESI-MS we have generated the 
most comprehensive list of the alkylamides to date, many of which are proving to be 
actives of Echinacea purpurea root extracts. 
 
Methods 
 
Reagents 
 
The following chemicals and reagents were used: Acetonitrile (high-performance 
liquid chromatography (HPLC) grade (Honeywell Burdick and Jackson, Muskegon, MI), 
acetic acid (Fisher Chemical, Fairlawn, NJ),  alkylamide standards (Chromadex Inc., Santa 
Anna, CA) ethanol (AAPER, Shelbyville, KY), nanopure water (Nanopure Diamond 
D11931, Barnstead International, Thermolyne, Dubuque, IA). 
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Plant Material 
 
Cultivation of E. purpurea took place in Grants Pass, OR at Pacific Botanicals. 
Fresh, dormant roots of E. purpurea were harvested in March 2007. Species was verified 
by Richard Cech (Horizon Herbs, Williams, OR) and voucher specimens were submitted 
to the University of North Carolina Herbarium in Chapel Hill, NC (accession numbers 
583416 and 583417).  The roots were two-years-old at time of harvest.   
 
Plant Extractions  
 
A typical protocol (Adams and Tan, 1999) for the manufacture of ethanolic extracts 
was followed in all extractions, except that post washing, the roots were briefly soaked (5 
min) in 70% ethanol as a disinfectant, and blown partially dry with compressed air. A loss 
of the isomeric dodeca-2,4,8,10-tetraenoic acid isobutylamides (tetraenes) of 1.4% (against 
final fresh root concentrations) was calculated from the initial rinse. The roots were then 
cut into small pieces (≤ 1 cm wide) and treated using three different extraction techniques, 
fresh root extraction (1:2 w:v) and dry root extraction at two different root to solvent 
ratios, 1:11 and 1:5 (w:v) as shown in Table 2.1. All ratios are expressed as mass raw plant 
material (E. purpurea roots) in weight (g) per volume (mL) of extraction solvent.  
To prepare fresh root extracts, samples of the cut roots (65 g) were blended using a 
Waring Blender (Tarrington, CT) in a solvent of 95% ethanol (AAPER, Shelbyville, KY) 
at a ratio of 1 g roots:2 mL solvent. Samples of root from the same batch were dried in an 
oven at 50 °C and water content was determined to be 74.5% (Table 2.1). Dry root 
extractions were carried out with the same method as the fresh except that the solvent 
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consisted of 74.5% ethanol and 25.5% water (to account for the plant water removed upon 
drying). To make these dry root extracts, 16.6 g of dried root was added to 179 mL of 
solvent (74.5% ethanol) for a ratio of 1:11 and 16.6 g of dried root was added to 83 mL of 
solvent (74.5% ethanol) for a ratio of 1:5 (Table 2.1). Four replicate extracts were prepared 
at each extraction ratio (fresh 1:2, dry 1:11 and dry 1:5). 
 
Table 2.1. Solvent and root ratios for the extracts 
Designation E. purpurea 
root (g) 
Ethanol 
(mL) a 
Water 
(mL)b 
Final ratio dry plant 
material:solvent 
(mg:mL)c 
% 
alcohold 
Fresh 1:2 65.0 130 48 17:178 or 1:11 69 
Dry 1:11 16.6 130 49 17:179 or 1:11 69 
Dry 1:5 16.6 60 23 17:83 or 1:5 69 
a. This value represents the quantity of ethanol (95%) added to the plant material in the extraction 
process.   
b. This value represents the quantity of water added to the plant material in the extraction process.  For 
the fresh extract, additional water is contributed by the plant roots.   
c. This ratio, the ratio of plant material to solvent in the final extract, is calculated by dividing the dry 
weight of the plant material by the total volume of solvent (including water contributed by the fresh 
plant material, which contains 74.5% water).   
d. This percentage represents the amount of alcohol in the final extract.  It includes both the quantity of 
water used to prepare the extract and the quantity of water contributed by the fresh plant material.   
 
To prepare fresh root extracts, samples of the cut roots (65 g) were blended using a 
Waring Blender (Tarrington, CT) in a solvent of 95% ethanol (AAPER, Shelbyville, KY) 
at a ratio of 1 g roots:2 mL solvent. Samples of root from the same batch were dried in an 
oven at 50 °C and water content was determined to be 74.5% (Table 2.1). Dry root 
extractions were carried out with the same method as the fresh except that the solvent 
consisted of 74.5% ethanol and 25.5% water (to account for the plant water removed upon 
drying). To make these dry root extracts, 16.6 g of dried root was added to 179 mL of 
solvent (74.5% ethanol) for a ratio of 1:11 and 16.6 g of dried root was added to 83 mL of 
solvent (74.5% ethanol) for a ratio of 1:5 (Table 2.1). Four replicate extracts were prepared 
at each extraction ratio (fresh 1:2, dry 1:11 and dry 1:5). 
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Aliquots (dry root 1:11, 200 µL) for the extraction as a function of time study were 
taken on a daily basis (days 2-33) during the process of maceration and stored at -70° C 
until the time of analysis for alkylamide content. After maceration for one month, the 
solvent was removed from all of the extracts using a hydraulic press.   The extracts were 
then aliquoted into 1 mL portions in polypropylene microcentrifuge tubes and kept in the 
dark at room temperature until needed for analysis. Previous investigations have 
established stability of alkylamides under these conditions (Livesey et al., 1999). All 
extractions were macerated at 24 °C. 
 
Sample preparation 
 
Prior to analysis, samples were removed from storage and allowed to reach room 
temperature.  Aliquots (500 µL) from all extractions were centrifuged at 14,000 rpm 
(Savant Speedvac Sc110, Farmingdale, NY) for 5 minutes. Supernatant was then diluted in 
the same solvent used for extraction (70% ethanol), and pipetted (300 µL) into autosampler 
vials (Agilent Technologies, Santa Clara, CA) for LC-MS analysis.  Several dilutions were 
prepared from each extract to provide samples for which the alkylamides of interest were 
present at concentrations within the linear dynamic range of the method.  Neat samples 
were used for determination of dodeca-2E-ene-8,10-diynoic acid, 100-fold dilutions were 
used for analysis of dodeca-2E,4E-dienoic acid , and1000-fold dilutions were used for 
analysis of the isomers of dodeda-2,4,8,10-tetraenoic acid isobutylamide. 
 
Chapter 2  Extraction of Alkylamides 
59 
 
Determination of yield of dissolved solids 
 
Polypropylene microcentrifuge tubes (1.5 mL) were weighed before addition of 
500 µL aliquots of centrifuged extracts. After dehydration in the speedvac for 39 hours at 
24 °C, the mass of dissolved solids for each sample was determined. The ratio of the mass 
of dissolved solids to the amount of dry root used in the equivalent volume of extract was 
then calculated, providing a measure of the quantity of dissolved solids extracted per mass 
of Echinacea root (extract yield).  For the fresh extract, the dry weight of the root used for 
the extract was calculated by subtracting the mass of the water contained in the roots from 
the total mass of the fresh roots. 
 
Preparation of Alkylamide Standard Solutions 
 
The alkylamide standards were purchased from Chromadex (Santa Anna, CA) with 
certificates of analysis verifying identity by NMR and HPLC. Primary stock solutions of 
undeca-2E-ene-8,10-diynoic acid isobutylamide (molecular weight 231.34, lot #21235-
501), dodeca-2E-ene-8,10-diynoic acid isobutylamide (molecular weight 245.37, lot # 
04950-601), dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (molecular weight 
247.38, lot # 04953-102) and dodeca-2,4-dienoic acid isobutylamide (molecular weight 
251.41, lot # 04951-101) were prepared in ethanol and stored at 4 
○
C. The stock solution 
was then diluted in ethanol to produce final concentrations of 0.1, 10, 50, 100, 500 µM, 
depending on the instrument sensitivity to the particular compound. 
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HPLC-ESI-MS Analysis   
 
An ion trap mass spectrometer with electrospray ionization source (LCQ 
Advantage, ThermoFisher, San Jose, CA) was employed. The solvent gradient, which was 
a minor variation on that previously published (Cech et al., 2006a), was as follows, where 
solvent A is aqueous acetic acid (17mM, original pH 2.74) and solvent B is neat HPLC 
grade acetonitrile.  For t = 0 to 4 min, a constant composition of A-B (90:10 v/v); for t = 4 
to 15 min, a linear gradient from A-B (90:10, v/v) to A-B (60:40, v/v); for t = 15 to 30 min, 
a linear gradient from A-B (60:40,v/v) to A-B (40:60, v/v); for t = 30.1 to 35 min, a 
constant composition of A-B (0:100,v/v); for t = 35.1 to 43 min, a constant composition of 
A-B (90:10, v/v). The mass spectrometer was operated in the positive ion mode with a scan 
range of 50.00-2000.00.  Spray, capillary, and tube lens offset voltages were 4.5 kV, 3 V 
and -60V, respectively. MS/MS studies were performed by programming the MS to the ion 
masses shown in Tables 2.2A and B.  
Constituents in the extracts were identified according to their molecular weights, 
HPLC retention times, and previously established MS–MS fragmentation patterns (Cech et 
al., 2006a; Hiserodt et al., 2004). Quantitation was accomplished using the previously 
published methods (Cech et al., 2006a; Sasagawa et al., 2006) based on the available 
alkylamide standards.  Briefly, calibration curves were plotted for each alkylamide as the 
peak area of the selected ion chromatogram for the protonated molecular ion of the 
alkylamide of interest versus concentration.  A concentration range of 0.1 to 100 µM was 
used for all alkylamides except dodeca-2,4-dienoic acid isobutylamide, which was plotted 
over a range of 10-500 µM due to poor instrument sensitivity to this molecular species. 
The structure of the alkylamides that functioned as standards are noted with an asterisk in 
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Tables 2.2A and 2.2B.  For the extraction as a function of time study, samples from daily 
collections were analyzed in a single run within 10 weeks of the initial sample collection.  
 
Statistical analysis 
 
The means standard error of the mean (SEM) were determined for each set of 
concentrations or peak areas. Data is expressed as the mean ± SEM and means were 
compared using a two-tailed t-test for paired data when differences were observed. The 
mean values were considered significantly different if p < 0.05. Where appropriate, 
outlying data points were rejected on the basis of the Q-test. Statistical analyses were 
performed with Microsoft Excel (2003).  
 
Results  
 
In this section, several types of results are presented.  First, a comprehensive profile 
of alkylamide constituents in E. purpurea is listed, with a description of how these 
compounds can be identified using HPLC-ESI-MS.  Second, quantities of dissolved solids 
and specific alkylamides present in various E. purpurea extracts are compared.  The 
extracts analyzed here were prepared using several different procedures commonly 
employed in the dietary supplement industry.  Analysis of these extracts provides insight 
into the similarities and differences in extract composition that result from these variations 
in extraction technique.   
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Identification of Alkylamides 
 
Tables 2.2A and 2.2B show the structures and relevant data for alkylamides that 
have previously been identified from Echinacea purpurea. The references in the farthest 
right column refer to the publications in which these identifications were made.  This is the 
most comprehensive listing of alkylamides of E. purpurea root to date.  Most reports and 
reviews list some, but not all, of the alkylamides present in this species (Bauer et al., 
1988b; Gotti et al., 2002; Gray et al., 2003; Wills and Stuart, 1999). Past estimates suggest 
the presence of eleven alkylamides in the roots of E. purpurea (Bauer, 1998; Pietta et al., 
2004). Tables 2.2A and 2.2B are more comprehensive, listing a total of 17 compounds, 
although, as described later on, some of these identifications are only tentative and one 
compound (C) was not detected in our samples of E. purpurea. 
Figure 2.1 illustrates two compilations of selected ion chromatograms obtained 
from analysis of the 1:5 dry root E. purpurea extract. The ions plotted correspond to the 
m/z of the protonated (MH
+
) forms of various alkylamides in E. purpurea, with the letters 
above the peaks corresponding to the designations of structure in Tables 2.2A and 2.2B.   
The higher intensity ions, m/z 230, 250, and 248 (Figure 2.1A), were plotted 
separately from the lower intensity ions 244, 252, 258, 262 (Figure 2.1B) for ease of 
visualization.  
A number of the alkylamides in Tables 2.2A and 2.2B are isomers, and their MH
+
 
ions, therefore, are detected at the same m/z values.  Such isomeric alkylamides can be 
distinguished on the basis of retention time (Binns et al., 2001; Cech et al., 2006a) and/or 
MS-MS fragmentation (Cech et al., 2006a; Sloley et al., 2001).  In Figure 2.1, undeca-
2E,4Z-diene-8,10-diynoic acid isobutylamide (A) has a distinct peak, as does its 
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Table 2.2A. Alkylamides from E. purpurea.    
 
 
Desig- 
nation 
Alkylamide 
nomenclature 
Structure Amide 
Moiety 
Total 
MW 
Ref 
 
A 
Undeca-2E,4Z-
diene-8,10-
diynoic acid 
isobutylamide 
O
N
 
Isobutyl 229.32 
(Bauer 
et al., 
1988b) 
B 
Undeca-2Z,4E-
diene-8,10-
diynoic acid 
isobutylamide 
O
N
 
Isobutyl 229.32 
(Bohlm
ann 
and 
Grenz, 
1966) 
 
C* 
*Undeca-2E-
ene-8,10-diynoic 
acid 
isobutylamide 
O
N
 
Isobutyl 231.34 
(Binns 
et al., 
2002b) 
D  
Undeca-2E,4Z-
diene-8,10-
diynoic acid 2-
methylbutyl 
amide 
N
O
 
2-
methyl 
butyl 
243.35 
(Bauer 
et al., 
1988b) 
E  
 
Undeca-2Z,4E-
diene-8,10-
diynoic acid 2-
methylbutyl 
amide 
N
O
 
2-
methyl 
butyl 
243.35   
F  
Dodeca-2Z,4E-
diene-8,10-
diynoic acid 
isobutylamide 
N
O
 
Isobutyl 243.35 
(Bohlm
ann 
and 
Grenz, 
1966) 
 
G 
Dodeca-2E,4Z-
diene-8,10-
diynoic acid 
isobutylamide 
N
O
 
Isobutyl 243.35 
(Bauer 
et al., 
1988b) 
H 
Dodeca-
2E,4E,10E-
triene-8-ynoic 
acid 
isobutylamide 
N
O
 
Isobutyl 
 
245.37 
 
(Bauer 
et al., 
1988b) 
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Table 2.2B. Alkylamides from E. purpurea continued. 
 
a.  Bohlman  & Grenz, 1966 identified the mixture of the tetraenes K, L & M (in root) 
b.  Bauer et al, 1988 determined the stereochemistry of K & L; 
c.  Matovic et al, 2007 identified the third tetraene isomer M. 
d.  Compounds C, J, L and O, marked with an asterisk (*) were utilized as standards. 
Desig-
nation 
Alkylamide  
nomenclature 
Structure Amide  
Moiety 
Total  
MW 
Ref 
J* 
*Dodeca-2E-
ene-8,10-
diynoic acid 
isobutylamide 
N
O
 
Isobutyl 245.37 
(Binns 
et al., 
2002b) 
Kab 
Dodeca-
2E,4E,8Z,10E-
tetraenoic acid 
isobutylamide 
N
O
 
Isobutyl 247.38 
(Bauer 
et al., 
1988b) 
Lab* 
*Dodeca-2E,4E, 
8Z,10Z-
tetraenoic acid 
isobutylamide 
O
N
 
Isobutyl 247.38 
(Bauer 
et al., 
1988b) 
Mac 
Dodeca-2E,4E, 
8E,10Z-
tetraenoic acid 
isobutylamide 
N
O
 
Isobutyl 247.38 
(Matovi
c et al., 
2007) 
N 
Dodeca-
2E,4E,8Z-
trienoic acid 
isobutylamide 
N
O
 
Isobutyl 249.40 
(Bauer 
et al., 
1988b) 
O* 
*Dodeca-2E,4E-
dienoic acid 
isobutylamide 
O
N
 
Isobutyl  
251 
.41 
(Bauer 
and 
Remige
r, 1989) 
P 
Trideca-2E,7Z-
diene-8,10-
diynoic acid 
isobutylamide 
N
O
 
Isobutyl  257.38 
(Bauer 
and 
Remige
r, 1989) 
Q 
Dodeca-2E,4Z-
diene-8,10-
diynoic acid 2-
methylbutyl 
amide 
N
O
 
2-
methyl 
butyl 
257.38 
(Cech 
et al., 
2006a) 
R 
Dodeca-
2,4,8,10-
tetraenoic acid 
2-methylbutyl 
amide 
N
O
 
2-
methyl 
butyl 
261.41 
(He et 
al., 
1998) 
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Figure 2.1. A & B  Characteristic selected ion chromatograms obtained by liquid chromatography-mass 
spectrometry analysis of an E. purpurea root extract (1:5). 
The designating letters correspond to the alkylamides in Tables 2.2 A and B.  The chromatogram in (A) was 
derived by plotting a combination of the selected ion chromatograms for ions with m/z 230 (alkylamides A 
and B) m/z 248 (alkylamides K, L & M), and m/z 250 (alkylamide N).  Chromatogram B was obtained by 
plotting selected ion chromatograms for some of the minor alkylamide ions, m/z 244 (alkylamides D, E, F & 
G), m/z 252 (alkylamide O), m/z 258 (alkylamides P and Q), and m/z 262 (alkylamide R)  From these 
chromatograms, it is apparent that the 8,10 alkyne alkylamides A/B undeca-2E/Z,4E/Z-diene-8,10-diynoic 
acid isobutylamide; D/E undeca-2E/Z,4E/Z-diene-8,10-diynoic acid 2-methylbutylamide ; F/G dodeca-
2E/Z,4E/Z-diene-8,10-diynoic acid isobutylamide; P/Q dodeca-2Z,4E-diene-8,10-diynoic acid 2-
methylbutylamide elute before the olefinic alkylamides that function as CB2 ligands – dodeca -
2E,4E,8Z,10Z-tetraenoic acid isobutylamide (L); dodeca-2E,4E-dienoic acid isobutylamide (O); 
dodeca-2E,4E,8Z-trienoic acid isobutylamide (N). 
 
isomer, undeca-2E,4Z-diene-8,10-diynoic acid  isobutylamide (B), consistent with reports 
by Cech et al. (Cech et al., 2006a).  The isomeric alkylamides D/E (both with MH
+
 values 
of 244) elute as a single peak, as do the isomeric pair F/G (also with MH
+
 244).  By relying 
on MS-MS fragmentation spectra (Figure 2.2), it is possible to determine that each peak 
corresponds to a pair of isomers.  Additionally, as shown in Figure 2.2, MS-MS spectra 
can also be helpful for further structural assignment of isomeric compounds that are 
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resolved chromatographically, such as the isomers P and Q (both with MH
+
 ions at m/z 
258).  
The isomeric compounds D, E, F and G all demonstrate MH
+
 ions at m/z 244 and 
compounds P and Q both have MH
+
 ions with m/z 258. Nonetheless, each alkylamide is 
uniquely associated with its retention time and mass spectrum, and is readily 
distinguishable.  Table 2.3 illustrates the primary fragments that result from collisionally 
induced dissociation of several isomeric alkylamides.   Structurally similar fragments have 
been grouped with designations of i, ii, iii, iv and v for ease of reference.  
One of the major groups of fragments formed by collisionally induced dissociation 
is the acyllium ion (fragment group i in Table 2.3). The formation of acyllium fragments 
from alkylamides was recently reported by Hiserodt et al. (Hiserodt et al., 2004).  These 
ions form due to a charge-remote hemolytic cleavage that yields a resonant distonic radical 
cation, which subsequently undergoes hydrogen rearrangement.  Alkylamides F and G 
(Figure 2.2 D and E) show an acyllium ion at m/z 171, while alkylamides D and E (Figure 
2.2 A and B) result in the acyllium ion at m/z 157. The acyllium ion and the first 
generation fragment resulting from the subsequent loss of CO, indirectly leads to the 
elucidation of the alkyl moiety length. Utilizing MW of these fragments, it is implicit that 
an alkyl moiety with 12 carbons for F, G & Q is present as compared to 11 carbons (D, E) 
or 13 carbons (P) is present Table 2.3.   
Two additional fragments useful for elucidation of alkylamide structure are the 
group ii and group iii fragments (Table 2.3).  The group ii fragments result from the loss of 
the amide portion alkylamide, and correspond to the remaining alkyl chain.  The group iii 
fragments are observed at an m/z value 2 amu above the group ii fragments.  Past research 
has tended to ignore these ions, even though they are of high intensity, perhaps due to 
Chapter 2  Extraction of Alkylamides 
67 
 
uncertainty as to how they are formed. Recent work utilizing deuterated alkylamides 
suggests that in the diene alkylamides, these fragments are formed when an unsaturated 
bond is lost and the remaining double bond shifts to the 3 position (in 2,4-dienes), with a 
subsequent gain of 2 hydrogens (Hiserodt et al., 2004).   
In combination, the group ii and iii ions can be used to determine 1) whether the 
alkylamide is a diene; 2) how many carbons are present in the akyl chain; and 3) the 
identity of the amide moiety (isobutyl versus 2-methylbutyl).  Isobutylamides will have 
two fragments corresponding to a loss of 101 (group ii) and 99 (group iii) from the MH
+
 
precursor ion (Figure 2.2 D, E, and F).  For 2-methylbutylamides, the fragments will 
reflect the additional carbon in the amide moiety, and fragment ions corresponding to a 
loss of 115 (group ii) and 113 (group iii) from the MH
+
 precursor ion will be observed 
(Figure 2.2 A, B and C). 
The group iv fragments (Table 2.3) correspond to the MH
+
 ion of the protonated 
alkylamide that remains after loss of the N-alkyl group.  Abebe et al (1997) suggest that 
ionized amides lose their N-alkyl substituent group with moderate facility. Loss of the N-
isobutyl group results in a significant fragment (relative intensity 26-60%) at m/z 188 for 
compounds F and G and 185 for compound Q, while loss of the N-(2-methylbutyl) group 
results in a fragment with m/z 174 for compounds D and E (relative intensity 56-100%) 
and a fragment with m/z 202 for compound P.  This confirms the presence of an isobutyl 
group (MW 56) in the structure of compounds F & G [(M+H) – (M – N-alkyl); 244 – 188 
= 56] as does P [258 – 202 = 56]. This is compared to D & E [244 – 174 = 70] which 
contain a N-2-methylbuyl amide moiety (70). This also shows that alkylamide Q contains a 
2-methylbutyl amide [258 – 188 = 70]. The mass that is lost to form the group iv fragment 
serves as additional confirmation to distinguish isobutylamides from 2-methylbutylamides. 
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The final fragments that result from collisionally induced dissociation of 
alkylamides are group v in Table 2.3.  They are formed by cleavage of various C-C bonds 
on the N-alkyl substituent (Figure 2.2).  The group v fragments are useful for verifying 
whether the N-alkyl substituent is a 2-methylbutylamide or isobutylamide. 
Table 2.3.  MS/MS Analysis of Echinacea alkylamides. Fragments produced by collision-induced 
dissociation of selected parent ions and their suggested structures are shown 
Designation, name,  m/z 
 
group i 
4 
 
RI
3
 30-
90% 
 
group ii 
5 
 
RI 30-90% 
 
group iii 
6 
 
RI 60-100% 
  
group iv 
7
 
 
RI 26-100% 
 
group v 
8
 
RI < 3-
20% 
D 
244
1 
Undeca-2E,4Z-diene-
8,10-diynoic acid 2-
metylbutyl amide 
157 129 131 174 
188,202
, 
216 
E 
244 
Undeca-2Z,4E-diene-
8,10-diynoic acid 2- 
methylbutylamide
2
 
157 129 131 174 
188,202
, 
216 
F 
244 
Dodeca-2Z,4E-diene-
8,10-diynoic acid 
isobutylamide 
171 143 145 188 
202, 
216 
G 
244 
Dodeca-2E,4Z-diene-
8,10-diynoic acid 
isobutylamide 
171 143 145 188 
202, 
216 
P 
258 
Trideca-2Z,7E-diene-
8,10-diynoic acid 
isobutylamide 
185 157 159 202 216,230 
Q 
258 
Dodeca-2E,4Z-diene-
8,10-diynoic acid 2-
methylbutylamide  
171 143 145 188 
202, 
216 
 
1. The number beneath the letter designation indicates the m/z value for the MH+ ion. 
2. Proposed structure for compound E based on retention time and MS/MS fragmentation.  
3. RI corresponds to relative Intensity. 
4. The group i fragments correspond to acyllium ions as shown in Figure 2.2. 
5. The group ii fragments are carbocations that correspond to the alkyl chain of the alkylamide and are 
formed by loss of the amide portion (isobutylamide or 2-methylbutylamide). 
6. The group iii fragments correspond to the alkyl chain of the alkylamide and are formed by the loss of the 
amide portion of the molecule and saturation of one of the double bonds on the akyl chain.  
7. The group iv fragments correspond to the protonated alkylamide minus the N-alky group 
8. The group v fragments correspond to the protonated alkylamide minus various portions of the N-alkyl 
group (see Figure 2.2)
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2-methylbutyl amides Isobutyl amides 
  
  
  
Figure 2.2. D, E, F, G, P Q. MS/MS Spectrum of Isomeric Alkylamides.  The above Diagrams illustrate the utility of MS/MS 
under low-energy collisional induced dissociation. This generates a characteristic pattern of relatively few primary fragments 
that are 1) structurally diagnostic; 2) easily interpreted due to uncomplicated spectra; and 3) have enhanced relative intensity. 
Thus the isomeric alkylamides of MW 244 and 258 (MH+) can be distinguished with ease between isobutyl amides and 2-
methylbutyl amides. In addition the number of carbon atoms in the alkyl moiety is elucidated by the peaks for the acyllium ion 
and the loss of the carbonyl and amide groups. Note that the proposed structure for alkylamide E follows the fragmentation 
pattern of alkylamide D and the elution order of the alkylamides F and G.  
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An example of the utility of MS-MS for structural elucidation of alkylamides can 
be demonstrated for the specific case of alkylamide P, trideca-2E,7Z-diene-8,10-diynoic 
acid isobutylamide.  The MS-MS spectrum of the precursor ion at m/z 258 for this 
compound is shown in Figure 2.2 F.  In Figure 2.2 F, the acyllium ion (group i fragment) is 
present at an m/z value of 185 m/z.  This suggests a thirteen carbon alkyl chain. (An alkyl 
chain with eleven carbons would produce an acyllium ion with m/z 157 and one with 12 
carbons would yield an acyllium ion at m/z 171.)  The group ii fragment at m/z 157 
provides further confirmation of the 13-carbon alkyl chain length. The presence of the 
group iii fragment (m/z 159) indicates that the compound is indeed a diene alkylamide, 
and, further, the characteristic loss of 99 to form this fragment (258-159 = 99) suggests that 
the compound is an isobutylamide rather than a 2-methylbutylamide. The high intensity 
group iv fragment at m/z 202 further confirms that the N-alkyl group is an isobutylamide. 
The low intensity group v fragments also confirm an N-isobutyl group rather than an N-2-
methylbutyl group; additional group v fragments would be observed for a 2-
methylbutylamide.  Thus, based on the MS-MS spectrum (Figure 2.2F) the identity of the 
compound is proposed to be  trideca-2E,7Z-diene-8,10-diynoic acid isobutylamide, which 
has previously been shown to occur in E. pallida, but rarely is reported as occurring in E. 
purpurea (Bauer and Remiger, 1989). It should be noted that the MS-MS spectra do not 
provide confirmation of E/Z stereochemistry.  The E/Z assignments have been made based 
on comparison of the relative retention times observed in this study with those reported 
previously (Bauer and Remiger, 1989), and are only tentative without NMR confirmation. 
With HPLC-ESI-MS and MS-MS data such as those shown in Figure 2.1 and 
Figure 2.2, all of the previously identified alkylamides from E. purpurea in Tables 2.2 A 
and B except undeca-2E-ene-8,10-diynoic acid isobutylamide (compound C) were 
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identified in the extracts prepared in this study.  Although several papers cite the presence 
of undeca-2E-ene-8,10-diynoic acid isobutylamide in E. purpurea root (Binns et al., 
2002b; Matthias et al., 2005b), this compound was not detected in the echinacea extracts 
used for these studies.  A commercially available standard of this compound was readily 
detectable with limit of detection of 0.15 μM, therefore, it can be concluded that undeca-
2E-ene-8,10-diynoic acid isobutylamide was not present in the extracts at concentrations 
above 0.15 μM.  When selected ion monitoring is used with LC-MS, a peak with m/z 232 
(the MH
+
 ion of 231) is apparent, but it corresponds to the MH
+
 (+ 1) isotope of undeca-
2E,4Z-diene-8,10-diynoic acid isobutylamide (A) and undeca-2Z,4E-diene-8,10-diynoic 
acid isobutylamide (B) (Figure 2.1A).  The presence of this isotope ion may have mislead 
some investigators analyzing echinacea with LC-MS and could be responsible for some 
literature reports of the presence of this compound in E. purpurea (Binns et al., 2002b; 
Hudaib et al., 2002).  Another possible reason for conflicting results concerning the 
presence of undeca-2E-ene-8,10-diynoic acid isobutylamide may be differences in the 
genetics of plant material, or the environmental conditions under which it was grown. 
Binns et al. (Binns et al., 2002a), using solely UV spectra and retention time, identified 
this compound in E. purpurea roots of wild plants but not cultivated germlings. Hence, it is 
possible that some genetic strains of E. purpurea contain undeca-2E-ene-8,10-diynoic acid 
isobutylamide while others do not.  It is also possible that cultivation conditions may result 
in expression patterns different than that for plants surviving in a less controlled 
environment. However, our laboratory has investigated over 20 different US sources of E. 
purpurea and thus far not detected this compound (data not included). Another possibility 
is that previous reports of the presence of undeca-2E-ene-8,10-diynoic acid isobutylamide 
in E. purpurea were due to improperly identified plant material. Another Echinacea 
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species, E. angustifolia, does produce significant levels of undeca-2E-ene-8,10-diynoic 
acid isobutylamide, and the misidentification of echinacea species has often been 
documented (Bauer et al., 1988a; Foster, 1985; Rogers et al., 1998). 
In addition to aiding in structural elucidation of known alkylamides, with HPLC-
ESI-MS it was possible to tentatively identify a new alkylamide, the structure of which has 
not been previously published.  This compound is undeca-2Z,4E-diene-8,10-diynoic acid 
2-methylbutylamide (compound E in Table 2.2A).  Identification of this compound was 
based on rentention time and the correlation between MS-MS fragmentation pattern and 
alkylamide structure. The mass and fragmentation pattern for compound E (Figure 2.2) 
confirms that it is a 2-methylbutylamide, and indicates the level of saturation and length of 
the carbon chain.  The mass spectral data do not indicate stereochemistry or bond position; 
however, relative retention time does suggest that this compound is the 2Z/4E isomer of 
compound D.  For the previously identified alkylamide isomers that vary by the 2E/4Z and 
2Z/4E stereochemistry, such as compounds A/B and F/G, we have demonstrated (Figure 
2.1) that the 2E/4Z isomer elutes before the 2Z/4E isomer.  Thus, it is logical to assume a 
similar relationship in stereochemistry between compounds D and E. However, as noted 
earlier, without NMR confirmation, the reported stereochemistry of this new alkylamide is 
only tentative.   
Bauer et al. previously demonstrated that with reversed phase HPLC, alkylamides 
with terminal alkynes elute early in the separation followed by tetraene alkylamides (Bauer 
and Remiger, 1989). For the purposes of this discussion, compounds A-G, J, P and Q are 
designated as polyacetylene amides (A-E and P are also known as terminal alkynes), while 
the term “tetraenes” refers to the isobutyl amide isomeric compounds K (dodeca-
2E,4E,8Z,10E-tetraenoic acid), L (dodeca-2E,4E,8Z,10Z-tetraenoic acid) and M (dodeca-
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2E,4E,8E,10Z-tetraenoic acid ) which contain for alkene groups in their fatty acid moiety.  
As shown in Figure 2.1, the observed elution orders for alkylamides in our study are 
consistent with those published by Bauer. The polyacetylene amides  as a group (A, B, C, 
D/E, F/G, H, J, P, Q) elute early in the separation, between 25 and 31 minutes, followed by 
the tetraenes (K, L and M, N, O).  These findings are significant in that alkynes, 
specifically 8,10 terminal alkynes, have been shown to modulate CYP 450 function 
(Matthias et al., 2005b), while tetraene isomer L and alkylamides N and O are ligands of 
the CB2 receptor (Raduner et al., 2006).  The results in Figure 2.1 suggest preparatory 
scale HPLC could be used to separate groups of alkylamides with differing physiological 
and pharmacological activity. 
 
Method Validation 
 
Table 2.4 illustrates the linear regression equations and statistical data for the 
alkylamide standards. Calibration curves were plotted as area of the selected ion 
chromatogram for the protonated alkylamide versus concentration. The linear range of the 
calibration curves was from 3 to 100 µM, except for dodeca-2,4-dienoic acid 
isobutylamide (compound O) which demonstrates lower sensitivity with this analytical 
method than do the other alkylamides. The linear range for this compound was 5 -500 µM. 
Correlation coefficients (R
2
) of the alkylamide standards ranged from 0.996-1.000.  The 
limit of detection (concentration required to give a signal to noise ratio, S:N, of 3:1) for 
isobutylamides dodeca-2E-ene-8,10-diynoic acid, dodeca-2,4,8,10-tetraenoic acid and 
dodeca-2E,4E-dienoic acid were 0.051, 0.99 and 1.2 μM respectively.  Limits of 
quantitation (based on S:N of 10:1) were 1.7, 3.3 and 4.1 μM, respectively.  Repeatability, 
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which was assessed by calculating the standard deviation for triplicate injections of the 
same extract, ranged from 0.2 to 0.5 for all compounds quantified.  It should be noted that 
for these studies, all samples that were quantitatively compared were analyzed on the same 
day by the same operator in a single run.  Therefore, the repeatability of the method is a 
true measure of the limitations of the method for quantitative comparison, and there can be 
no concern that differences in instrumental response from run to run (poor reproducibility) 
were responsible for any of the differences in alkylamide quantity described in the 
following sections. 
In order to keep the analysis of the alkylamides in linear range of detection, 10, 100 
and 1000 fold dilutions were necessary, depending on the alkylamide of interest. 
Quantitative analysis was possible only for the alkylamides that were available as 
standards, which at the time of the analysis included compounds C, J, the tetraenes (K,L 
and M) and compound O. Alkylamide C is not listed in Table 2.4 because it was not used 
for quantitation, as this particular alkylamide could not be found in the extracts 
investigated. 
Table 2.4. Calibration Parameters and Repeatability for Quantification of Alkylamides 
Isobutylamide 
Slope 
(±SE
a
) 
Intercept 
(±SE
a
) 
R2 
Linearity 
(in µM) 
Repeatability 
Limit of 
Detection 
(in μM) 
Limit of 
Quantitation 
(in μM) 
Dodeca-2E-ene-
8.10-diynoic acid 
2.93 x107 
(±1.3 x106) 
2.0 x 108 
(±1.3 x 108) 
0.996 
0.100 – 
100 
0.5 
 
0.051 1.7 
Dodecatetraenoic 
acid 
4.447 x106 
(±2.8 x104) 
3.3 x 106 
(±1.4x 106) 
1.000 
1.0 – 
100 
0.2 
 
0.99 3.3 
Dodeca-2E,4E-
dienoic acid 
4.386 x104 
(±2.2 x102) 
1.95 x 105 
(±6.4 x 104) 
1.000 
10.0 – 
500 
0.2 
 
1.23 4.1 
a.  SE – Standard Error 
b. Repeatability is calculated as the standard deviation of the calculated concentration for triplicate injections 
of the same sample within a single analysis.   
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Comparison of alkylamide yield in various E. purpurea extracts 
 
Three extracts were chosen for comparison of alkylamide content.  One of these 
was prepared from fresh E. purpurea roots using 1 g roots for every 2 mL of solvent.  This 
extract is designated “fresh 1:2” in Table 2.5, consistent with the convention for expressing 
plant:solvent ratios in the dietary supplements industry.  The other two extracts were 
prepared from dry E. purpurea roots with different ratios, one using 1 g dried roots per 11 
mL solvent (1:11) and the other1g dried roots per 5 mL solvent (1:5).  As demonstrated in 
Table 2.1, all of three extracts contain the same percentage of ethanol (69%).  The extracts 
differ only in the nature of starting material (fresh or dry root) and the ratio of root:solvent.  
Once the mass of the fresh roots is adjusted to account for water content, the fresh 1:2 and 
dry 1:11 extract have equivalent ratios of dry weight plant material:mL solvent (Table 2.1). 
Therefore, by comparing the composition of the fresh 1:2 and dry 1:11 extracts, it should 
be possible to determine how extract composition differs depending on whether fresh or 
dried roots are used for extraction.  The two extracts prepared from dried E. purpurea 
differ only in the ratio of g root:mL solvent (1:11 versus 1:5), therefore, by comparing the 
composition of the dry 1:11 and dry 1:5 extracts, it should be possible to determine 
whether changing the root:solvent ratio has an effect on extract composition.  
Utilizing available alkylamide standards, the quantities of particular alkylamides in 
the fresh and dry E. purpurea root extracts were determined. Table 2.5 displays these 
results in terms of concentrations of the isomeric tetraenes (compounds K, L and M), 
dodeca-2E,4E-dienoic acid isobutylamide (compound O) and dodeca-2E-ene-8,10-diynoic 
acid isobutylamide (compound J) per mL of solvent. The three different Echinacea 
extracts, fresh 1:2, dry 1:11 and dry 1:5, all contained detectable amounts of these 
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alkylamides.  However, as shown in Table 2.5, the dry 1:5 extract contained the greatest 
amount of these compounds.  This is to be expected given the lower ratio of g roots:mL 
solvent used in the preparation of the 1:5 extract.   
One notable result from the quantitative analysis of akylamide content shown in 
Table 2.5 is that the concentrations of compound O (dodeca-2E,4E-dienoic acid 
isobutylamide) are similar to the concentrations of tetraenes. Previous investigations have 
not reported dodeca-2E,4E-dienoic acid isobutylamide as a major constituent of E. 
purpurea root (Binns et al., 2002b; Qu et al., 2005; Wills and Stuart, 1999).  The 
importance of this compound may have been overlooked due to poor sensitivity of various  
Table 2.5. Quantification of Alkylamides K, L & M; O; and J in Ethanolic Extracts of E. purpurea 
root. 
Concentrations are recorded in mM and mg/mL except in the case of compound J, for which concentrations 
are expressed in μM and µg/mL.  
Extract Concentration of 
Type Alkamides K, L & M  
 mg/mL mMa SDb 
Fresh 1:2 1.9 
e
7.6 1.0 
Dry 1:11 2.1 
e
8.3 0.5 
Dry 1:5 6.9 28.0 5.0 
 ConcentratIon of  
 Alkamide O 
 mg/mL mMa SDb 
Fresh 1:2 1.8 
c
7.1 3.7 
Dry 1:11 2.1 
d
8.4 2.0 
Dry 1:5 6.2 25.0 5.7 
 Concentration of 
 Alkamide J 
 μg/mL μM
a
 SD
b
 
Fresh 1:2 6.17 
c
25.2 2.5 
Dry 1:11 9.2 
f
37.4 1.0 
Dry 1:5 15.6 63.4 2.8 
a.  The mean concentration was calculated for four replicate extractions 
b.  SD represents standard deviation of the concentrations in mM (μM for J). 
c.  Represents statistically significant difference as compared to the 1:5 root extraction, p <0.05 
d. Represents statistically significant difference as compared to the 1:5 root extraction, p <0.01 
e. Represents statistically significant difference as compared to the 1:5 root extraction, p <0.005 
f. Represents statistically significant difference as compared to the 1:2 root extraction, p <0.001 
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analytical methods to this particular compound (Woelkart et al., 2005a).  The finding that 
dodeca-2E,4E-dienoic acid isobutylamide is a major constituent of E. purpurea may be of 
future significance given that this compound, like the tetraene isomers, is known to be a 
CB2 ligand (Gertsch et al., 2004; Raduner et al., 2006; Woelkart et al., 2005b).  
In order to easily compare how efficiently alkylamides were extracted in the three 
different E. purpurea extracts, the quantity of each alkylamide (mg) was divided by the dry 
weight of E. purpurea root (g) used to prepare an equivalent volume of extract.  The 
resulting value is referred to as “alkylamide yield” (Figure 2.3).   
As discussed previously, the only difference in the fresh 1:2 versus the dry 1:11 
extracts is whether fresh or dry root was used in their preparation.  Therefore, assuming no 
loss of alkylamide during the drying process, alkylamide yield would be expected to be 
very similar for these two extracts.  Indeed, the alkylamide yield for the fresh 1:2 versus 
the 1:11 were comparable for the tetraenes (K, L and M-Figure 2.3A) (20.4 +2.8 vs. 22.2 
+1.5 mg/g, respectively) and compound O (Figure 2.3B- 19.4 +1.7 vs. 22.6 +1.1 mg/g, 
respectively).  For alkylamide J, the yield was somewhat lower in the 1:2 extract as 
compared to the 1:11 extract (0.0667 + 00.0067 vs. 0.0989 + 0.0027 mg/g, respectively).  
This difference could be due to differences in particle size between the extracts, which may 
have given rise to slightly more efficient extraction in the dry as compared to the fresh 
extract.  Importantly, comparison of alkylamide yield for the 1:2 and 1:11 extracts does not 
indicate any significant degradation of alkylamides due to drying.  The extracts in this 
study were prepared from roots immediately after completion of oven drying.  Kabganian 
et al. (2002) came to the same conclusion finding no degradation of alkylamides in roots 
that were oven dried. Whether or not there is a loss in alkylamide content in E. purpurea 
roots stored for long periods of time would be a worthy subject of a future investigation.   
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In comparing the extraction yield of the alkylamides between the 1:11 versus 1:5 
dry root extracts, a logical prediction, provided a 1:5 extract is not saturated, would be that 
the alkylamide yield would be the same in the two extracts. As can be seen in Figure 2.3, 
however, this is not the case.  While alkylamide yield is similar in the two extracts, there 
are statistically significant differences, and the nature of these differences varies depending 
on the alkylamide examined.  For alkylamides K, L, M and O (Figure 2.3 A and B), 
extraction is more efficient in the 1:5 as compared to the 1:11 extract.  This is the opposite 
of what would be expected if the solution were saturated in the case of the 1:5 extract; 
therefore, saturation is not the cause of the differences.  Conversely, for alkylamide J, 
extraction is more efficient in the 1:11 extract than the 1:5 extract (Figure 2.3C).  Previous 
studies have established that solvent interactions of N-alkylamides differ depending on 
molecular structure (Liu and Murphy, 2007; Martińez et al., 2002) and the surrounding 
phytochemical matrix (Liu and Murphy, 2007). Therefore, it is plausible that extraction of 
certain alkylamides is favored in more dilute extracts, while concentrated extracts favor the 
extraction of structurally different species. 
 
Comparison of yield of dissolved solids in various E. purpurea extracts 
  
Although the analysis of alkylamides is particularly relevant due to their 
pharmacological importance, it was also of interest to provide a broader perspective on 
how composition of E. purpurea root extracts differs depending on extraction conditions.  
This was accomplished by comparing the amount of total dissolved solids in the three 
extracts described in Section 3.3.  The quantity of total dissolved solids is determined by 
removing the solvent from the extract and weighing the residue.  The resulting mass is a 
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measure of how much material overall (alkylamides as well as other compounds) was 
dissolved in the original extract. When the mass of dissolved solids is divided by the dry 
weight of the plant material used to produce an equivalent volume of extract, the resulting 
value is referred to as “extract yield.”  The extract yield is a measure of how much of the 
initial starting material was converted into extract. 
Figure 2.3 displays the extract yield (mg dissolved solids/g dry root) for the three 
E. purpurea extracts under investigation.  Overall, the extract yield was similar for all three 
extracts.  However, the yield for the fresh root extract (196.6 ± 2.7 mg/g.) was slightly 
lower than the two dry root extracts (269 ± 12 and 290 ± 24 mg/g for the 1:11 and 1:5 
extracts, respectively, p < 0.001).  As mentioned previously, a similar effect was observed 
for alkylamide yield.  Again, this difference could possibly be attributed to differences in 
particle size in fresh versus dry extractions.  Between the two dried extracts, there was no 
statistically significant difference in extract yield.  This similarity between 1:11 and 1:5 
extracts indicates that it is possible, by doubling the quantity of root used for the 
extraction, to double the amount of material dissolved in the solvent, at least up to a ratio 
of 1:5.  It should be pointed out that because of the greater amount of root used to prepare 
the 1:5 extract, this extract does, overall, contain a greater concentration of dissolved solids 
then the 1:11 extract.  However, there is no significant difference between the two extracts 
when the amount of dissolved solids is expressed relative to the mass of root used in the 
extract. 
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Figure 2.3. A,B,C. Comparison of alkylamide concentrations in fresh 1:2, dry 1:11 and dry 1:5 E. purpurea 
root ethanolic extracts.   Each panel represents a different set of alkylamides, with the tetrane isomers 
dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide and dodeca-2E,4E,8E,10Z -tetraenoic acid 
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isobutylamide (alkylamides K, L & M) displayed in Figure 2.3A, dodeca-2E,4E-dienoic acid isobutylamide 
(alkylamide O) in Figure 2.3B, and dodeca-2E-ene-8,10-diynoic acid isobutylamide (alkylamide J) in Figure 
2.3C. As illustrated a higher concentration of tetraenes and dodeca-2,4-dienoic acid (alkylamide O) results 
from the 1:5 vs. the 1:11 root extracts, but this is limited to ≈36% and 28% increase respectively, despite 
extracting twice the plant material. However, for dodeca-2E-ene-8,10-diynoic acid isobutylamide 
(alkylamide J), the 1:11 extraction appears to be more efficient than the 1:5 with a 20% increase in extraction 
efficiency. The fresh root extractions (1:2) appear to be roughly equivalent to the dry 1:11 extractions, except 
for alkylamide J. Note that the tetranenes and alkylamide O occur in similar concentrations in these extracts. 
All concentrations represent the mean from four replicate extractions at room temperature. Error bars denote 
SEM. Comparisons were made between Fresh 1:2, Dry 1:11 and 1:5 extracts, with * indicating p<0.05; ** 
indicating p<0.005; and *** indicating p<0.001 
 
Extraction of the tetraene isomers as a function of maceration time 
 
Lastly, the quantity of the isomeric dodeca-2,4,8,10-tetraenoic acid isobutylamides 
present in a macerating E. purpurea extract against time was measured (Figure 2.5).  The 
results are all displayed relative to that achieved on the first day that concentration was 
measured (day 2). These tetraene isobutylamides are significant because they typically 
compose from 30 – 70% of the total alkylamides in echinacea products (Modarai et al., 
2007). The results in Figure 2.5 demonstrate that the extraction of the dodeca-2,4,8,10-
tetraenoic acid isobutylamides  is complete by day 2. Thus, in terms of the extraction of 
specifically these compounds, maceration beyond day 2 should not be necessary. While 
commonly used long maceration times seem to have little effect on alkylamide content, 
long maceration times could actually be detrimental if some compounds degrade during 
maceration.  Future investigations of the optimal maceration time for producing an extract 
with maximal concentrations of all desirable constituents are warranted.  
Thus far, we are unaware of any other reports comparing extraction efficiency of 
fresh and dry root ethanolic extractions of E. purpurea. Previous work by Gafner et al. 
(2005) has found that a heat treatment in the initial stage of extraction (70 
○
C for 30 min) 
of fresh E. purpurea aerial parts decreases the enzymatic degradation of the tetraenes as 
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well as the caffeic acid derivatives. As a result, this was found to improve extraction 
efficiency.  
 
 
Figure 2.4. Yield of dissolved solids in ethanolic extracts of Echinacea purpurea roots. 
Mass of dissolved solids was determined by evaporation of the ethanol/water solvent from aliquots of 
extracts, and this value was ratioed to the quantity of root (dry weight) used to prepare an equivalent volume 
of extract to calculate dissolved solids yield. Yield of dissolved solids in the 1:11 extraction does not 
statistically differ from 1:5 extraction. The fresh root extraction (1:2) differs from the 1:11 and the 1:5 
extraction by 26.8% and 32.4% respectively. *indicates p<0.005 ** indicates p<0.001.    
 
Ultimately, extraction efficiency depends on extraction conditions, the constituent or group 
of constituents in question, the plant part and whether the starting plant material is fresh or 
dry. 
 
Discussion 
The previous data reports the alkylamide content of ethanolic extractions from 
fresh versus dry root and dry 1:11 versus dry 1:5 (root:menstruum) E. purpurea. We report 
relatively no differences in the extraction of alkylamides in fresh versus dry 1:11 E. 
purpurea root ethanolic extraction and variable gains in concentrations of alkylamides for 
only the tetraene isomers J, K & L (dodeca-2E,4E,8Z,10E/Z-tetraenoic acid & the newly 
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identified dodeca-2E,4E,8E,10E-tetraenoic acid isobutylamide) in dry 1:5 versus dry 1:11 
ethanolic extraction. Thus far, we are unaware of any other reports comparing different 
strengths of dry root ethanolic extractions. Previously, differences have been found in the 
extraction of fresh versus dry plant echinacea. Sun et al. (2002) utilizing a supercritical 
extraction technique found about 3.5 fold increases in alkylamide extractions from dry 
versus fresh E. angustifolia. It should be noted though, that the use of carbon dioxide with 
significant pressure (>34 MPa) affords significantly different extraction conditions. This 
technique is not practiced by the majority of the manufactures in the natural products 
industry. A past analysis of fresh versus dry echinacea extractions by Stuart et al. (2004) 
found a significant difference in extraction of polysaccharides in fresh versus dry E. 
purpurea, perhaps partly because of degradation of the polysaccharides in dry plant 
material but, alkylamide content was not assessed.  
 
Figure 2.5. Relative concentration of dodecatetraenoic acid isobutylamides (alkylamides K, L and M) in an 
E. purpurea root extraction over time.  Relative concentrations were calculated by dividing the concentration 
of each sample by the concentration at day 2 and converting to percent.  Samples were taken daily over 28 
days from dry root (1:11) ethanolic maceration of E. purpurea. Results show that maximal extraction of 
dodecatetraenoic acid isobutylamide is achieved by day 2. 
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In addition, these data show for the first time that alkylamide extraction from E. 
purpurea root is not improved by longer steeping times in ethanolic macerations. The 
tetraene extraction from E. purpurea radix is complete by day 2 (Figure 2.5). Curiously, it 
appears that this conclusion had already been realized by previous generations: The 
nineteenth edition of the United States Dispensatory (Wood et al., 1907), the 1942 
National Formulary (Committee On The National Formulary VII, 1942) and the 1961 
Remington’s Practice of Pharmacy (Remington, 1961) state that the appropriate time for a 
macerating tincture of medicinal plant to steep was 3 days or until the soluble matter is 
dissolved. Many manufacturers of medicinal plant products, as well as phytotherapists, 
currently suggest that the appropriate time for a maceration to steep is 2 – 4 weeks, 
depending on the part of the plant. According to the above results, this could be excessive. 
Due to the poor stability of the Echinacea spp. phenylpropanoids (caftaric acid, cichoric 
acid, cinnamic acid, echinacoside etc.) in alcohol (Gafner and Bergeron, 2005; Livesey et 
al., 1999), longer steeping times may produce inferior products due to the oxidation of 
these constituents (Livesey et al., 1999). Considering that the lipophilic constituents are 
generally the least extractable by ethanol and that the tetraenes are lipophilic and appear to 
be fully extracted in 2 days, the suggestion by manufacturers that the strength of an 
echinacea maceration improves due to longer steeping times needs to be reconsidered. 
Furthermore, if upcoming research elucidates in vivo phenylpropanoid mediated immune 
or antioxidant activity, reconsideration of the shelf life of echinacea products may prove 
advantageous to optimizing the pharmacological activity of these remedies. More research 
is needed on the optimization of echinacea and other medicinal plants extractions.  
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These results demonstrate that extraction of particular alkylamides is more efficient 
when the ratio of solvent to plant material is smaller, as in the case of the fresh root 1:2 or 
dry root 1:11 extractions as compared to the dry root 1:5 extraction. This suggests that 
increasing the ratio of plant to solvent does not necessarily result in an extract with all 
alkylamides represented. Accordingly, we show that increasing the ratio of root to solvent 
changes the qualitative profile (and expectedly, the quantitative profile) of alkylamides 
present in an ethanolic extraction. This may be significant because differing alkylamides 
have demonstrated different activities; cannabinoid activity (Gertsch et al., 2006; Gertsch 
et al., 2004; Matovic et al., 2007; Muller-Jakic et al., 1994; Raduner et al., 2006; Woelkart 
et al., 2005b), lipoxygenase activity (Merali et al., 2003; Muller-Jakic et al., 1994), 
cyclooxygenase activity (Muller-Jakic et al., 1994), fungicidal activity (Merali et al., 2003) 
and antiviral activity (Hudson et al., 2005; Vimalanathan et al., 2005). 
Consequently, the qualitative chemical character of ethanolic extracts needs to be 
considered when investigating biological activity of complex chemical extracts such as 
echinacea remedies. The generally agreed upon observation that several constituent groups, 
besides the alkylamides, are responsible for the pharmacological activity of echinacea 
(Bauer, 1998; Islam and Carter, 2005; Vimalanathan et al., 2005) and the lack of clinical 
studies undertaken with pure compounds (until recently), beyond a preliminary 
investigation with polysaccharides (Melchart et al., 1993), create a situation where the 
native extracts of echinacea must still be regarded as the “active principles” (Bauer et al., 
2005). Thus, biological activity of dilute versus concentrated tinctures may vary beyond 
just what might be expected for a more concentrated product.  
The above issues exponentially add to the challenge at hand in research 
laboratories, clinical settings and commerce in regard to extractions of medicinal plants: 
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The extraction of bioactive phytochemicals in a complex phytochemical matrix is 
inherently difficult to investigate in terms of extraction, stability, degradation, and 
ADMET (absorption, distribution, metabolism, excretion and toxicity) properties.  
 
Summary 
 
With these investigations, it has been demonstrated that HPLC-ESI-MS is an 
excellent technique for comprehensive analysis of alkylamides from Echinacea purpurea. 
Using HPLC-ESI-MS, a more comprehensive alkylamide profile was obtained than is 
typically possible with other analytical approaches.  By relying on collisionally induced 
dissociation, it was possible to distinguish between isomeric alkylamides, and to 
tentatively identify a new E. purpurea alkylamide, undeca-2Z,4E-diene-8,10-diynoic acid 
2-methylbutylamide.  
All three extraction techniques investigated here (fresh 1:2, dry 1:5 and dry 1:11) 
resulted in very similar alkylamide profile, and gave similar yields of alkylamides and of 
total dissolved solids. The similarity in alkylamide content in fresh 1:2 and dry 1:11 
extracts indicates that drying of root material at 50 °C does not result in a loss of 
alkylamides.  It appears that either fresh or dried roots can be used to prepare extracts with 
high alkylamide content, although the overall yield was slightly lower for fresh extracts.  
Lastly, the analysis of a 1:2 fresh root ethanolic extract suggest that the maximum 
concentration of the tetraenes (dodecatetraenoic acid isobutylamides) is achieved by day 2 
in an ethanolic extraction.  
Although alkylamide yields were, overall, similar with the three extraction 
techniques, there were some statistically significant differences in quantities of 
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alkylamides extracted.  Notably, several alkylamides quantified (the isomeric tetraenes and 
dodeca-2,4-dienoic acid isobutylamide) were extracted more efficiently with a root to 
solvent ratio of 1:5 (w:v) as compared to a ratio of 1:11, while another alkylamide (dodeca-
2E-ene-8,10-diynoic acid isobutylamide) was extracted more efficiently with a ratio of 
1:11. Given that the biological activity of alkylamides differs depending on structure, these 
suggest that pharmacological activity of Echinacea purpurea extracts could differ 
depending on the ratio of root:solvent used in extraction. Ultimately, in vitro and in vivo 
studies are needed to elucidate the differences in pharmacokinetic and pharmacodynamic 
activity of various Echinacea extracts. The results presented in this paper do, however, 
suggest that it would be erroneous to assume that all ethanolic extracts of Echinacea 
purpurea result in equivalent phytochemical profiles. 
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Chapter 3 
 
An HPLC-ESI-MS evaluation of the stability of 
alkylamides in ethanolic extract, cut/sift and powdered E. 
purpurea root 
 
Introduction 
 
Recent sales of medicinal plant products in the U.S. reached 4.8 billion dollars 
(Cavaliere et al., 2009). The National Health Interview Survey estimates that 10% of the 
US population, about 29 million Americans, uses herbal products (Pleis and Lethbridge-
Cejku, 2006). A significant portion of these products come in either powdered form (in 
bulk or in capsules), cut and sift (cut/sift-small cuttings of plant material sold in bulk) or 
ethanolic extracts. Regardless of the form of plant material purchased ultimately, much of 
this material becomes galenic ethanolic extracts, prepared by maceration or percolation of 
the starting plant material in a variable ratio of ethanol and water depending on plant 
species, plant part and manufacturing practices. While there is little research that elucidates 
the stability of herbal products, some have suggested that the shelf life of these products is 
unlimited (Low Dog, 1991). Of the investigations that have been done, in some cases 
shelf-lives of less than 6 months have been reported for popular herbs in ethanolic extract 
form (Bilia et al., 2002a). Unfortunately, storage conditions are a commonly unassessed 
and unreported factor in research assessing medicinal plant efficacy, leaving a gap in the 
assessment of the research on medicinal plants and a possible explanation for 
inconsistencies in outcomes in such popular herbal remedies such as Echinacea spp. 
Echinacea products reach sales well over U.S. 15 million in 2008 (Cavaliere et al., 
2009) and 182.9 tons of echinacea were wild harvested in 2004 (American Herbal Products 
Association, 2007).  Echinacea spp., are now grown in Austria, Germany, Russia, New 
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Zealand, Ukraine, Yugoslavia, and the Republic of South Africa (Letchamo et al., 2002), 
as well as in Australia, where the annual production is more than 40 tons (Stuart et al., 
2004). Additionally, Asia, Latin America and the Middle East are involved in cultivation, 
processing and marketing of Echinacea (Letchamo et al., 2002). E. purpurea is the 
dominant species used in global production representing 80% of commercial production 
(Li, 1998).  
Currently it is known that of the constituents considered active in E. purpurea 
products, alkylamides, phenylpropanoids, polysaccharides, and glycoproteins (Bauer, 
1996, 1998), that not all of these constituents are stable in ethanolic extracts.  As 
mentioned in Chapter 2, in ethanolic extractions above 40%, there are very few 
polysaccharides left in suspension and denaturing of proteins is expected (Dalby-Brown et 
al., 2005), however these compounds extract well in glycerin (Bergeron and Gafner, 2007) 
but are unstable in fresh plant material (Stuart et al., 2004). The phenylpropanoids (caffeic 
acid derivatives such as cichoric acid (2R,3R-dicaffeoyl tartaric acid) (Bauer et al., 2001; 
Hudec et al., 2007) are antioxidants known to be highly efficient (Hudec et al., 2007) and 
active in immunological assays (Bauer, 1999; King et al., 1999; McDougall et al., 1998; 
Nusslein et al., 2000). These, constituents are known to degrade rapidly in both cut/sift and 
ethanolic extracts depending on the form of the preparation (Gafner and Bergeron, 2005; 
Stuart and Wills, 2000). Accordingly of the four constituents considered active in E. 
purpurea the only remaining constituent after a few weeks on the shelf in ethanolic 
extracts are the alkylamides.  
Thus far, of the constituents considered active in Echinacea spp. pharmacokinetic 
studies suggest that alkamides are the predominant constituent circulated in human plasma 
(Matthias et al., 2005; Woelkart et al., 2006) although in vitro investigations of 
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immunological activity have suggested multiple active constituents of Echinacea spp. 
(Bauer, 1998).  A recent small trial (n = 8) of the pharmacokinetics of E. purpurea (95% 
herb, 5% root) demonstrated that the alkylamides from the tincture (65% ethanol) were 
shown to be more bioavailable than from the capsule. However, equivalent immune 
activity was shown for both preparations (Woelkart et al., 2006).  
The stability of the highly unsaturated alkylamides in Echinacea spp. are an issue 
that has yet to be adequately addressed, especially considering that they are likely to 
oxidize (Bauer et al., 1988; Livesey et al., 1999). Specific to the alkylamides in E. 
purpurea root, Stuart and Wills (2000) suggest stability of various alkylamides in dry root 
and aerial material at 20 °C for 4 months, while Livesey et al.(1999) suggest stability up to 
7 months regardless of temperature (-20, 25 or 40 °C) of the isomeric dodeca-2,4,8,10-
tetraenoic acid isobutylamides from roots. Conversely, Rogers et al. (1998) found levels of 
alkylamides fell by 16% over 8 weeks. Perry et al. (2000) found a decline in alkylamide 
over 16 months storage regardless of temperature (-18 & 24 °C) with the degree of 
degradation depending on the molecular species of alkylamide. Finally, McCann et al. 
(2007) demonstrated an increase of various alkylamides in E. purpurea at -20 over two 
year’s time. Considering the previous data there appears to be a wide variance in results for 
the stability of the alkylamides.  
As for the stability of the alkylamides in medicinal plants whether in ethanolic 
extracts, powder or cut/sift, the few investigations that have examined the stability of these 
fatty acid derivatives offer conflicting information on their stability. Although Bohlmann 
(1973) suggested over 3 decades ago that alkylamides were unstable in medicinal plants, 
Stuart and Wills (2000) suggest that the alkylamides are stable in ethanolic extracts at 20 
°C for 4 months in E. purpurea radix. Livesey et al. (1999) suggests stability up to 7 
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months at -20 °C, 25 or 40 °C in the E. purpurea root of the lipophilic constituents with an 
80% decrease under the same conditions of the cichoric acid. Kabganian et al. (2002) 
found that the isobutylamides undeca-2E-ene-8,10-diynoic acid and the isomers of dodeca-
2,4,8,10-tetraenoic acid (the tetraenes) in the roots of E. angustifolia, dried from 23 to 60 
°C, were stable. while McCann et al. (2007) found an increase in alkylamide 
concentrations in E. purpurea, but no change in E. angustifolia and E. pallida. 
Conversely, in powdered root of E. purpurea root the tetraenes degraded by 80% 
over 7 months at 24 °C and a 95% reduction was observed at 40 °C (while the cichoric 
acid did not) compared to samples at -18 °C (Livesey et al., 1999). Perry et al. (2000) 
found that in cut/sift form the dodeca-2,4-ene-8,10-diynoic acid isobutylamide isomers 
were significantly decreased in 48 hours as compared to unchopped roots, but no other 
alkylamides were changed. Rogers et al. (1998) found that E. angustifolia root powder loss 
of 13% in 8 weeks (total alkylamides). Perry et al. (2000) found that concentrations of 
dodeca-2,4-diene-8,10-diynoic acid isomers decreased in cut/sift (48 hr drying time) and 
they reported declines of 80% or more, depending on the alkylamide, in cut/sift root stored 
at 24 °C and  60% declines in alkylamide levels over 16 months at -18 °C. Yang (2008) 
found degradation of the hydroxylated alkylamide, hydroxyl-sanshool, in 80% ethanol 
with a 70% decrease in 24 hours and complete degradation in 4 hours due to UV light 
exposure. Interestingly, these authors also suggested that the taste of huajiao (fruit of 
Zanthoxylum bungeanum or Z. schinifolium), in this case relating to the characteristic 
alkylamide induced tingling sensation, was not significantly changed after one year of 
storage at room temperature (Yang, 2008). In the case of extracts from Echinacea spp. 
traditional healers have suggested that the quality of the extract is proportional to the 
amount of tingling produced by a few drops on the tongue.  
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Of particular concern is that the in vitro immunological activity of E. purpurea 
extracts have been found to change after storage (McCann et al., 2007; Senchina et al., 
2005). This is unfortunate as E. purpurea and E. angustifolia are reported to be one of the 
most frequently used medicinal plants in clinical settings. Of the most commonly 
prescribed drugs in Germany, echinacea preparations have been in the top 200 for a 
number of years (Der Marderosian, 1991). Considering the documented changes in 
immunological effects as well as the global use of echinacea products by laboratories, 
clinicians and consumers and the differing results in the stability studies, there is a need for 
further evaluation of the degradation of the alkylamides of the echinacea species. The 
following data demonstrates the degree of degradation of alkylamides in E. purpurea root 
in various preparations (ethanolic extractions, cut/sift, powder) over one year’s time.  
 
Methods 
 
Preparation of Echinacea purpurea Extracts 
 
E. purpurea roots were cultivated in Grants Pass, OR at Pacific Botanicals and 
harvested in a fresh, dormant state at two years of age. Species verification was performed 
by Richard Cech (Horizon Herbs, Williams, OR). Voucher specimens are available at the 
University of North Carolina Herbarium in Chapel Hill, NC (accession numbers 583416 
and 583417).  Water content was determined to be 74.5% after samples were dried at 50 
°C. To prepare the extracts, roots were washed thoroughly, briefly soaked (5 min) in 70% 
ethanol as a disinfectant, and blown partially dry with compressed air. Approximately 16.6 
g of dried root was added to 83 mL of solvent (74.5% ethanol + 25.5% distilled water) for 
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the 1:5 extractions within 6 hours of drying and within 72 hours of harvest. This 
constitutes a ratio of 1g plant material: 5 mL solvent, hitherto referred to as 1:5. The same 
root material was then stored in powdered or in cut/sift form. One year later the stored 
material was then extracted at 1:5 in the same manner as previously mentioned. All 
extracts were macerated for one month at which time the solvent was removed using a 
hydraulic press. Four replicate extracts were prepared for each extraction (original extract, 
one year aged cut/sift, one year aged powder).     
 
Analysis of extracts  
 
An aliquot of each sample (500 µL) was centrifuged to remove particulate matter 
and the supernatant was run undiluted and diluted (1000-fold) in 75% ethanol and analyzed 
using a validated liquid chromatography-mass spectrometry (LC-MS) method (Spelman et 
al., 2009b). An ion trap mass spectrometer with electrospray ionization source (LCQ 
Advantage, Thermo Finnigan, San Jose, CA) was employed. The solvent gradient and 
instrument conditions have been previously published (Spelman et al., 2009b). All 
analyses for the comparison of cut/sift and powder storage forms against the one year old 
ethanolic extract of E. purpurea root were performed in a single run to minimize 
variability due to fluctuation in instrument response over time.  Quantification was 
accomplished using a validated method  based on alkylamide standards.(Spelman et al., 
2009b)  Calibration curves were generated for available alkylamides (Chromadex, Santa 
Anna, CA) dodeca-2E-ene-8,10-diynoic acid isobutylamide (MW 245.37) and dodeca-
2E,4E,8Z,10Z-tetraenoic acid isobutylamide (MW 247.38) as previously described 
(Spelman et al., 2009b). Calibration curves consisted of concentration ranges of 1.0 to 100 
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µM for the dodeca-2,4,8,10-tetraenoic acid isobutylamides (R
2
 > 0.992) and 1.0 to 500 μM 
for dodeca-2E-ene-8,10-diynoic acid isobutylamide (R
2
 > 0.998). Plant extracts were 
analyzed within 24 hours of pressing (separation of plant material from solvent).  
 
Statistics analysis 
 
The standard error of the mean (SEM) was determined for each set of 
concentrations. Data is expressed as the mean ± SEM and comparison of means was 
conducted using a two tailed t-test for paired data when differences were observed. The 
mean values were considered significantly different if p < 0.05. Statistical analysis was 
performed with Microsoft Excel (2007).  
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Figure 3.1. Quantified Alkylamides in E. purpurea preparations. 
A. Dodeca-2E,4E,8Z,10E-tetraenoic acid isobutylamide (one of 3 isomeric tetraenes) 
B. Dodeca-2E-ene-8,10-diynoic acid isobutylamide (a polyacetylinic alkylamide) 
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Results 
 
Determination of alkylamide identity 
  
Figure 3.1 illustrates the structures of the alkylamides quantified in this study. The 
identity of the isobutylamides dodeca-2,4,8,10-tetraenoic acid (tetraenes, an isomeric 
mixture MW 247.3) and dodeca-2E-ene-8,10-diynoic acid (MW 245.3) were confirmed by 
retention times and MW weights of the standards. A number of other alkylamides for 
which standards were not commercially available were also identified in the E. purpurea 
root extracts. The alkylamide identities in E. purpurea root have been extensively reported 
elsewhere (see Spelman et al., 2009b and Chapter 2).  
 
Quantitative determination and comparison of alkylamide content in one year old 
aged ethanolic extract vs. freshly made ethanolic extract 
 
Figure 3.2 exhibits the data comparing the concentrations of the isomeric tetraenes 
and dodeca-2E-ene-8,10-diynoic acid isobutylamide in the newly made (within 72 hours of 
harvest) vs. the same extract one year later of E. purpurea root extracts. Figure 3.2A shows 
the tetraene concentration at 6.27 mg/mL (± 0.73 mg/mL) in the newly made extract. The 
tetraene concentration, in the aged extract, shows no statistically significant difference. 
Conversely, Figure 3.2B illustrates a substantial loss of the diactylene isobutylamide 
dodeca-2E-ene-8,10-diynoic acid. The newly made extract contained 27.1 μg/mL (± 4.0 
μg/mL) and one year later the concentration of this alkylamide had declined to 13.3 μg/mL 
(± 0.41 μg/mL). 
Chapter 3  Degradation of Alkylamides 
104 
 
 
 
 
 
Figure 3.2. Comparison of alkylamide stability in E. purpurea root ethanolic extracts over one year’s time.  
 
A. Dodeca-2,4,8,10-tetraenoic acid isobutylamides remain at the original concentration after one year’s storage.  
B. Greater loss of alkylamide dodeca-2E-ene-8,10-diynoic acid isobutylamide is observed in the same extract with 
a loss from 27.1 (± 4.0) μg/mL to 13.3 (± 0.41) μg/mL over one year’s storage. All concentrations represent the 
mean from four replicate extractions (dry 1:5) at room temperature displayed in mg/mL (tetraenes) and μg/mL 
(dodeca-2E-ene-8,10-diynoic acid isobutylamide). Error bars denote standard error of the mean (SEM). 
Comparisons are made between newly made extract and one year old extracts with * indicating p<0.05.  
 
Chapter 3  Degradation of Alkylamides 
105 
 
Comparison of alkylamide content in one year old E. purpurea root in cut/sift, 
powder and ethanolic extracts 
 
Figure 3.3 exhibits the percentage remaining of the two quantified alkylamides in 
root samples that were stored at room temperature in the dark. These samples, all 
originating from the same batch of E. purpurea root, were stored as powder, cut/sift and in 
the original extraction. Thus, a comparison is possible for extracts that have aged one full 
year. A substantial loss of tetraenes is seen for both the cut/sift and the powdered root in 
Figure 3.3A. The cut/sift shows a tetraene loss of 42.2% (57.8% ± 3.1% remaining) while 
the powder form has lost 89.2% (10.8% ± 1.3% remaining) of its tetraenes as compared to 
the original ethanolic extraction. Figure 3.3B illustrates a 50.5% (49.5% ± 1.5% 
remaining) loss in the ethanolic extract and 75.7% (24.3% ± 0.23% remaining) and 82.9% 
loss (17.1% ± 0.36% remaining) of dodeca-2E-ene-8,10-diynoic acid in the cut/sift and 
powder, respectively.  
 
Discussion 
 
Bohlmann et al. (1973) initially reported alkylamides to be unstable and this is 
supported by work with the isolates, in which oxidation, photodegradation, isomerization 
and hydrolysis are known to occur under normal storage conditions (Livesey et al., 1999; 
Yang, 2008). However, research has resulted in conflicting data on the stability of 
alkylamides in ethanolic extracts, we show a reduction of alkylamides in all storage forms 
of E. purpurea root investigated; ethanolic extract, cut/sift and powder, with the exception 
of the tetraenes in a dry 1:5 extract. While the presented results for the dry 1:5 ethanolic 
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Figure 3.3. Percentage of alkylamides remaining after one year’s storage in ethanolic extract, cut/sift and 
powdered E. purpurea root.  
 
A. Dodeca-2,4,8,10-tetraenoic acid isobutylamides remaining in cut/sift vs. powdered root is 57.8 (± 3.1)% and 
10.9 (± 1.3) % after one year’s storage, respectively. B.Dodeca-2E-ene-8,10-diynoic acid isobutylamide remaining 
after one year’s storage of extract, cut/sift and powdered root is 49.1 (± 1.5) %, 24.3 (± 0.22) % and 17.1 (± 0.36) 
% respectively.  All concentrations represent the mean from four replicate extractions at room temperature, stored 
at room temperature in the dark. Error bars denote standard error of the mean (SEM). Comparisons were made 
between newly made dry 1:5 extract, one year old dry 1:5 extract and one year old cut/sift and powdered root. 
Comparisons are made between each newly made extract (original) and each bar (one year old extracts for cut/sift 
and powder) with * indicating p<0.05; ** indicating p<0.005. 
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extracts concur with previously published investigations (Perry et al., 2000; Rogers et al., 
1998), they stand in stark contrast to others (Livesey et al., 1999; Stuart and Wills, 2000; 
Wills and Stuart, 2000). The presented results for dry forms of echinacea are comparable to 
other reports on the stability of alkylamides (Livesey et al., 1999; Perry et al., 2000; Wills 
and Stuart, 2000). Though, following the degradation of alkylamides in E. purpurea root in 
various forms over one year, are novel. 
The alkylamides in E. purpurea are mainly derived from undeca and dodecanoic 
amides, with varying degrees of unsaturation and different double bond configurations in 
the alkyl moieties (E/Z).  The alkylamides quantified in these investigations, the tetraenes 
and dodeca-2E-ene-8,10-diynoic acid isobutylamide (Figure 3.1), comprise 60% of the 
total alkylamides in roots of E. purpurea. While in the aerial parts, the tetraenes alone 
constitute about 76% of total alkylamides in E. purpurea, the vast majority from the flower  
(Wills and Stuart, 1999). Other investigations have evaluated the less prominent 
alkylamides (Liu and Murphy, 2007; Perry et al., 2000). Liu and Murphy (2007) showed 
that the undeca-2,4-dienes with a diacetylinic tail degraded faster than the dodeca-2,4-
dienes with acetylenic tails, the triene compound, dodeca-2E,4E,10E-trien-8-ynoic acid, or 
the tetraenes in both dry films and DMSO. Both Perry (2000) and Liu and Murphy (2007) 
reported that the 2-methylbutyl amide, dodeca-2E,4E-diene-8,10-diynoic acid, had the 
slowest degradation kinetics. Of interest, the terminus of the alkyl group, either H or CH3, 
affects the degradation rate. Alkylamides with a polyacetylene alkyl moiety that ends in an 
H degrades faster than the polyacetylene moiety terminating in a CH3. The degradation rate 
of all alkylamides followed apparent first-order reaction kinetics for both Liu and Murphy 
(2007) and Perry et al. (2000).  
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The presented data demonstrates that the olefinic tetraene isobutylamides degraded 
at a lesser rate than the acetylenic isobutylamide dodeca-2E-ene-8,10-diynoic acid in 
cut/sift and ethanolic extract. In the cut/sift the polyacetylene alkylamide measured appears 
to degrade faster than the tetraenes at 42.2 (± 3.1) and 75.7 (± 0.23%) % loss, respectively 
(Figure 3.3). The measured alkylamides in the powdered echinacea root appear to degrade 
at a similar rate. Perry (2000) reports that dodeca-2,4-diene-8,10-diynoic acid 
isobutylamide, a similar structural theme as the measured dodeca-2E-ene-8,10-diynoic acid 
isobutylamide, degraded in 48 hours of drying time (32 °C) as compared to the tetraenes. 
Kabganian et al. (2002) found that the isobutylamides undeca-2E-ene-8,10-diynoic acid 
and the isomers of dodeca-2,4,8,10-tetraenoic acid (the tetraenes) in whole roots of E. 
angustifolia were stable regardless of drying temperatures from 23 to 60 °C over 10 days.  
Although ethanol extracts represent the common solvent used for preservation in 
the natural products industry, differing solvents appear to influence stability for the 
alkylamides (Liu and Murphy, 2007; Martińez et al., 2002). The presented data show a 
50.5% loss of the polyacetylene alkylamide dodeca-2E-ene-8,10-diynoic acid 
isobutylamide, as compared to no loss of olefinic tetraenes in ethanolic extracts (Figure 
3.2). Alklylamides in aqueous or acidic extractions have previously shown to breakdown 
rapidly. Isolated hydroxylated alkylamides in an 80% ethanolic solution are reported to 
degrade by 70% in 24h (Yang, 2008). Conversely, others report that alkylamides were 
stable for 7 months in ethanol (Livesey et al., 1999). McCann et al. (2007) found no 
change in E. angustifolia radix extracts, but an increase in alkylamide concentrations in E. 
purpurea radix. The increase was speculated to be due to solvent evaporation over two 
years. Alkylamides from lyophilized ethanolic extracts of E. purpurea root reconstituted in 
DMSO degraded faster than the dry film of E. purpurea root extracts (Liu and Murphy, 
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2007), while alkylamides in 70% methanol are reported to be stable at least 5 months 
(Gafner and Bergeron, 2005). Perry et al. (2000) suggest that alkylamides are stable in 
acetonitrile for at least 2 years. In regard to laboratory research, considering the solubility 
issues reported for the alkylamides (Cech et al., 2006), this issue should be carefully 
considered in regard to experimental protocols. The commonly used DMSO is not a 
favorable solvent for alkylamide solubility/dissolution perhaps due to its polar nature.   
Besides solvents, various constituents in E. purpurea extracts also appear to 
influence the degradation rate of alkylamides. Previous results have suggested that the 
phenylpropanoids retard degradation of the alkylamides. Cichoric acid, the major 
phenylpropanoid in E. purpurea, and echinacoside, from E. angustifolia have been 
reported to be the most potent antioxidants of the phenylpropanoids (Dalby-Brown et al., 
2005; Pellati et al., 2005). The phenylpropanoids (cichoric acid, caftaric acid, caffeic acid, 
chlorogenic acid) in dry E. purpurea extracts have been reported to retard the degradation 
of the alkylamides as compared to phenylpropanoid free extracts (Liu and Murphy, 2007). 
However, this does not hold true for all solvents. In DMSO extracts, phenylpropanoid rich 
extracts degraded faster than phenylpropanoid-poor extracts (Liu and Murphy, 2007). 
Adding to the complexity, the phenylpropanoid content, common to many medicinal plant 
species, have been reported to vary remarkably in echinacea products, ranging from 0.0 to 
8.3 mg/g  (Wills and Stuart, 1999). This is likely due to wide variations of quality in the 
starting plant material. To complicate matters further, the phenylpropanoids are suggested 
to breakdown quickly during the extraction process (Gafner and Bergeron, 2005; Nüsslein 
et al., 2000), which may facilitate the degradation of alkylamides in ethanolic extracts (Liu 
and Murphy, 2007). These issues should be carefully considered before making blanket 
statements concerning the stability of echinacea products.   
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As previously mentioned, oxidation and hydrolysis of alkylamides are known to 
occur under normal storage conditions (Livesey et al., 1999; Yang, 2008). Hence, an 
interesting direction to explore would be the addition of antioxidants to alkylamides in 
solution. This strategy has been shown to be effective for the stabilization of 
phenylpropanoids in Echinacea spp. but has not been explored for the alkylamides. For 
example, the addition of citric acid, malic acid or hibiscus extract were effective at 
retarding the degradation rates of phenylpropanoids (Bergeron et al., 2002). Ascorbate has 
also been shown to preserve the phenylpropanoids (Nusslein et al., 2000). Retarding the 
degradation of the phenylpropanoids, would logically lead to the stabilization of the 
alkylamides.  
Considering that recent work has demonstrated activity in both the polyacetylene 
alkylamides and the olefinic alkylamides (Raduner et al., 2006; Spelman et al., 2009a), 
these results are of significance to laboratory outcomes and the efficacy of echinacea 
products in the natural products industry. Importantly, the presented data, as well as the 
reviewed data, suggest that prudence must be observed when echinacea extracts are 
evaluated for biological activity due to rapid degradation of particular alkylamides.  
The degradation of key constituents in medicinal plant preparations are not unique 
to echinacea. Other species of medicinal plant extractions have also shown significant loss 
of key constituents. Previous investigations have demonstrated that ethanolic extracts of 
calendula flower (Calendula officinalis), milk-thistle (Silybum marianum), passionflower 
(Passiflora incarnata), hawthorn (Cratagaegus oxycantha), hawkweed (Hieracium 
pilosella) St. John’s Wort (Hypericum perforatum) and artichoke (Cynara scolymus) have 
short shelf-lives (t90; i.e., 10% potency loss from the initial value of a compound) due to 
the degradation of active constituents or marker compounds (Bilia et al., 2002a; Bilia et al., 
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2002b; Bilia et al., 2007). For example, the napthodianthrone compounds hypericin, of 
Hypericum perforatum, have a shelf-life of only 2 months. The flavolignans of silymarin in 
ethanolic extracts; silybin, silychristin and silydianin (Bilia et al., 2002a), and the luteolin 
flavonoids of Cynara scolymus (Bilia et al., 2002b) have shown shelf-lives (25 
○
C) as short 
as three months depending on water content of the extract and/or concentration of the 
extract. Reports for Calendula officinalis and Passiflora incarnata suggest shelf-lives of 4 
and 6 months respectively, as assessed by the flavonoid content (Bilia et al., 2002a). 
Hawthorn is reported to have a shelf-life of only 7 months as measured by 
proanthocyanidin concentrations (Bilia et al., 2007). Besides normal aging processes at 
room temperature, extracts of medicinal plants have been shown to be highly sensitive to 
changes in storage conditions such as humidity, temperature, and light (Kopleman et al., 
2001; Yang, 2008).  
While assuring the quality of medicinal plant preparations is important, attempting 
to quantify the quality of medicinal plant products with 1 or 2 marker compounds does not 
ensure chemical equivalence nor necessarily equivalent pharmacological activity of 
complex extracts (Kopleman et al., 2001).  Gafner and Bergeron (2005) point out that the 
future of understanding these compounds lies in embracing these extracts as patterns of 
chemical information in contrast to more stringent legal requirements based on a single 
marker compound.  Indeed there have been recent attempts at using information theory to 
aid in the understanding of complex extracts (Gong et al., 2003; Liang et al., 2004). And 
since many of the secondary metabolites, considered superfluous to activity, have been 
shown to induce a physiological response, pharmacological understanding of these 
compounds must come from a global view as offered by systems biology or network 
pharmacology.  
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Summary 
 
Medicinal plant extractions are carried out with various methods in the research 
laboratories and the natural products industry and these methods may affect quality. 
Besides handling and extraction methods, solvents used and storage conditions such as 
temperature, exposure to light, co-occurring constituents and the addition of antioxidants 
influence the stability of these preparations. Specifically, in the case of Echinacea 
purpurea the presented data demonstrate that there is a remarkable loss of alkylamides in 
cut/sift and powder forms of root. In addition, there is a 50.5% loss of dodeca-2E-ene-
diynoic acid isobutylamide over 12 months in the ethanolic extracts but the tetraenes are 
stable. These investigations suggest that the best preservation of the alkylamides is in 
ethanolic extracts.  
These data also show that for the ethanolic extracts of echinacea the alkylamides 
are relatively stable as compared to the cut/sift or powdered form of E. purpurea roots. It 
should be noted that a significant portion of herbal products that are not extracted with 
ethanol are stored and sold as powder and cut/sift. The presented results demonstrate that 
storage in powder form and cut/sift results in significant degradation of alkylamides. This 
may result in suboptimal concentrations of alkylamides available for research purposes and 
producing efficacious products. It is reasonable to extrapolate these data to storage of other 
medicinal plant species containing alkylamides with a similar structural theme. 
Stabilization of medicinal plant preparations is key to providing high quality material to 
research laboratories, clinicians and consumers. The presented data suggest that mass 
marketed herbal products should contain a harvest date and a processing date, as well as a 
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shelf-life expiration date. These results emphasize the problems for quality control of 
medicinal plant preparations, in which the biologically active components may be unstable.  
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Chapter 4 
 
Metabolism of the alkylamides in Echinacea spp. by 
Human Liver Microsomes and CYP450 isoforms 
 
Introduction 
 
A large variety of phytochemicals are found in foods, beverages, spices
 
and 
medicinal plants commonly consumed in the human diet. Many of these phytochemicals 
are seen as having a health promoting or disease preventing activity (McCarty, 2004). In 
addition, many of the same phytochemicals are known to change their activity after 
metabolism as well as influence the metabolism of other exogenous agents such as 
pharmaceutical drugs (Ioannides, 1999). Interestingly, the health effects of phytochemicals
 
are still considered debatable despite substantial in vitro, in vivo and epidemiology data for 
many phytochemical groups. Few health claims on
 
such phytochemicals have so far been 
approved by regulatory
 
authorities. Conversely, the scant data on metabolism of 
phytochemicals has spawned a sizable body of literature known as herb-drug interaction, 
and has generated a staunch dogma on the dangers of phytochemical mixtures. This is in 
spite of a long evolutionary precedent of human food sources including substantial 
quantities of medicinal and food plants and their inherent phytochemical mixtures.    
An example of medicinal plants with a long history of human use is the taxa 
Echinacea, which Native Americans introduced to European settlers. Shortly thereafter, it 
became one of the most popular remedies used by the Eclectic physicians for a variety of 
conditions, including  septicemia, typhoid fever and catarrhal conditions of the respiratory 
and reproductive tracts (Felter, 1922; King et al., 1898). Additionally, physicians 
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practicing from the 19
th
 century through the mid 20
th
 century used echinacea to treat other 
infections and counteract venomous snakebites (Barrett, 2003b). Echinacea was included 
in the National Formulary from 1906 until 1950, eventually falling out of favor as 
pharmaceuticals came to dominate clinical therapeutics. Currently, the aerial portion of E. 
purpurea and the roots of E. pallida are approved for colds and infection of the respiratory 
and urinary tracts by the German Commission E (Blumenthal et al., 1998). 
Some of the Echinacea spp. phytochemicals,
 
such as polyphenols, and alkylamides, 
have raised considerable interest for their favorable
 
effects on health and the prevention of 
various diseases. Early research suggests that polyphenols, including the phenylpropanoids 
found in echinacea, have antioxidant activity and may prevent cardiovascular diseases, 
cancers, diabetes, osteoporosis,
 
and neurodegenerative diseases (Hudec et al., 2007; 
Scalbert et al., 2005).  
Alkylamides, although not as widely known, also have considerably broad effects, 
including anesthetic, (Greger, 1984), insecticidal (Greger, 1984; Jacobson, 1948; Jacobson, 
1967; Jondiko, 1986; Meisters and Wailes, 1966; Towers and Champagne, 1988), anti-
parasitic (Douvres et al., 1980; Foster et al., 1996; Lozano et al., 1984) and oncolytic 
(Voaden and Jacobson, 1972), and most recently anti-plasmodial activity (Spelman et al., 
2009a). The alkylamides are also known to have particularly intriguing immunological 
activity (Gertsch et al., 2006; Goel et al., 2002; Maass et al., 2005; Spelman et al., 2009b). 
Consequently, Echinacea spp. preparations are one of the best sellers in the dietary 
supplements industry and regularly prescribed in Germany to boost immune function in 
cases of upper respiratory tract and urinary tract infections (Blumenthal et al., 1998).  
Despite a long history of use in medicine, there is relatively little information on 
the metabolism in mammalian cells of the constituents of Echinacea spp., especially the 
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alkylamides. At the same time, there appears to be a plethora of literature that is suggestive 
of the effects of echinacea on the metabolism of exogenous agents, primarily concerning 
the cytochrome P450 system. 
The bulk of the available data on possible drug-echinacea interactions concerns the 
cytochrome P450s (CYP450), an ancient superfamily of primarily microsomal and 
mitochondrial heme-thiolate proteins. It has been estimated that 400 million years ago a 
dramatic expansion of this enzyme family driven by several factors including the 
introduction of plant allelochemicals into the diet (when aquatic organisms moved to land) 
(Danielson, 2002). CYP 450 genes code for enzymes that play a role in the metabolism of 
drugs and foreign chemicals as well as arachidonic acid metabolism and formation of 
eicosanoids, cholesterol metabolism, bile acid synthesis, steroid metabolism, vitamin D 
and vitamin A metabolism (Nebert and Russell, 2002). CYP450s are crucial in 
understanding the clinical pharmacology of drug interactions in addition to inter-individual 
variability in drug metabolism.  
Though detoxification is a limited aspect of the CYP450 overall function, particular 
families of the CYP450 system (CYP2, CYP3 , CYP4 and CYP6) do play a crucial role in 
Phase I detoxification (Danielson, 2002). Although Phase I detoxification is generally 
associated with hepatic tissue, these enzymes are found in many other tissue types (Nebert 
and Russell, 2002). Reactions such as epoxidation, hydroxylation, heteroatom oxidation, 
and N- or O- dealkylation, are common strategies for the oxidation of generally unreactive 
hydrocarbons (Equation 4.1).  
 
P450[Fe
+3
]-RH + O2 + NADPH + H+ → P450[Fe+3] + ROH + H2O + NADP+ 
Equation 4.1. The catalytic cycle of cytochrome P450 
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The above redox reaction takes place by initial activation by the heme group of 
cytochrome P450 of the oxygen molecule. The first step in the process involves two 
electrons from NADPH being passed to the heme by way of a reductase. These electrons, 
via oxygen, form a molecule of water. The highly charged remaining oxygen is then 
primed to oxidize the substrate.  
Even though, there appears to be abundant literature on the Echinacea spp. effects 
on metabolism through the CYP450 system, in reality there are only 10 papers in the 
primary literature that provide original data. The metabolic influence of Echinacea spp. 
and the alkylamides mainly focuses on the predominant alkylamides known to be 
responsible for drug interactions with the CYP1, CYP2 and CYP3 families. 
 
CYP1A2 
 
In vitro investigations have found no overall effect of the tetraenes (isomers of 
dodeca-2,4,8,10-tetraenoic acid isobutylamide) and dienoic (dodeca-2E,4E-dienoic acid 
isobutylamide) isobutylamides on CYP1A2 even at high extract concentrations (up to 200 
mM), but found that an extract of E. purpurea herb and root did have an inhibitory effect 
(IC50 = 30.21 μg/mL) (Modarai et al., 2007). Both Gurley et al. (2004) and Gorski et al. 
(2004) report human pharmacokinetic results involving 1A2. In a study of 12 volunteers 
who took 1600 mg/d Echinacea purpurea root for 8 days, Gorski et al. (2004) found 
significant reduction in oral caffeine clearance by 27%. The authors postulated that 
inhibition at this level could affect 1A2 substrates with narrow therapeutic index such as 
theophylline, and clozapine. Gurley et al. (2004) found no significant inhibition of 1A2 in 
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healthy volunteers after 28 days of 1600 mg/d of whole-plant extract of Echinacea 
purpurea, although a 13% decrease in 6 hr paraxanthine/caffeine values suggested a 
possible inhibitory effect of E. purpurea whole plant extract on 1A2. This effect, however, 
was not statistically significant and was not considered clinically significant by the authors.  
 
CYP2C9 
 
Yale and Glurich (2005) using an unrevealed concentration of a remarkably 
concentrated 50:1 E. purpurea aerial extract, reported mild in vitro inhibition. Gorski et al. 
(2004) reported an 11% reduction in clearance of tolbutamide, a substrate of 2C9, after 8 
days of E. purpurea root supplementation. Gorski and colleagues (2004) suggest this 
interaction is not clinically significant.  
  
CYP2C19 
 
Modari et al. (2007) found an IC50 on the CYP2C19 isoform at 60.87 μg/mL for 
an extract of E. purpurea herb and root and 18.9 μg/mL for the tetraenes. 
 
CYP2D6 
 
CYP2D6 is one of the most important mixed-function oxidases involved in the 
metabolism of a wide range of xenobiotics. Interestingly, CYP2D6 also shows the largest 
phenotypical variability, due to genetic polymorphisms of all of the CYPs. Evidence from 
the Gurley et al. (2004)  and Gorski et al. (2004) studies presented above, as well as in 
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vitro evidence from Yale and Gurlich (2005) and have shown no interaction between 
Echinacea purpurea (aerial parts or root) and CYP2D6. However, Modari et al. (2007) 
showed activity of an E. purpurea extract of herb and root had an inhibitory concentration 
at 50% IC50 of 69.40 μg/mL and specific alkylamides (tetraenes) had an IC50 as low as 
6.8 μg/mL. Both human studies concluded that no interactions were expected between 
Echinacea purpurea and substrates of CYP2D6.  
 
CYP2E1 
 
Gurley et al. (2004) found no significant effects on CYP2E1 after 28 days of 1600 
mg/d E. purpurea whole plant extract. In vitro data  from Raner et al. (2007), suggest 
inhibition of CYP2E1 by an ethanolic extract of E. purpurea root, reporting a 
concentration of 2 µL/mL of a 95% EtOH extract producing a 27 – 29 % inhibition. Of 
particular interest was the finding that the same concentration of a 33% EtOH extract of E. 
purpurea root did not demonstrate 2E1 inhibition.  
 
CYP3A4 
 
Conflicting data were reported for 3A4; in vitro research, some at concentrations 
not obtainable with oral dosing, suggested mild to strong inhibition on 3A4 while human 
trials show no overall 3A4 activity. Budzinski et al., using benzyloxyresorufin as a 
substrate and extract of 1) the E. purpurea aerial portion or 2) a mixture of E. purpurea 
aerial portions and E. angustifolia root (1:1), observed moderate inhibition of 3A4 
(unspecified extract ratio, IC50 >5% and <10%). Using solely the roots of both 
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angustifolia and purpurea resulted in higher inhibition of 3A4 (unspecified extract ratio, 
IC50 >1% and <5%) (2000). The concentrations of extracts used in these assays, if typical 
of commercial extracts, are unobtainable by oral dosing.  
Further in vitro research by Budzinski et al. (2000) reported a significant difference 
in the effects of E. purpurea versus E. angustifolia roots on 3A4. While E. angustifolia 
demonstrated a strong inhibitory effect on 3A4 activity, E. purpurea was found to be a 
mild inhibitor of CYP3A4 for 7-benzyloxy-4-trifluoromethylcoumarin metabolism and had 
no activity on resorufin benzyl ether metabolism, except at non-relevant physiological 
concentrations (resulting in mild inhibition) (Gurley et al., 2004). Another in vitro 
investigation  demonstrated hydroethanolic extracts of E. purpurea aerial portion and a 
combination of E. purpurea and E. angustifolia (plant parts unspecified) moderately 
inhibited CYP3A4-mediated 7-benzyloxyresorufin metabolism while root extracts of E. 
purpurea and E. angustifolia demonstrated strong inhibition (Budzinski et al., 2000). 
Unfortunately, not enough data was provided to calculate the concentration of plant 
material that generated these results. Finally, more recent work showed that all echinacea 
extracts studied (E. angustifolia, E. pallida, E. purpurea) had the potential to inhibit 
CYP3A4. However, the investigators commented that the inhibitory potency was overall 
weak and varied considerably between extracts. The effects of isolated alkylamides, the 
tetraenes and diene isobutylamides were reported to be 1.9 and 5.2 μg/mL, respectively.  
Human investigations by Gorski et al. (2004), found no changes in the metabolism 
of midazolam, a 3A4 substrate, after participants ingested 1600 mg of E. purpurea root 
daily for 8 days. While these investigators observed an 85% increase in intestinal 
availability of midazolam, a 15% reduction of hepatic availability (p < 0.003) was also 
noted. The authors postulated that the induction of hepatic 3A4 counteracted inhibition of 
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intestinal 3A4, leading to little to no effect in midazolam metabolism overall (Gorski et al., 
2004). Using E. purpurea whole plant extract (aerial and root combined) in a human trial 
Gurley et al. (2004) found no statistically significant differences in 3A4 phenotypic ratios. 
CYP 450 phenotypic ratios have been shown to provide a practical method for predicting 
CYP mediated drug interactions (Gurley et al., 2004). 
 
Organic anion-transporting polypeptide (OATP-B) 
 
Fuchikami et al. (2006) found inhibition of OATP-B by the aerial parts of E. 
purpurea in vitro. The clinical significance of this finding is unclear, as few drugs are 
metabolized via this pathway and the findings have not been demonstrated in vivo.  
 
P-glycoprotein 
 
Romiti et al. (2008) report that the hexane root extracts of all three Echinacea 
species inhibited Pgp, with E. pallida, a little used species, having an effect at 3 μg/mL. 
The E. angustifolia and E. purpurea extracts were inhibitory at 30 μg/mL (Romiti et al., 
2008). The ketone compounds of E. pallida were found to be inhibitory as low as 3 μg/mL. 
 
The following experiments were designed to investigate the generation of 
metabolites of the predominant alkylamides, the tetraenes, in Echinacea spp. by human 
liver microsomes and investigate which isoforms of CYP450 are responsible for 
metabolism of the tetraenes in hopes of contributing to the scant data thus far available. 
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Methods 
 
Extract preparation 
 
The echinacea extract used in these experiments was supplied by a previous 
graduate student at the University of North Carolina, Greensboro and was prepared as 
follows: E. purpurea was cultivated at Horizon Herbs Inc. (Williams, OR, USA) and the 
species was verified by Richard Cech (Owner, Horizon Herb, LLC). A voucher specimen 
was collected and submitted to the University of North Carolina Herbarium in Chapel Hill 
accession number 583422. Glassware and utensils for the preparation of the extract were 
soaked overnight in Minntech cold sterilant (Minneapolis, MN, USA) to control for 
bacterial contamination. After scrubbing the roots of E. purpurea and rinsing with 
deionized water, the roots were soaked for 20 minutes in 95% ethanol, which was then 
discarded. The roots were blended in ethanol (ratio 1g:2 mL ethanol), pressed and allowed 
to macerate for 7 days at 4 ºC. Extracts were then filter sterilized and stored a -70 ºC until 
the time of experiments. Extracts were assayed utilizing the Limulus Amoebacyte Lysate 
(LAL) assay (Cambrex Bioscience, Rockland, ME, USA) for endotoxins which proved to 
be negative.  
 
Liver microsome and CYP450 assays 
 
Dodeca-2E,4E,8Z,10Z-tetranoic acid isobutylamide (Z-tetraene, Chromadex, Santa 
Ana, CA, USA) and E. purpurea radix extract were prepared at a concentration of 10 and 
100 μg/mL in ethanol, respectively and added to the assay tubes. Assay tubes also included 
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pooled human liver microsomes or CYP450 isoforms (40 µL, Moltox, Boone, NC, USA), 
NADPH (1 mM) or cell culture grade water, in addition to sterile phosphate buffer (pH 
7.4, 0.1 M) bringing volume to a total of 1 mL. Assays were terminated by the additions of 
400 μL of reagent grade ethanol to precipitate proteins. Samples were then centrifuged for 
5 minutes at 12,000 rpm and supernatant was filter sterilized through a 0.2 μM cellulose 
acetate membrane filter for preparation of LC-MS analysis. 
 
HPLC-ESI-MS Analysis   
 
An ion trap mass spectrometer with electrospray ionization source (LCQ 
Advantage, ThermoFisher, San Jose, CA) was employed. The solvent gradient, has been 
previously described (Spelman et al., 2009c), as follows, where solvent A is aqueous acetic 
acid (17mM, original pH 2.74) and solvent B is neat HPLC grade acetonitrile.  For t = 0 to 
4 min, a constant composition of A-B (90:10 v/v); for t = 4 to 15 min, a linear gradient 
from A-B (90:10, v/v) to A-B (60:40, v/v); for t = 15 to 30 min, a linear gradient from A-B 
(60:40,v/v) to A-B (40:60, v/v); for t = 30.1 to 35 min, a constant composition of A-B 
(0:100,v/v); for t = 35.1 to 43 min, a constant composition of A-B (90:10, v/v). The mass 
spectrometer was operated in the positive ion mode with a scan range of 50.00-2000.00.  
Spray, capillary, and tube lens offset voltages were 4.5 kV, 3 V and -60V, respectively.   
Quantitative analysis of the Z-tetraene was carried out for triplicate supernatants 
from the liver microsome assays. Quantitation was accomplished using the previously 
published methods (Cech et al., 2006a; Sasagawa et al., 2006).  Briefly, calibration curves 
were plotted for the Z-tetraene as the peak area of the selected ion chromatogram for the 
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protonated molecular ion versus concentration.  A concentration range of 1.0 to 50 µM was 
used.  
The concentrations of metabolites (Figure 4.2) were calculated via the calibration 
curve for Z-tetraene. These were calculated as µg/mL eq to signify a concentration in units 
equivalent to µg/mL of the Z-tetraene. This approach has been previously utilized for the 
quantification of alkylamides in echinacea (Matthias et al., 2005).  It should be noted that 
this method results in estimates of metabolite concentration, due to the likely differing 
sensitivity of the metabolites within the mass spectrometer, which likely differ from that of 
the standard.  This does, however, allow for concentrations to compare metabolites 
between samples.  
 
Statistical analysis 
 
The mean and the standard error of the mean (SEM) were determined for each set 
of concentrations. Comparison of means was conducted using a two tailed t-test for paired 
data when differences were observed. The mean values were considered significantly 
different if p < 0.05. Where appropriate, outlying data points were rejected on the basis of 
the Q-test. Statistical analyses were performed with Microsoft Excel (2003).  
 
Chapter 4  Metabolism of the Alkylamides 
 
128 
 
Results 
 
Metabolites of dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide 
 
Figure 4.1 illustrates the selected ion chromatograms of the Z-tetraene sample after 
exposure to human liver microsomes for 120 minutes.  The m/z of the compound in Figure 
4.1B increased by 16 amu compared to the parent compound, suggesting that it is 
hydroxylated or epoxidised. A shorter retention time in the reverse phase chromatography 
was also observed as would be expected due to increased polarity.  A second metabolite 
was identified in negative and positive ion mode (Figure 4.1 C and D) having an m/z of 
276 and 278 respectively. The increase of 30 amu can be explained by addition of two 
oxygen atoms and loss of two hydrogens, suggesting the introduction of a carboxyl (COO) 
group. The proposed structures of these metabolites are shown in Table 4.1.   
Previous reports have demonstrated that cytochrome P450 isoforms hydroxylate 
and epoxidate alkylamides (Cech et al., 2006b; Matthias et al., 2005). Matthias has 
persuasively argued, through H NMR, that the epoxide addition is at either C8-C9 or C11-
C12, with a preference for C11-C12 (Matthias et al., 2005). Hydroxylation can take place 
on C4-C12 and it is uncertain which product would dominant. For the Z-tetraene it can be 
observed (Figure 4.3) that a few possible structural variations are present for m/z 
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Figure 4.1  Selected ion chromatograms of the Z-tetraene and its metabolites 
After incubation of the Z-tetraene (chromatogram A-248) with human liver microsomes for 120 minutes 
(positive mode), the hydroxylated metabolite is observed in chromatogram B (positive mode-264). 
Chromatogram C displays the base peak of the anionic COO-tetraene in negative ionization mode (276). 
Chromatogram D illustrates the cationic COO-tetraene in positive ionization mode (278).  
 
264, which could correspond to both hydroxylated and epoxidized products. The 
carboxylated species (Table 4.1 structure D), was a previously unreported product of 
microsomal redox of alkylamides (Cech et al., 2006b). Cech et al. (2005) point out that 
there are 3 primary carbons that are available for oxidation to carboxylate on the tetraenoic 
isobutylamide (Table 4.1 structure A), the C12 of the fatty acid group and C3 or C4 on the 
isobutylamide group. The elucidation of the carboxyl group on the C12 derives from the  
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Table 4.1. Parent compound & metabolite structural assignment after oxidation by human liver microsomes  
Structure MW 
 
O
N
H
A. Dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (Z-tetraene) 
247.3 
 
O
N
H
OH
B. dodeca-2E,4E,8Z,10Z-tetraene-7-hydroxl acid isobutylamide (OH-tetraene) 
263.3 
 
O
N
H
O
C. dodeca-2E,4E,8Z,10Z-tetraene-10,11-epoxy acid isobutylamide 
263.3 
O
N
H
O
HO
D. dodeca-2E,4E,8Z,10Z-tetraene-12-oic acid isobutylamide (COO-tetraene) 
277.3 
 
Compound A, the Z-tetraene, is the most abundant alkylamide in Echinacea purpurea and parent compound 
for the metabolites.  After oxidation by human liver microsomes, the hydroxylated (B), epoxidated (C) and 
carboxylated (D) metabolites shown are the postulated metabolites.  LC/MS in positive ion mode shows 
above structures [M +1 (MH
+
)]. The carboxylated metabolites were detectable for both as M +1 (MH
+
) and as 
M-1 (M-H
-
) ions (negative ion mode). The metabolites shown here for the Z-tetraene were observed in the 
Echinacea purpurea extract as well.  
 
candidates MS/MS studies. A fragment at m/z 74 which corresponds to the isobutylamide 
fragment of the COO-tetraene has previously been demonstrated to correspond to a typical 
isobutylamide fragment (Spelman et al., 2009c). Consequently, this rules out the carboxyl 
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group location on any carbon but C12 of the fatty acid moiety. MS/MS fragmentation in 
past studies has been demonstrated to be effective for identification of alkylamides and is 
discussed at length in chapter 2 (Spelman et al., 2009c). 
Besides MS/MS fragmentation, the identity of the carboxylated metabolite was 
deduced from the increase of mass of 30 amu, characteristic of the addition of a carboxyl 
group and the ability to detect the metabolite in question in the negative ion mode of the 
MS, which indicates the presence of an acidic moiety (Figure 4.1C). Finally, Cech et al. 
(2006b) report undeca-2E-ene-8-10-diynoic acid isobutylamide, which has a terminal 
ending of a hydrogen, makes terminal carboxylation impossible. Thus, this alkylamide 
forms hydroxylated but not carboxylated metabolites. Consequently, this rules out the 
carboxyl group location on any carbon but C12 of the fatty acid moiety.   
Other studies have also shown that the extract of E. purpurea radix also contains a 
peak at 278 after exposure to liver microsomes, corresponding to the 278 peak found in the 
MS studies of isolated tetraenoic acid (data not shown) (Cech et al., 2006b).  
 
Metabolite formation as a function of incubation time 
 
Figure 4.2 exhibits the appearance of metabolites as a consequence of the redox 
reactions over 120 minutes that the Z-tetraene undergoes. Figure 4.3 shows the 
chromatogram of the unmetabolized the Z-tetraene and as such, serves as a control. Figure 
4.3B illustrates the chromatogram of the metabolized the Z-tetraene at 20 minutes. The 
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Figure 4.2.  Time dependent metabolism of the Z-tetraene.  
 
Concentrations of the metabolites, hydroxylated (OH-tetraene) and carboxylated (COO-tetraene), after 
incubation with human liver microsomes. The error bars represent the standard deviation of the 
concentrations determined for triplicate assay tubes.  
 
OH-tetraene is formed and as illustrated by the ions at m/z 264 peaks. As seen, it 
appears that there may be several possible structures forming such as the epoxide and OH-
tetraene metabolites (Table 4.1, structure C). By 60 minutes it appears that the various ions 
at m/z 264 have been reduced to a few dominant structures (Figure 4.3C). Figure 4.2 
Shows that the formation of the OH-metabolite increases over 60 minutes and then is 
reduced at 120 minutes. The longer incubation times (120 min) favor the production of the 
COO-tetraene over the hydroxylated molecular species (Figure 4.2; Figure 4.3D). In 
addition, it is apparent that the parent compound decreases in intensity (Figure 4.3D) and 
decreases in concentration (Figure 4.2) over time.  
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Figure 4.3. Selected ion chromatograms of the Z-tetraene and metabolites as a function of time. 
The increase in peak areas of the metabolites as a function of time, as the parent compound, a standard, 
decreases in peak area as displayed in the chromatograms. All chromatograms are selected for 248, 264, 278 
ions. A. The control at time 0. B. At time 20 minutes the largest peak area in the chromatogram is the parent 
compound the Z-tetraene. The development of several metabolites with a weight 264 ± 0.15 amu is seen, 
likely representing the addition of a hydroxyl group on various locations on the carbon chain of the parent 
compound. C. At time 60 minutes a clear development of the preferred OH-tetraene is seen. In addition, the 
carboxylated parent compound is seen increasing in peak area. D. At time 120 minutes, the COO-tetraene is 
seen to be the dominant metabolite while the peak area of the tetraene is greatly reduced.  
 
Previous reports suggest that the formation of the tetraene metabolites in E. 
purpurea radix extracts is less complete than for the Z-tetraene standard (Cech et al., 
2006b). Matthias et al. (2005) suggest that the isobutylamides with a terminal alkyne group 
may inhibit particular CYP450 isoforms. This may be at least partially responsible for this 
effect. It is likely that the polyphenols, with their known affect on CYP450 activity, may 
also play a role in the inhibition of the oxidation of the tetraenes.   
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CYP450 1A1 is responsible for the formation of dodeca-2E,4E,8Z,10Z-tetraene-7-
hydroxl acid isobutylamide 
 
Figure 4.4 shows the mass spectrometry results of an experiment analyzed after the 
Z-tetraene was incubated with CYP1A1 without NADPH (Figure 4.4A) and with 
 
 
Figure 4.4  Metabolism of dodecatetraenoic acid isobutylamide by CYP450 1A1 
 
A. Incubation of the tetraenoic isobutylamide with CYP1A1 without NADPH serves as a control. As 
demonstrated by the selected ion (248, 264) chromatogram there is no OH-tetraene present.  
B. With the addition of NADPH to CYP1A1 and the tetraenoic isobutylamide the formation of the OH-
tetraene ion is present at 264 (MH
+
). 
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NADPH  (Figure 4.4B). In the chromatogram in Figure 4.4A the absence of NADPH 
serves as a control. It can be seen that there are no other peaks present except for the parent 
compound. The appearance of the m/z 264 peak in Figure 4.4B after 60 minutes incubation 
demonstrates that CYP1A1 has metabolized the OH-tetraene to a compound with a weight 
of 263 (MH
+
 = 264). The base peak at m/z 264 elutes at the same time as the compound at 
m/z 264 when the Z-tetraene is incubated with the human liver microsomes, suggesting 
that this is the same compound. 
 
Figure 4.5. Incubation of the Z-tetraene with CYP450 isoforms 1A2, 1B1, 2A6, 3A4. 
 
Incubation of the Z-tetraene with various CYP450 isoforms shows no apparent metabolite formation. A-D 
represent experiments with different isoforms of CYP450, 1A2, 1B1, 2A6, 3A4, respectively. All 
chromatograms displayed are experiments conducted with NADPH. The controls (without NADPH) are not 
shown. As illustrated there are no detectable metabolites present as can be seen by the absence of peaks other 
than 248. Drift of the 248 peak is seen due to an extended run of the LC-MS. 
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Figure 4.5 depicts the results of experiments conducted with other isoforms of the 
CYP450 enzyme family. As is depicted by these chromatograms, there appear to be no 
other metabolites generated under these experimental conditions. Under these conditions 
the only CYP450 isoform that generates detectable metabolites of The Z-tetraene are 
CYP1A1. 
 
Discussion 
 
Three possible structural assignments have been proposed for the metabolites of the 
Z-tetraene after the incubation with human liver microsomes. Whereas a role for enzymes 
such as flavin-containing monooxygenases or peroxidases cannot be excluded, the 
NADPH dependence exhibited for the formation of these metabolites argues for a role of 
the CYP450 families. The presented data suggest that CYP1A1 is involved in the 
generation of the OH-tetraene. The CYP1 family contains both CYP1A1, CYP1A2 and 
CYP1B1. The isoforms CYP1A1 and CYP1A2, are substrate-inducible cytochrome P450s 
with 70% homology, that are responsible for the metabolism of numerous xenobiotics, but 
contain very different patterns of tissue expression. While CYP1A2 is expressed primarily 
in the liver, CYP1A1 is expressed predominantly in extrahepatic tissues such as the lungs, 
lymphocytes and placenta (Raunio et al., 1998; Shah et al., 2009). CYP1A1 is also known 
to have a rapid transcript turnover. This has been postulated to be an evolutionary 
advantage and appears to be conserved across species (Lekas et al., 2000).  
Of pertinence to the metabolism of the tetraenes, 1A1 is known to metabolize 
arachidonic acid and eicosapentaenoic fatty acids which are both highly unsaturated as are 
the tetraene isomers, which are fatty acid derivatives (Schwarz et al., 2004). As can be seen 
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in Figure 4.4B, the hydroxylated metabolite (m/z 264) is seen only after the Z-tetraene and 
CYP1A1 is incubated in the presence of NADPH. While the identity is not certain, it is 
highly likely that the structural assignment given to this metabolite (Table 4.1B) is correct 
due to the identification of this metabolite by other researchers (Cech et al. 2006; Matthias 
et al. 2005) and the subsequent MS/MS studies (Cech et al. 2006).   
While the data suggest that CYP1A2 and CYP3A4 are not involved in the 
metabolism of the alkylamides, some investigations suggest that extracts of E. purpurea 
root may mildly reduce clearance of substrates of CYP1A2 and CYP3A4. Human trials by 
Gorski et al. (2004) and Gurley et al. (2004) demonstrate wide inter-individual variability 
of metabolism of various echinacea preparations. Gurley et al. (2004) conclude that there 
is a minimal risk of drug interaction from echinacea preparations. These data suggest that, 
as is the case with pharmaceutical drugs, while the general effect on drug metabolism by 
echinacea products on consumers may be insignificant, rare individuals within the group 
could possibly experience a more significant induction or inhibition of these enzyme 
systems or drug transporters. In general, further study of inter-individual variability is 
needed.  
CYP1A2, which metabolizes theophylline and other pharmaceuticals, may be 
particularly relevant for asthma patients. It must be mentioned, however, that clinicians 
have observed an improvement of asthma and bronchitis with echinacea use, suggesting 
that echinacea may be useful to asthmatics (Stansbury, 1993). Supporting these 
observations, Sharma et al. (2006) found that preparations of root and aerial portions of 
echinacea reversed the inflammatory response of human bronchial epithelial cells to 
rhinovirus. Furthermore, particular alkylamides of Echinacea spp. are cyclooxygenase 
(Hinz et al., 2007; Muller-Jakic et al., 1994) and lipoxygenase (Merali et al., 2003; Muller-
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Jakic et al., 1994) inhibitors, as well as antiviral (Hudson et al., 2005; Vimalanathan et al., 
2005) and cannabionomimetic (Gertsch et al., 2006; Gertsch et al., 2004; Matovic et al., 
2007; Raduner et al., 2006; Woelkart et al., 2005). Considering that such activity may offer 
a significant reduction of spasm and the inflammatory processes of asthma (Lunn et al., 
2006; Pertwee and Ross, 2002; Singh and Budhiraya, 2006), possibly protect against upper 
respiratory tract infections (Schoop et al., 2006) and that echinacea inhibition of CYP1A2 
is insignificant to mild as found in the human trials reviewed here, recommendations for 
individuals with asthma to halt echinacea should be reserved for exceptional 
circumstances.   
Echinacea may mildly inhibit the cytochrome P450 3A4 enzyme system; this 
inhibition may be tissue specific. For example, Mouly et al. (2005) report that selected 
substrates can increase hepatic CYP3A activity, yet have no effect on intestinal CYP3A4 
or, conversely, substrates may generate CYP intestinal activity without inducing hepatic 
effects. Gorski et al. (2004)  also report tissue specific activity, finding that E. purpurea 
root extracts demonstrate inhibition of intestinal, and induction of hepatic, CYP3A 
activity. The molecular rationale behind these differential effects is still unclear. Gorski’s 
group (2004) suggests that echinacea root preparations taken with high oral 
availability/low clearance drugs (e.g. alprazolam) may induce hepatic CYP3A4 resulting in 
decreased serum concentrations of CYP3A4 substrates. Conversely, they suggest that low 
oral clearance/first-pass metabolism drugs (e.g. buspirone) taken with echinacea might 
result in increased drug serum concentrations. More data is needed to support this 
contention.   
It has been suggested that CYP3A4 is the most important enzyme for the 
metabolism of antineoplastic drugs (Meijerman et al., 2006). Thus the information that 
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echinacea may modulate, even weakly, the activity of 3A4 may encourage healthcare 
providers to warn against the use of echinacea with patients undergoing chemotherapy. 
However, such warnings could be disadvantageous to the patient; in vivo studies of E. 
purpurea aerial parts demonstrate a reduction in chemotherapy induced leucopenia (Bauer, 
1996; Melchart et al., 1995; Roesler et al., 1991; See et al., 1997; Steinmuller et al., 1993), 
while E. purpurea root has demonstrated stimulation of natural killer cells (Delorme and 
Miller, 2005; Gan et al., 2003; Lersch et al., 1990) and prolongation of life in leukemic 
mice (Currier and Miller, 2001). Additionally, a number of Echinacea species and 
constituents have demonstrated direct antineoplastic activity in vitro (Chicca et al., 2007; 
Currier and Miller, 2000; Melchart et al., 2002). Thus again, case by case 
recommendations are needed for cancer patients rather than a generalized recommendation 
to halt echinacea use.  
Another isoform of the CYP 450 system, 2D6, is known to play a primary role in 
the metabolism of pharmaceuticals used to treat psychiatric disorders (attention 
deficit/hyperactivity disorders, bipolar disorder, depression, schizophrenia) as well as 
cardiovascular disorders (β-blockers). This potential of 2D6 metabolism of the alkylamides 
was not tested in these studies. However, Echinacea purpurea products containing root or 
aerial parts in both human (Gurley et al., 2004) and in vitro models (Yale and Glurich, 
2005) has shown no activity on 2D6 substrate metabolism. The available research suggests 
that no interactions are expected between Echinacea purpurea products and substrates of 
CYP2D6. 
Other possible enzymes that deserve investigation for the metabolism of 
alkylamides include CYP1B1 and CYP2E1which are native to leukocytes, as well as the 
CYP2 CYP4, CYP5 and CYP8 families, many of which are expressed in the liver. 
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CYP4A, CYP5 and CYP8A are known to metabolize eicosanoids. CYP2A6 was 
investigated, however, CYP2C9 was not investigated and is known to metabolize 
arachidonic acid. The CYP4A isoforms (primarily kidney expression, secondarily hepatic 
tissue), such as CYP4A1, CYP4A2, CYP4A3, CYP4A8, are also known to metabolize 
arachidonic acid and other unsaturated fatty acid derivatives (Cowart et al., 2002). All of 
the isoforms previously mentioned were, unfortunately, unavailable for investigation.  
In reference to the effects of the alkylamides on drug metabolism, no case reports 
were found documenting an echinacea-drug interaction, a finding supported by other 
reviewers (Basch et al., 2005; Dergal et al., 2002; Fugh-Berman and Ernst, 2001; Izzo and 
Ernst, 2001; Messina, 2006). The fact that echinacea products rank second in sales of 
herbal remedies in the U.S. (Blumenthal et al., 2006) and the number of people using 
multiple pharmaceuticals (>75 million) (Slone Epidemiology Center), suggest that drug-
herb interactions with echinacea products are uncommon events. Barrett (2003a) concludes 
that less than 100 serious adverse events have been reported involving echinacea for an 
estimated >10 million courses of treatment, leaving the risk estimate of less than 1 in 
100,000.  
While there are scant data on the metabolism of echinacea constituents and their 
effects on metabolism of exogenous chemicals, there is even less data on the influence of 
the metabolites of Echinacea spp. on immunomodulatory activity. The only paper thus far 
found is by Cech et al. (2006) that alkylamide metabolism caused a decrease in 
immunomodulatory effects as compared to the native alkylamides. Specifically the 
carboxylated metabolite (Table 4.1, structure D) of the Z-tetraene loses its IL-2 inhibitory 
effect (Cech et al. 2006).  However, it is possible that the novel metabolites reported here 
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could also influence other immune parameters, such as monocyte/macrophage and 
neutrophil activity.  
Medicinal plants, while necessarily part of healthcare in developing regions, are 
becoming increasingly popular in the industrial nations. Estimates suggest that up to 30% 
of the North American population use herbal supplements (Nelson and Perrone, 2000). 
Given that nearly 3.6 billion prescriptions were purchased in 2005 (Kaiser Family 
Foundation, 2006) and 30% of Americans report using five or more drugs in the same 
week (Slone Epidemiology Center) it comes as no surprise that the incidence of consumers 
taking herbs in conjunction with prescription medications is quite high. Eisenberg et al. 
(1998) found that up to 15 million adults were concurrently using prescription medications 
and herbal supplements. A nationwide telephone survey by Kaufman et al. (2002) supports 
this, finding that 16% of respondents had taken both prescribed medications and 
supplements in the week preceding the interview. Consequently, the study of the 
metabolism of phytochemicals and these phytochemicals effect on metabolism are crucial. 
Even though 80% of the echinacea products sold to consumers are made from 
purpurea (Li, 1998), the current body of scientific literature on echinacea can be confusing 
due to the multiple species in use – namely E. purpurea, E. pallida and E. angustifolia - 
which have phytochemical similarities, but also have notable differences, particularly 
around the identity and concentration of alkylamides and other key constituents (Bauer, 
1996; Chen et al., 2005; Hudson et al., 2005). In addition, all three species are often used 
interchangeably for the treatment of cold, flu, respiratory infection, and inflammation 
(Bauer and Foster, 1991). Multiple species, plant parts, and preparations are also used, 
each of which may have a different constituent profile (Spelman et al., 2009c; Williamson, 
2006). “Echinacea” may refer to the roots, aerial parts, whole plant or a combination of the 
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above; echinacea products can be made from fresh or dried plant parts, and may be 
prepared by juicing, alcohol extraction, infusion, decoction, or consumed as tablets or 
capsules (Mills and Bone, 2000).   
Currently, it has not been clearly elucidated as to how constituents of echinacea are 
metabolized by the body or which of those constituents affect the metabolism of other 
exogenous chemical inputs. Preliminary studies suggest that extraction conditions, the 
various species and botanical part of echinacea have differing effects on the cytochrome 
P450 enzyme system (Raner et al., 2007). For example, Raner et al. (2007) found that the 
hydrophobic constituents of E. purpurea (e.g. alkylamides) are much more inhibitory to 
CYP450 than its hydrophilic constituents (e.g. phenylpropanoids) and this work is in 
agreement with other CYP450 evaluations (Matthias et al., 2005). Modari et al. (2007) 
found that higher alkylamide content of echinacea preparations was associated with greater 
CYP3A4 inhibitory activity, although the inhibitory activity was overall weak in effect. 
Recent work by Spelman et al. (2009c) demonstrated quantitative and qualitative 
differences in alkylamide concentrations, including the alkylamides reported to modulate 
CYP activity, depending on the extraction technique and the use of fresh or dry plant 
material in ethanolic preparations of Echinacea purpurea radix (see chapter 2). Thus, 
ethanolic extracts as well as other echinacea preparations may differ in their activity on the 
CYP 450 system and therefore generalizations about metabolism of echinacea products 
and their possible influence on the metabolism of drugs may be misleading (Freeman and 
Spelman, 2008). 
The search for and appraisal of information relating to the metabolism of 
phytochemicals and the phytochemical influence of drug metabolism has thus far been a 
challenge for researchers and educators, and readily accessible information among the 
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scientific and medical community is lacking. Metabolic studies on phytochemicals have 
only recently been published in the scientific literature. Unfortunately, it appears that in 
regard to phytochemical influence on the metabolism of pharmaceuticals, much of the 
literature does not evaluate the quality of evidence from which conclusions are drawn. 
Of particular concern for healthcare providers, Freeman and Spelman (2008) report 
that drug-herb interactions related to echinacea products were cited in some 49 articles, 
only 16% (8) of these 49 papers contained primary data relevant to interactions between 
echinacea products and pharmaceuticals. Two studies were clinical trials (Gorski et al., 
2004; Gurley et al., 2004) and the remaining were in vitro assays, three of which did not 
contain complete information about the concentration of extract used (Budzinski et al., 
2000; Foster et al., 2003; Yale and Glurich, 2005); only half of the studies verified the 
authenticity of the echinacea (Gorski et al., 2004; Moulick and Raner, 2003; Raner et al., 
2007; Yale and Glurich, 2005). Yet, there are very few investigations investigating the 
metabolites that result from echinacea phytochemicals. 
Previous researchers have demonstrated that the Z-tetraene is a CB2 ligand 
(Gertsch et al., 2004; Matovic et al., 2007; Raduner et al., 2006). Hence, it has been 
suggested that considering the strict structural requirements for ligands of the cannabinoid 
2 (CB2) receptors, that the COO-tetraene likely has a greatly reduced affinity for CB2 
(Cech et al. 2006). However, recent evidence suggests that the IL-2 effect is due, at least in 
part, to PPARγ activity (Spelman et al., 2009b). Consequently, it is also possible, 
especially considering the considerable promiscuity of the PPARγ receptor to divergent 
phytochemical structural motifs (Spelman and Burns, 2009), that tetraenoic isobutylamide 
is converted from an agonist to an antagonist with the carboxylation of this alkylamide. In 
addition, the ligand binding domain of PPARα PPARβ/δ PPARγ is particularly 
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homologous (Shearer and Billin, 2007). Considering that epoxyeicosatrienoic acids, 
carboxylated fatty acid derivatives, are known to activate human and mouse peroxisome 
proliferator-activated receptor-alpha (Cowart et al., 2002), the possibility of the tetraenoic 
isobutylamide metabolites activating isoforms of PPAR needs to be explored. 
 
Summary 
 
The generation of metabolites from alkylamides and the effect on alkylamides and 
Echinacea spp. on metabolic processes is poorly represented in the literature at this point 
in time. The presented data suggest that metabolites from the alkylamides are generated by 
the cytochrome P450 system. The above data suggest that there are metabolites formed 
from the predominant alkylamide dodeca-2,4,8,10-tetraenoic acid isobutylamide that 
possible include; epoxidizee, hydroxylated and carboxylated metabolites. These data 
suggest that CYP450 1A1 is responsible for the formation of the hydroxylated metabolite.   
In addition Echinacea purpurea root appears to have a relatively low potential to 
produce CYP-mediated effects on drug metabolism. However, further pharmacokinetic 
testing is required before conclusive statements can be made.  
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Chapter 5 
 
The activation of PPARγ by undeca-2E-ene-8,10-diynoic 
acid isobutylamide 
 
Introduction 
 
Recent investigations utilizing alkylamides from the genus Echinacea demonstrates 
that dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (Z-tetraene) and dodeca-2E,4E-
dienoic acid isobutylamide have a reasonable affinity for the cannabinoid receptors, 
binding CB2 (Ki ~ 50 nM) with ca. 30 to 50 fold selectivity over CB1 (Raduner et al., 
2006). Broad-based receptor screening demonstrates that binding to CB2 is highly 
selective (Gertsch et al., 2006). Accordingly, this has provided an explanation, although 
limited, to the basis for the immunomodulation of Echinacea spp. (Woelkart et al., 2005).  
There have been frequent reports in the primary literature that suggest cannabinoid 
ligands may have CB independent activity. For example, 2-arachidonoylglycerol (2-AG) is 
known to modulate a number of immune processes, including cytokine secretion via CB2. 
Supporting this is the significant up-regulation of 2-AG production by a number of WBC 
species upon activation (Berdyshev, 2000). Derocq et al. (1998) showed that the 
cannabinoid ligands anandamide, as well as (R)-methanandamide and 
palmitylethanolamide, potentiated the growth of the murine interleukin (IL)-6 dependent 
lymphoid cells and IL-3 dependent myeloblastic cells. They believe that this effect was a 
noncannabinoid receptor-mediated process: CP 55940 which is a highly potent synthetic 
cannabinoid with affinity for both CB1 and CB2 was inactive; the CB1 and CB2 
antagonist SR 141716A and SR 144528 alone or in combination could not block the 
cannabinoid activity; inactivation of both CBs by pertussis toxin did not change the 
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activity of anandamide; and the fatty acid, arachidonic acid, which has no affinity for CB 
receptors, was able to trigger comparable activity to the structurally similar anandamide. 
Although cytokine inhibition by leukocytes is speculated to be transduced by CB2, non-
cannabinoid modes of activity appear to be involved as well (Klein, 2005; Pertwee and 
Ross, 2002). 
Other receptor systems are known to respond to fatty acids and their derivatives. 
For example, the peroxisome proliferator-activated receptors (PPARs) consist of a set of 
three receptor sub-types which are members of the nuclear receptor superfamily of ligand-
activated transcription factors. They function as lipid sensors, regulating gene expression 
in a variety of metabolically active tissues and have a significant role in cellular energy 
balance, fuel utilization, the metabolism of fatty acids and other lipids. They also play a 
role in the fibrotic and hypertrophic responses in the heart and vascular wall and the 
generation and remodeling of adipose tissue (Bishop-Bailey and Wray, 2003).  
Recently PPARγ, PPARα and PPARβ/δ agonists have been demonstrated to exhibit 
anti-inflammatory and immunomodulatory properties thus opening up new avenues for 
research. For example, B and T lymphocytes and monocytes are known to express PPARγ. 
Both anandamide and 2-AG, in a number of models, demonstrate concentration dependent 
inhibition of IL-2 production, a classical sign of T cell activation (Rockwell et al., 2006). 
Moreover, anandamide induces a concentration-dependent inhibition of interleukin-2 in 
primary splenocytes which is unaffected by SR141716A and SR144528. In the same 
model, arachidonic acid shows similar activity as anandamide which is attenuated by 
pretreatment with nonspecific cyclooxygenase (COX) inhibitors as well as COX-2 specific 
inhibitors.  Pretreatment with the PPARγ antagonist T0070907 also attenuated anandamide 
mediated suppression of IL-2 secretion (Rockwell and Kaminski, 2004). Yang et al. (2000) 
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observed that PPARγ free Jurkat cells did not respond to PPARγ ligands troglitazone and 
15d-PgJ2 (an endogenous ligand), but PPARγ expressing Jurkats did exhibit IL-2 
inhibition in response to PPARγ agonists.  
IL-2, an autocrine/paracrine factor, plays a key role in multiple processes of T cell 
biology. Initially, activation of the IL-2 receptor (IL-2R) was found to be crucial for 
inducing proliferation of T cells in vitro (Hatakeyama et al., 1989).  Subsequent 
investigations revealed that IL-2R signaling activates genes such as c-myc and c-fos, which 
are crucial to proliferation (Miyazaki et al., 1995; Nelson and Willerford, 1998). Later 
investigations demonstrated that IL-2 plays an important role in sensitizing T cells for 
activation-induced cell death (Lenardo, 1991) and plays a key role in autoimmunity 
(Suzuki et al., 1995; Willerford et al., 1995). Currently it is known that IL-2 dependent 
signals are required for T regulatory development, homeostasis and function (Burchill et 
al., 2007). Opportune for laboratory investigations, IL-2 production is a characteristic  
response of T cell activation, exhibiting virtually no basal level expression, but is rapidly 
secreted upon T cell activation (Rockwell et al., 2006). For full activation of the IL-2 
response, multiple transcription factors are involved including NFκB and cooperative 
binding of NFAT and AP-1 for transcriptional activity of the IL-2 gene (Jan et al., 2002). 
AP-1 is generated by dimerization of c-jun and c-fos for the transcription of IL-2. 
Helper T-cells produce IL-2 in response to antigen recognition by signaling through 
the T-cell receptor. In particular, the E6.1 cell line (Jurkats), established from a 14 year old 
boy with T cell leukemia, is a widely used model for studying IL-2 regulation due to their 
basal levels of IL-2 being nearly absent (<50 pg/mL). Upon dual stimulation, phorbol 
esters and either lectins or monoclonal antibodies against the T3 antigen, large amounts of 
IL-2 are produced by Jurkats (Weiss et al., 1984).  
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Jurkat T cells exhibit low levels of surface CB2 receptors (Bouaboula et al., 1993). 
And while, Raduner et al. (2006) found high affinity of 2E,4E,8Z,10E/Z-tetraenoic acid 
isobutylamide (tetraenes) and dodeca-2E,4E-dienoic acid isobutylamide for CB2 they also 
suggested the possibility of the involvement of a second receptor due to the fact that 
SR144528 is incapable of fully inhibiting influx of Ca
2+
 in HL60 cells induced by 2-AG 
and alkylamides. Consequently, although alkylamide binding to CB2 is established, there 
may be other targets beyond the CB2 for specific alkylamides. Consequently, the focus of 
the present studies was to investigate the effects of an alkylamide that has been previously 
established to have negligible CB2 affinity on IL-2 production using the Jurkat cell line. 
Hence, the hypothesis that signal transduction by undeca-2E-ene-8,10-diynoic acid 
isobutylamide (UDA) inhibits the release of IL-2 in Jurkat cells by PPARγ was tested. 
 
Methods 
 
Reagents 
 
All reagents were from Sigma-Aldrich (St. Louis, MO) except the following: 
undeca-2E-ene-8,10-diynoic acid isobutylamide (UDA, MW 231.34; certificate of analysis 
verified identity by NMR and HPLC, and purity of ≥99% by HPLC lot #21235-501; 
(Chromadex Inc., Santa Anna, CA); troglitazone (MW 441.5; Rezulin, abbreviated as 
TZD, gift from Ron Morrison, UNCG, Department of Nutrition); T0070907 (MW 277.7; 
Cayman Chemicals, Ann Arbor, MI); ethanol (AAPER, Shelbyville, KY); nanopure water 
(Nanopure Diamond D11931, Barnstead International, Thermolyne, Dubuque, IA); calf 
serum (Colorado Serum Co., Denver, CO); human IL-2 Duo Set ELISA Kit-DY202 (R&D 
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Systems, Minneapolis, MN); Jurkat E6.1 cells (ATCC, Manassas, VA); 3T3-L1 
preadipocytes (a gift from Ron Morrison); nitro-cellulose membranes (Bio-Rad, Hercules, 
CA); anti-human PPAR γ primary antibody (Aviva Systems Biology, San Diego, CA); and 
goat anti-rabbit conjugated to horse radish peroxidase (US Biological, Swampscott, MA).  
 
Immunodectection of PPARγ protein in Jurkat cells by Western blotting  
 
Cells were harvested (2 x 10
6
 cells) and lysed by boiling for 5 minutes. Cell 
extracts were analyzed in a denaturing 10% polyacrylamide gel, electrotransferred to a 
supported nitro-cellulose membrane, and immunoblotted with the PPARγ primary 
antibody (Aviva Systems ARP32880_T100). The membranes were soaked in blocking 
buffer [5% nonfat dry milk diluted in Tris-buffered saline-0.1% Tween-20 (TBS-T)] for 1 
h at room temperature with the indicated primary antibody (1:10,000). After
 
washing, 
membranes were developed with horseradish peroxidase-conjugated
 
secondary antibodies 
and visualized with a chemiluminescent detection system (GE Healthcare/Amersham 
Biosciences, Buckinghamshire, England). A double band is the expected image resulting 
from this antibody due to the non-specific binding to PPARγ1 and PPARγ2 which have 
slight weight differences. 
 
Mitogenic stimulation 
 
Optimal stimulant conditions to elicit sub-maximal IL-2 production by Human E6.1 
Jurkat T cells were determined using phorbol 12-myristate 13-acetate (PMA, Sigma-
Aldrich) and phytohemagglutinin (PHA, Sigma-Aldrich, Milwaukee, WI). Jurkat cells 
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(2×10
6
 cells/mL, ATCC, Manassas, VA) were treated with 0.125 – 4 μg/mL PHA with 1, 2 
or 3 ng/mL PMA; or individually with PMA (1 and 3 ng/mL) and PHA (0.25 and 2.0 
μg/mL) at various concentrations and incubated at 37 °C, 5% CO2, and 95% relative 
humidity. Supernatants were harvested after 24 h and immediately assayed for IL-2 with an 
ELISA kit (IL-2 DuoSet, R&D Systems Minneapolis, MN). Secreted IL-2 concentration 
vs. PMA/PHA concentrations were plotted and IL-2 concentration determined by the 
association curve produced using Excel (2007). 
 
Jurkat cell culture and IL-2 ELISA 
Jurkat T cells were cultured in Roswell Park Memorial Institute (RPMI) 1640  
medium with 10% FBS, 2 mM L-glutamine and 1 mM Na pyruvate. After serum starvation 
for 7 hours, Jurkat cells were plated in 96 well culture plates at 1.25 x 10
5
 cells/mL in 
RPMI 1640 (without phenol red) with 10% FBS. Cells were treated with PMA (1.25 
ng/mL) and PHA (0.25 μg/mL) and the selective antagonist T0070907 or DMSO vehicle 
was added to appropriate wells and incubated at room temperature  for 15 minutes after 
which alkylamides and thiazolidine (TZD) were added. Plates were then incubated for 18 
hours. Cell supernatants were collected (100 µL) and assayed for IL-2 by ELISA (Human 
IL-2 Duo Set ELISA Kit). All test conditions were assayed in triplicate and verified with 
repeated experiments three times. The IL-2 calibration curve determined by ELISA was 
R
2
= 0.9996. 
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Cell Survival by XTT assay 
 
The cytotoxicity of UDA was measured by the XTT colorimetric assay (Scudiero et 
al., 1988), which was performed with the same plated cells cultured for the IL-2 cytokine 
testing in dual ELISA/XTT assays.  In the dual assay, cells are harvested for XTT assays 
and the supernatant is harvested for the ELISA assay. For the cell viability standard curve, 
unstimulated cells were plated in triplicate at 2.5 x 10
4
, 2 x 10
4
, 1.5 x 10
4
, 7.5 x 10
3
, 5.0 x 
10
3
, and 2.5 x 10
3
 cells/well. After removal of 100 µL supernatant from all wells, 100 μL 
of 1 mg/mL of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide 
(XTT) plus 0.02 mM phenazine methosulfate (PMS), in medium was added. After 5 h 
incubation, ODs at 450 nm (Teacan Sunrise plate reader, Grödig, Austria) were measured 
and cell concentrations extrapolated from known cell concentrations in standard curve. 
Test conditions were assayed in triplicate and repeated in two experiments.  
 
Reverse Transcription PCR Analysis 
 
Cell extracts were prepared from the Jurkats cells run under described conditions 
and total RNA was isolated using the Qiagen (Valencia, CA) Minikit 50.  Primer and probe 
sequences used were sense 5V-ggatagcctctcttactaccac-3V and antisense 5V-
tcctgtcatggtcttcacaacg-3V  for c-fos (280 base pairs); sense 5V-caggtggcacagcttaaaca-3V 
and antisense 5V-  tttttctctccgtcgcaact-3V  for c- jun (180 base pairs). First strand cDNA 
was synthesized from mRNA with Qiagen Onestep RT-PCR kit. The cDNA was reverse 
transcribed (RT) and amplified. Distilled water was substituted for cDNA template as a 
negative control. The resultant cDNA samples were subjected to 35 cycles of PCR 
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amplification in the presence of specific sense and antisense primers. The RT denaturing, 
annealing and extension temperatures are below.  
 
1. Reverse transcriptase 50 ○C x 30’  
2. Denaturing of  reverse transcriptase/DNA 95 ○C x 15’ 
3. Denaturing 94 ○C x 1’ 
4. Annealing 59 ○C x 1’ 
5. Extension 72 ○C x 1’ 
6. Go to 3 
7. Extension 72 ○C x 1’ 
 
The amplified PCR products were resolved on a 1.5% agarose gel visualized with 
ethidium bromide under UV light illumination. Gel imaging and densitometry was aquired 
with Αlpha Innotech Corporation (Alexandria, VA) utilizing UV transillumination. 
Relative quantitation was made spectrophotometrically by densitometry. 
 
Fibroblast cell culture and differentiation 
 
3T3-L1 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) plus 
10% calf serum, 4 mM L-glutamine and 1 mM Na pyruvate. Cells were plated in 6 well 
plates in a total of 1.5 mL of medium and grown to confluence over 4-5 days. Forty-eight 
hours after confluence was achieved (Day 0), insulin (10 μg/mL) was added to all wells 
except the insulin free control. On day 2, media was changed to contain FBS and the 
following treatment conditions, which were added to separate triplicate wells: UDA (5.0 
μg/mL, 7.5 μg/mL and 10 μg/mL); TZD positive control (10 μM);  insulin negative control 
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(10 μg/mL); and vehicle control  (EtOH:DMSO 0.4%:0.1%) were added.  Every 2 days, 
the media
 
and all reagents, including treatments, were replenished after a PBS wash. The 
experiment was halted on day 5, at which time adipogenesis was determined by 
photomicroscopy by morphology and the presence of the obvious prominent lipid 
vacuoles. Images were taken with a SPOT digital camera mounted on an
 
Olympus BX60 
fluorescence microscope.  
 
Statistical analysis 
 
All data are expressed as means ± SE of experiments conducted in triplicate. 
Statistical analysis was performed using Student’s t-test and analysis of variance (one-way 
ANOVA). The accepted level of significance was p < 0.05. 
O
N
 
Figure 5.1. Undeca-2E-ene-8,10-diynoic acid isobutylamide (UDA). 
 
Results  
 
PHA titration to determine submaximal IL-2 production 
 
Immune stimulants for Jurkats lymphocytes were selected based on confirmatory 
experiments as well as previous studies (Sasagawa et al., 2006).  Previous work has 
determined that in order to demonstrate IL-2 inhibition in response to echinacea and its  
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Figure 5.2.  PMA/PHA optimization for IL-2 response. 
Cell concentration 2 x 10
4
 were incubated for 24 h under standard conditions. Insignificant differences are 
seen in PMA concentrations of 1,2 or 3 ng/mL with titration of PHA from 0.125 to 4.0 μg/mL. Error bars 
indicate standard error of the means. 
 
 
alkylamides, that suboptimal IL-2 response was necessary (Sasagawa et al., 2006).  
Through a few experiments, this was confirmed (data not shown).  
PHA or PMA, when tested in isolation with Jurkats, do not induce an IL-2 response 
over 24 h, but the combination is well established to induce IL-2 production. Figure 5.2 
demonstrates the optimal mitogenic stimulation conditions of Jurkats for PMA/PHA. 
Concentrations tested for PHA were 0.125, 0.25, 0.5, 1.0, 2.0, 4.0 μg/mL. This in turn, was 
assayed against PMA at 1, 2, 3 ng/mL.  PHA between 0.5 and 1.0 μg/mL was observed to 
give the optimal IL-2 response. At a cell concentration of 2 x 10
4
 cells the calculated PHA 
concentration necessary to stimulant ≈70% of the maximal IL-2 concentration (150 pg/mL) 
was 0.22 μg/mL. An IL-2 ELISA assay resulted in a 0.25 μg/mL for ≈70% of the maximal 
IL-2 concentration. This varied insignificantly at different PMA concentrations of 1, 2, or 
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3 ng/mL. Higher concentrations of PMA exhibited the same PHA pattern in that the PHA 
concentration of 0.5 μg/mL provided optimal IL-2 response.  
 
 
 
Figure 5.3. IL-2 response between 3 to 18 hours. 
A rapid increase of IL-2 is seen from 3 to 18 h after stimulation with PMA 1.0 ng/mL and PHA 0.25 μg/mL. 
Error bars indicate standard error of the means. 
 
 
 
Figure 5.4. IL-2 response between 18 and 48 hours. 
 
IL-2 levels are seen to fluctuate in response to PMA 1.0 ng/mL and PHA 0.25 μg/mL from 18 to 48 hour 
time interval. Statistical significance is for comparison of 18h vs. all other time points on the PMA/PHA 
curve only. * p<0.05; ** p<0.005 
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Determining optimal timing for IL-2 production   
 
Figures 5.3 and 5.4 illustrate the IL-2 response as a function of time as assessed by 
ELISA. Jurkat cells were stimulated with suboptimal PMA/PHA (1.0 ng/mL / 0.25 μg/mL) 
and allowed to incubate for 24 hours, with samples taken at 3, 9 and 18 hours (Figure 5.3). 
The experiment was repeated and samples of the supernatant were taken at 18, 24, 30, 36, 
42 and 48 hours (Figure 5.4). The IL-2 calibration curve determined by ELISA was 0.9999 
and 1.000 for Figures 5.3 and 5.4 respectively. 
The maxium secretion found for IL-2 was previously stated to be 24 hours in E6.1 
Jurkats (Sasagawa et al., 2006). Figure 5.3 and 5.4 exhibits the results of Jurkats incubated 
with suboptimal PMA/PHA immune stimulation as determined by the experiments 
illustrated in Figure 5.2. Maximal concentrations of IL-2 were determined to occur at 18 
and 30 hours, with a significant drop off starting at 36 hours. Comparison of the results of 
the 18 and 30 hour time intervals were not statistically significant.  
 
Figure 5.5. Immunodetection of PPAR in Jurkat cells by Western blotting. 
 
Nuclear extracts of untreated Jurkat E6.1 cells were treated with rabbit polyclonal PPARγ antibody from 1 
µg/mL to 4 µg/mL. A band at 55 kDa, which increases in intensity with increasing PPARγ antibody, 
confirms the expression of the PPAR-γ nuclear protein in these cells. Mass (kDa) of the marker proteins are 
shown on the right hand side of the blot. 
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Presence of PPARγ in Jurkat cells 
 
The Western blot technique was utilized to verify the presence of the PPARγ 
protein in Jurkats, although Jurkat cells have previously been demonstrated to contain the 
PPARγ nuclear hormone receptor (Clark et al., 2000). Nuclear extracts of untreated Jurkats 
were subjected to polyclonal PPARγ antibodies from 1 μg/mL to 4 μg/mL following 
standard Western blot procedures. Figure 5.5 confirms the presence of PPARγ receptor in 
Jurkat E6.1 cells. A faint signal is seen at 1 μg/mL that grows in intensity with increasing 
concentrations of antibody. These results demonstrate that while the PPAR protein is not 
highly expressed in this strain of Jurkats, it is present. The manufacturer suggest a double 
band is the expected result with the use of this particular PPARγ antibody as seen on their 
website and confirmed by Aviva’s technical support. The antibody binds both PPARγ1 and 
PPARγ2 which have a slight mass difference and result in the dual bands.  
 
   The PPARγ selective antagonist T0070907 attenuates the IL-2 inhibition of 
undeca-2E-ene-8,10-diynoic acid (UDA) at suboptimal Jurkat stimulation  
 
To assess the response of T cells to UDA (Figure 5.1), suboptimal IL-2 stimulation 
of Jurkats by PMA/PHA (PMA 1.25 ng/mL & PHA 0.25 μg/mL) was used. Previous work 
has utilized this model system to demonstrate that PPARγ mediates IL-2 inhibition in T 
cells (Clark et al., 2000; Rockwell and Kaminski, 2004; Rockwell et al., 2006). Cells were 
serum starved for 7 hours, plated and then exposed to vehicle control (EtOH/DMSO), 
positive control (TZD-a selective PPARγ agonist), positive control with antagonist 
(TZD/T0070907), UDA or UDA with antagonist (UDA/T0070907) at increasing 
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Figure 5.6. PPARγ antagonist T0070907 attenuates the UDA induced inhibition of  
IL-2 secretion by suboptimally stimulated Jurkat E6.1 cells. 
 
Cells were subjected to suboptimal mitogenic stimulation (PMA 1.25 ng/mL, PHA 0.25 μg/mL) after serum 
starvation, for induction of IL-2 in all cases except in the no treatment group (No Tx). The selective agonist 
troglitazone (TZD) represents a positive control (black bar). Stripped bars represents the combination of 2.5 
μM of T0070907 with the matched treatments (vehicle-VC, UDA, TZD) shown in the left bar of each pair. 
Results show a dose dependent response of IL-2  by UDA and the positive control TZD. The T0070907 
treatments dose-dependently attenuate the IL-2 inhibition  (up to 1 μg/mL UDA) that occurs upon treatment 
of Jurkat cells with increasing doses of UDA (grey bars). The positive control (TZD black bar), also shows 
significant inhibition of IL-2 which is blocked by T0070907. Values are mean ± S.E. of experiments 
performed in triplicate. One-way ANOVA was used to determine statistical significance between the vehicle 
(VC) versus the various treatments (UDA or TZD) treated groups (* p < 0.05) and the UDA versus the 
UDA/T0070907 treated groups († p<0.05). 
 
concentrations. T0070907 was held at constant concentration (2.5 μM). After 18 h 
incubation, ELISA of the supernatants collected from wells treated with the various 
conditions was performed. The results demonstrate that UDA dose-dependently inhibits 
IL-2 production beginning at 0.33 μg/mL (1.4 μM) (Figure 5.6). When the selective 
PPARγ antagonist T0070907 is added with UDA, a dose-dependent attenuation of the IL-2 
inhibition is seen starting at 0.33 μg/mL. At this concentration, the IL-2 level returns to 
baseline in the wells treated with T0070907. However, at higher levels of UDA treatment, 
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Figure 5.7. Cell survival assay (XTT assay) of Jurkat E6.1 cells treated with UDA and T0070907. 
 
Cells were subjected to identical conditions as the IL-2 assays. The selective agonist troglitazone (TZD) 
represents a positive control (black bar). Stripped bars represent the combination of 2.5 μM of T0070907 
with the matched treatments (vehicle-VC; UDA; or TZD) shown in the left bar of each pair. A proliferative 
effect by UDA (grey bars) on Jurkat cells is observed. A trend showing inhibition of proliferative effects is 
observed with the addition of the selective PPARγ antagonist T0070907.  The positive control, selective 
PPARγ agonist TZD combined with T0070907, shows a statistically significant inhibition of proliferation as 
compared to TZD alone (black bar). Values are mean ± S.E. of experiments performed in triplicate. One-way 
ANOVA was used to determine statistical significance between the vehicle (VC) versus the UDA- or TZD-
treated groups (* p < 0.05), and the UDA versus the UDA/T0070907 treated groups († p<0.05). 
 
the antagonistic effect of T0070907 on IL-2 secretion is lost, as would be expected in 
increasing concentrations of a competitive agonist and a fixed concentration of antagonist. 
 
Cell survival of Jurkats after treatment with UDA and UDA/T0070907 does not 
account for IL-2 modulation  
 
To confirm that the IL-2 changes seen in Jurkats treated in the experimental 
conditions were due to UDA and UDA/T0070907 and not due to decreases of cell number, 
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the same experimental conditions as run in the experiments illustrated by Figure 5.6 were 
assayed with XTT reagent. As Figure 5.7 demonstrates, there is a statistically significant 
(p<0.05) proliferative effect of UDA. Thus the IL-2 inhibition induced by UDA is not due 
to cell death. In addition the data demonstrate that the increase of the IL-2 by those cells 
treated with the PPARγ selective antagonist T0070907 are not due to an increase in cell 
number.  
 
Effect of PPARγ activation by UDA on transcriptional activation of c-jun and c-fos  
 
The IL-2 promoter contains several regulatory elements that can bind different 
transcription factors, including NFAT, AP-1, and NFκB (Crabtree, 1989). Recent 
investigations have demonstrated that UDA inhibits NFκB expression in Jurkats (Matthias 
et al., 2008). AP-1, a collaborator of NFAT, has also shown to be inhibited by 15d-PGJ2 
and ciglitazone, established ligands of PPARγ (Chung et al., 2003). C-fos protein and it 
heterodimeric partner, c-jun, generate the AP-1 complex (with other basic leucine-zipper 
proteins). Consequently, the role of PPARγ in Jurkat cells was investigated by measuring 
the transcript levels of c-jun and c-fos by RT-PCR. Under experimental conditions as 
previously described with the exception of using 1 and 20 μg/mL of UDA against 
PMA/PHA stimulated Jurkats, nuclear extracts were harvested for RT-PCR analysis and 
supernatants were collected for a confirmatory IL-2 ELISA. The ELISA confirmed 
statistically significant IL-2 inhibition for both concentrations tested (1 and 20 μg/mL) but 
unexpectedly, not for TZD (Figure 8A). 
Agarose (1.5%) gel electrophoresis analysis of RT-PCR products generated by different 
primer pairs (jun, fos) provided relative spectrophotometric quantitation (Figures 5.8B and  
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Figure 5.8. Relative quantitation in IL-2 protein and transcription factors c-fos and c-jun in response 
to UDA. 
  
All graphs and gels represent the same experiment with cells harvested for PCR and supernatants collected 
for IL-2 ELISA. Cells were exposed to 4.42 μg/mL TZD (black bars), 1.0 μg/mL UDA (light gray bars) and 
20 μg/mL UDA (dark grey bars) Expression normalized to the PMA/PHA stimulated groups (Vehicle 
Control) which were set at 1. Electrophories agarose gel (1.5%) images are stained with ethidium bromide 
and illuminated with UV light. A. IL-2 change in Jurkats as assessed by IL-2 ELISA. B. c-fos change as 
assessed by PCR. C. c-jun change as assessed by PCR.  
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5.8C). The various PCR analyses demonstrate effects on the transcription of the assayed 
genes by UDA and TZD (4.42 μg/mL positive control). The expected inhibition of c-fos by 
TZD was observed (Figure 5.8B) although it is mild, however TZD had a slight 
stimulatory effect on c-jun transcription (Figure 5.8C). Conversely, the UDA had a 
stimulatory effect on c-fos at both concentrations of 1 and 20 μg/mL (Figure 5.8B). A mild 
inhibitory effect was observed on c-jun at 20 μg/mL but not at 1 μg/mL (Figure 5.8C). 
Although by visual inspection, the appearance of the 1 μg/mL band appears to be more 
intense than the appearance of the vehicle control, the densitometry indicates otherwise. 
This was verified repeatedly, including by running a 10 fold dilution of the PCR products 
and confirming the number sets.  
The involvement of c-jun and c-fos in IL-2 expression has been previously 
established. The activity of the AP-1 transcription factor has been utilized to establish the 
involvement of the nuclear receptor and upstream transcription factor PPARγ. Modest 
decrease of AP-1 is correlated with PPARγ agonism (Rockwell et al., 2006). 
 
Treatment of 3T3-L1 preadipocytes with UDA as an indicator of PPARγ 
involvement 
 
The 3T3-L1 cell line has been widely established as a model to indicate PPARγ activity 
since Wright et al (2000) produced pharmacological data demonstrating that PPARγ 
function is required for hormonally induced differentiation. Considering that PPARγ is not 
highly expressed by Jurkats, 3T3-L1 differentiation was utilized to confirm or refute the 
hypothesis that UDA induces PPARγ activity.  
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Vehicle Untreated Vehicle Untreated + Insulin TZD 10 μM + Insulin 
UDA 5 μg/mL + Insulin UDA 7.5 μg/mL + Insulin UDA 10 μg/mL + Insulin 
 
Figure 5.9. Dose-dependent response of 3T3-L1 cell differentiation by UDA.  
 
Increasing concentrations of UDA enhance 3T3-L1 differentiation, as observed by microscopy. 3T3-L1 cells 
were plated in 6 well plates with 1.5 mL of medium and grown to confluence over 5 days. After confluence 
was achieved, UDA, insulin positive control (10 μg/mL), TZD (10 μM), or vehicle control (EtOH/DMSO) 
were added.  Medium and treatment conditions were replenished every 2 days after PBS wash. 
Photomicrographs were taken using an Olympus inverted microscope at day 5. Results shown are 
representative of triplicate experiments. 
 
 3T3-L1 cells were grown to confluence and then exposed to experimental 
conditions including a positive control (TZD 10 μM), a negative control (insulin-10 μg/mL 
and vehicle controls), and treatment with UDA (+ insulin 10 μg/mL) at increasing 
concentrations (5.0 μg/mL, 7.5 μg/mL and 10 μg/mL). It was been previously observed 
that because 3T3-L1 fibroblast adipogenesis typically requires approximately 7 days 
coupled with the efficient processing of lipids by 3T3-L1 cells, higher concentrations of  
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PPARγ agonists are generally required as compared to other short-term assays such as IL-2 
secretion in Jurkats (Rockwell et al., 2006).  
Differentiation of 3T3-L1s was assessed morphologically by the relatively round 
shape of the adipocytes and by the presence of the obvious prominent lipid vacuoles seen 
by microscopy. Figure 5.9 shows that the vehicle control and the insulin control exhibit no 
differentiation, while UDA induced a dose dependent adipogenesis in 3T3-L1 cells that 
was morphologically indistinguishable from that induced by the selective PPARγ agonist 
positive control (TZD).  
 
Discussion 
 
PPARγ plays a role in a variety of diseases including diabetes, atherosclerosis, 
inflammation, cancer and autoimmune disorders (Desvergne et al., 2004; Khan and 
Vanden Heuvel, 2003; Rees et al., 2008; Vamecq and Latruffe, 1999; Yuan et al., 2004). 
Thus, novel PPARγ ligands may offer further therapeutic options in a wide array of 
diseases.  PPARγ ligands include fatty acid derivatives, as well as the selective PPARγ 
agonists known as the thiazolidinediones (TZDs). Both class of compounds have been 
shown to reduce IL-2 levels in T cells (Clark et al., 2000; Cunard et al., 2004; Itoh et al., 
2008; Yang et al., 2000; Yang et al., 2002). This effect has been shown to be due to 
binding of the PPARγ nuclear receptor by reporter assays (Rockwell et al., 2006). 
Moreover, endocannabinoids, which share common structure with some of the unsaturated 
alkylamides, have been shown to reduce IL-2 levels via PPARγ (Rockwell and Kaminski, 
2004; Rockwell et al., 2006).  
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Previous work has demonstrated ambiguous results on the effects of alkylamides on 
IL-2. A number of isolated alkylamides from Echinacea spp., the 2,4-diene alkylamides,  
have shown IL-2 inhibition in a model utilizing PMA/PHA and Jurkat cells (Sasagawa et 
al., 2006). However, a model system using PMA/ionomycin along with purified 2,4-diene 
alkylamides showed no IL-2 effects on rat splenocytes  (Goel et al., 2002). Extracts of 
echinacea, rather than isolated alkylamides, have also shown ambiguous results.  Extracts 
void of alkylamides have no effect on IL-2 levels (Luettig et al., 1989), while 50% 
ethanolic extracts of the most common commercial Echinacea spp. also showed no effect 
on IL-2  in an ex vivo model of human T lymphocytes infected with influenza virus 
(McCann et al., 2007). In older subjects (> 64 y/o) IL-2 was reduced by the commercial 
species E. pallida and E. angustifolia, but not E. purpurea (50% ethanol extracts-ex vivo). 
In the same model system young subjects (age not specified) lymphocytes were isolated 
and showed no IL-2 response to any echinacea species (Senchina et al., 2006). Finally, an 
in vivo murine model using continuous dosing of aerial parts (unidentified echinacea 
species) demonstrated dramatic increases in IL-2 levels from weeks 4 to 6. This effect 
declined, but were still above the norm, at weeks 7 and 8 (Cundell et al., 2003). Thus, type 
of extraction, type of immune stimulation, subject age, dose duration and concentration all 
appear to be important factors in the IL-2 response of T cells to echinacea.    
The current trend in assigning a target for the immunomodulation induced by the 
alkylamides of Echinacea spp. has been to invoke the CB2 receptor. And while much of 
the evidence is compelling, it should be noted that the CB2 receptor has variable 
expression levels in white blood cell types. For example, B cells are reported to have the 
highest expression levels of CB2 followed by natural killer cells which have similar levels 
as neutrophils and CD8 T cells. Monocytes have less CB2 expression than CD8 T cells but 
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this is considerably greater than CD4 T cells, which are reported to have the lowest level of 
CB2 expression. The Jurkat cell line has been reported to not express CB2 (Bouaboula et 
al., 1993).  
CB-2 activity has been shown for the 2,4-diene olefinic alkylamides (Raduner et 
al., 2006), the alkylamide UDA (Figure 5.1) has shown negligible affinity for CB2 
(Kliewer et al., 1994).  Raduner et al. (2006) demonstrated that inhibition of TNF-α 
expression in macrophages is partially due to CB2 activity. Nevertheless, they also found 
that the CB2 protein could not fully account for the TNF-α inhibition due to the activity of 
UDA. Moreover, UDA has shown activity in Jurkat and macrophage assays, in some cases 
effects different than the high affinity CB2 ligand the Z-tetraene (Matthias et al., 2008; 
Matthias et al., 2007). For example, in Jurkats stimulated with PMA, UDA preexposure 
caused a profound decrease in NFκB at 200 ng/mL while the same dose of Z-tetraene had 
no effect. Conversely, in Jurkats stimulated with LPS, UDA preexposure had no effect on 
NFκB, while Z-tetraene increases levels of NFκB.  
IL-2 secretion is a characteristic response of T cell activation. This cytokine is vital 
in adaptive immune response due to essential roles in T cell proliferation, differentiation 
and cell survival. Central to our discussion, both anandamide and 2-AG, in a number of 
models, demonstrate concentration dependent inhibition of IL-2 (Rockwell et al., 2006). 
Moreover, anandamide and 2-arachidonylglycerol induce a concentration-dependent 
inhibition of interleukin-2 in primary splenocytes which is unaffected by the CB1 and CB2 
antagonist, SR141716A and SR144528 respectively (Rockwell and Kaminski, 2004; 
Rockwell et al., 2006). In the same model arachidonic acid shows similar activity as 
anandamide which is attenuated by pretreatment with nonspecific COX inhibitors as well 
as COX-2 specific inhibitors (Rockwell and Kaminski, 2004).  Pretreatment with the 
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PPAR-γ antagonist T0070907 also attenuated anandamide and 2-arachidonylglycerol 
mediated suppression of IL-2 secretion (Rockwell and Kaminski, 2004; Rockwell et al., 
2006).  
Yang et al. (2000) observed that PPARγ free Jurkat cells do not have an IL-2 
response to PPARγ ligands troglitazone and 15d-PgJ2, but PPARγ expressing Jurkats did 
exhibit IL-2 inhibition in response to the those PPARγ agonists. Clark et al. (2000) and 
Rockwell et al. (2006) also found PPARγ inhibitory activity on IL-2 secretion by the 
PPARγ agonists ciglitazone and 15d-PgJ2. Rockwell et al. also ruled out CB1 and CB2 
activity on inhibition of IL-2 in their model of Jurkat cells and 2-AG ligand by 
demonstrating the inhibition of transcriptional activity of the crucial IL-2 transcriptional 
factors, NFAT and NFκB. Thus, in the absence, but not in the presence, of T0070907 IL-2 
secretion was inhibited. Finally, Rockwell et al. (2006) also found that 2-AG treatment 
doubled the PPARγ/ PPAR response elements (PPRE) and suppressed mRNA levels for 
IFN-γ and IL-4 in Jurkats. As has been previously stated, PPARs are believed to be lipid 
sensors. Thus, select fatty acids and their derivatives are recognized as PPAR ligands 
(Nakamura et al., 2004; Rodriguez-Cruz et al., 2005).  Notably, the alkylamides in 
echinacea are fatty acid derivatives. 
Using two well established PPARγ mediated biological responses, IL-2 response 
and PPARγ-dependent adipogenesis in 3T3-L1 cells, the activity of UDA was probed. As 
shown in Figure 5.6, the selective PPARγ antagonist T0070907 at 2.5 μM is effective in 
attenuating the IL-2 inhibitory effects of UDA at alkylamide concentrations between 330 
ng/mL to 1 μg/mL. This is in range of relevant physiological alkylamide concentrations 
based on in vivo human pharmacokinetic data (Matthias et al., 2005a). T0070907 appears 
to lose its ability to attenuate the IL-2 inhibition at higher concentrations of UDA. This 
Chapter 5  Alkylamide Activation of PPARγ 
175 
 
apparent loss of antagonist activity is an expected observation of competitive agonism.  
The fixed dose of T0070907 (2.5 μM) appears to be overwhelmed by increasing 
concentrations of UDA ranging over two orders of magnitude.  It is also possible that at 
high UDA concentrations, IL-2 inhibition occurs independently of PPARγ activity.  
Alternatively, recent data suggests that the PPARγ receptor, which presents a particularly 
large binding cavity as compared to other nuclear receptors, may bind more than one 
ligand at a time (Itoh et al., 2008). For example, rosiglitazone, a selective PPARγ agonist 
structurally similar to the agonist used in these studies, occupies only about 40% of the 
ligand-binding site in the ternary complex of PPARγ, leaving adequate room for other 
ligands (Nolte et al., 1998). Crystal structures of PPARγ demonstrate that PPARγ can bind 
two 9-(S)-hydroxyoctadecadienoic acid molecules concurrently (Itoh et al., 2008). Thus a 
more involved explanation of the loss of the antagonism by T0070907 at higher UDA 
concentrations may be that PPARγ is binding both T0070907 and UDA at the same time 
and this may result in an overall IL-2 inhibitory effect.  
Past evidence demonstrates that PPARγ's ability to repress the activities of 
numerous transcription factors, including NF-κB, NFAT and AP-1 has diverse activity on 
immune and inflammatory responses (Jiang et al., 1998; Park et al., 2003; Ricote et al., 
1998; Shipley and Waxman, 2003).  For example, PPARγ is known to be up-regulated 
during the activation of mouse and human T cells (Cunard et al., 2002; Tautenhahn et al., 
2003; Wang et al., 2002) and this has been found to be time and concentration dependant 
(Cunard et al., 2002; Tautenhahn et al., 2003).  Intriguingly, up-regulation of PPARγ has 
been reported to be in response to the anti-inflammatory cytokine, IL-4, in murine T cells 
(Cunard et al., 2002).  In turn, the PPARγ ligand, rosiglitazone has been observed to up-
regulate IL-4 production (but is down-regulated by 2-AG) (Efrati et al., 2009).  
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The IL-2 promoter is reported to increase in activity after T cells are treated with 
PMA/PHA (Yang et al., 2000).  The IL-2 promoter contains several regulatory elements 
that can bind different transcription factors, including NFAT, AP-1, and NFκB (Crabtree, 
1989). AP-1, a dimer consisting of c-jun and c-fos, results in a cooperative composite 
enhancer (NFAT∙AP-1) that regulates expression of many cytokine genes including the 
upregulation of IL-2 (Macian et al., 2001). Without AP-1, NFAT cannot bind to DNA-
NFAT sites. However, on activation, PPARγ physically associates with the NFAT to block 
NFAT binding to DNA and thus, transcriptional activity. This ultimately blocks the 
production of IL-2 (Macian et al., 2001). 
Recent evidence has shown that anandamide and lipoxygenase products, previously 
discussed as agonists of PPARγ, also have an inhibitory role on IL-2 promoters (Sancho et 
al., 2003; Yang et al., 2002). NFκB inhibition has been found to be independent of CB1, 
CB2 and the vanilloid receptor (an alternative site for cannabinoid binding) (Sancho et al., 
2003). In addition, AP-1 is reported to be inhibited by known PPARγ ligands (Chung et al., 
2003). Specific to c-fos expression in murine mesangial cells exposed to ciglitazone, there 
is a marked down-regulation of c-fos (Ghosh et al., 2003).  
It is also possible that the IL-2 inhibition could be explained by UDA acting as a 
partial agonist. The prevailing dogma, suggest that ligands for the nuclear receptor 
superfamily are classified as either ‘agonists’ or ‘antagonists’. Sporn et al. (2001) suggest 
that this is misleading, pointing out that tamoxifen, classified as an estrogen antagonist, 
acts on bone and uterine tissue as an agonist. Moreover, activity is dependent on the 
cellular milieu; tamoxifen can act as an agonist in the absence of estrogen and as an 
antagonist in the presence of estrogen in MCF-7 cells. Alkylamides have recently been 
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suggested to act as partial agonists in a fibroblast/adipocyte model (Christensen et al., 
2009). 
Christensen et al. (2009) showed that hexadeca-2E,9Z,12Z,14E-tetraenoic acid 
isobutylamide, up to 200 μM, stimulated glucose uptake but did not induce adipocyte 
differentiation as compared to control. However, they did find induction of adipogenesis in 
a PPARγ activation dependent model (DEX) and inhibition of adipogenesis in a PPARγ 
independent model  (MDI) for an undisclosed concentration of dodeca-2E,4E-dienoic acid 
isobutylamide, an alkylamide found in both main commercial species of echinacea 
(Christensen et al., 2009).  However this alkylamide did not exhibit PPARγ activation 
except at high concentrations (80 μM).  
UDA, is considered a 2-ene alkylamide, which commonly contain diacetylinic tails. 
Levels of 2E-monoene diacetylenic alkylamides, like undeca-2E-ene-8,10-diynoic acid 
isobutylamide, appears to be dependent on the age of the echinacea plant. In the six species 
in which UDA has been identified, E. angustifolia, E. sanguinea, E. simulata, E. 
tennesseensis, E. atrorubens, E. laevigata, it is significantly higher in concentration in the 
older plants (Wu et al., 2004). Interestingly, previous work has suggested the highest 
concentration of UDA is found in E. sanguinea (Wu et al., 2004). E. simulata is also 
known to contain relatively large concentrations of UDA (Bauer and Foster, 1991). 
Of the two main commercial species that constitute echinacea extract preparations, 
E. angustifolia and E. purpurea, the 2-ene alkylamides are more characteristic of the 
alkylamides found in E. angustifolia. This is opposed to the 2,4-diene alkylamides, more 
characteristically found in E. purpurea, which are more commonly olefinic alkylamides. 
However, both echinacea species contain olefinic and acetylinic classes of alkylamides 
(Spelman et al., 2009). The olefinic 2,4-dienes have demonstrated moderate to high CB2 
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affinity, while the diacetylinic 2-enes have thus far, with few exceptions, demonstrated 
negligible CB2 affinity (Raduner et al., 2006). Considering Christensen et al. (2009) recent 
work demonstrating activation of PPARγ in fibroblasts with olefinic alkylamides at high 
concentrations (40-100 μM) and our results showing PPARγ activation with a diacetylinic 
alkylamide at much lower concentrations (22-44 μM), it is possible that other diacetylinic 
alkylamides which have lower affinities for CB2 than the olefinic alkylamides, may 
activate PPARγ.   
Accordingly, it may be that E. angustifolia and E. purpurea differ in the degree of 
PPARγ and CB2 mediated immunomodulation. Previous studies report that the alkylamide 
investigated here, UDA, comprises 5% of the alkylamide content of E. angustifolia root 
(Matthias et al., 2005b).  Furthermore, up to 55% of E. angustifolia alkylamides possess a 
diacetylenic tail like that of UDA, and a large percentage of these are also 2-ene 
alkylamides (Wills and Stuart, 1999). This is in contrast to E. purpurea root, which does 
not contain UDA in detectable concentrations (Spelman et al., 2009), and contains less 
than 45% diacetylenic alkylamides overall (Matthias et al., 2005b).  
A series of experiments comparing the ethanol extracts of E. angustifolia and E. 
purpurea on a series of cytokines, suggested that E. angustifolia had more immune activity 
than E. purpurea. Of interest, previous reports by the eclectic physicians of the early-mid 
19
th
 to mid 20
th
 century, who brought echinacea into clinical practice, suggested that the 
two species differed in effect (King et al., 1898).  Further research is needed to evaluate 
how E. angustifolia and E. purpurea vary in their effects, possibly due to differential 
actions on pathways such as PPARγ and CB2. Future investigations should explore if the 
echinacea alkylamides subtly shift endocannabinoid and PPARγ tone without the profound 
side effects observed with the synthetic cannabinoids and the PPARγ TZD ligands.  
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These results should be interpreted carefully. There are other proteins known to 
directly influence adipocyte differentiation besides PPARγ. This includes 
CCAAT/enhancer binding proteins (C/EBP), and the basic helix-loop-helix-leucine zipper 
transcription factor sterol regulator element-binding-protein-1c (Yeh et al., 1995).  
Synthetic and endogenous PPARγ agonists have been demonstrated to block C/EBP 
transcriptional activity by forming PPARγ∙C/EBPβ complexes. Activation of C/EBP is 
known to engage the PPARγ pathways in both 3T3-L1 cells (Lefterova et al., 2009) and T 
cells (Blanquart et al., 2003). Of particular relevance, a recent gene microarray suggested 
C/EBPβ is an upstream activation node for many of the pathways activated by echinacea 
(Altamirano-Dimas et al., 2007). Further investigations are needed to more clearly 
elucidate the role of PPARγ in the presented results.   
 
Summary 
 
These experiments illustrate the involvement of PPARγ in the inhibition of IL-2 
secretion by T cells in response to undeca-2-ene-8,10-diynoic acid isobutylamide. The data 
indicate a decrease in IL-2 levels in this model system starting at 330 ng/mL of undeca-2E-
ene-8,10-diynoic acid isobutylamide,  which is reversed by the addition of a PPARγ 
selective antagonist. In addition, preliminary PCR studies suggest that c-fos and c-jun 
expression is altered supporting the hypothesis of PPARγ involvement and the possibility 
that UDA function as a partial agonist to PPARγ.  In addition, the dose-dependent 
differentiation of 3T3-L1 fibroblast in response to undeca-2E-ene-8,10-diynoic acid 
isobutylamide also is indicative of induction of PPARγ activity.  
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However, the possibility that other targets are involved in this effect is not ruled out 
by these data. Consequently, it is possible that there is a combination of effects due to 
PPARγ and other targets that inhibit IL-2 production and induce adipocyte differentiation. 
These results, coupled with previous results demonstrating cannabinoid activity of the 
alkylamides, suggest that the immunomodulatory potential of the echinacea alkylamides is 
likely due to polyvalent activity. Further investigations are needed to elucidate the role of 
PPARγ and other potential targets in the IL-2 inhibitory response of T cells to alkylamides, 
including undeca-2E-ene-8,10-diynoic acid isobutylamide. 
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Chapter 6 
 
Discussion 
 
 
Natural products have been called “a population of privileged structures selected by 
evolutionary pressures to interact with a wide variety of proteins and biological targets for 
specific purposes”(Koehn and Carter, 2005). The short of this is that food and medicinal 
plants may often lead to broad spectrum effects, that over an evolutionary time scale have 
become conditionally essential for human health.  
In regard to echinacea, a past prominent remedy for U.S. physicians, one of the top 
sellers in the natural products industry and currently a frequently physician prescribed 
remedy in Germany, the hunt for bioactive constituents has lead investigators into the 
elucidation of a number of constituent groups. The phenylpropanoids, such as cichoric acid 
and echinacoside, the polysaccharides and glycoproteins, the alkylamides and, most 
recently, the lipoproteins (Pugh et al., 2008) have all been considered “actives” of 
echinacea. It seems likely, through the examples of other heavily researched medicinal 
plants, that the pharmacological effects of echinacea are best studied under a network 
pharmacology model which allow for the recognition of multiple actives and effects on 
diverse biochemical pathways (Spelman, 2009).  
Nonetheless, in the series of investigations presented here, it has been necessary to 
narrow the focus to one group of constituents, or at times, even one constituent.  As a 
result this discussion will focus on the alkylamides, their extraction, metabolism and 
stability, as well as the PPARγ activity of undeca-2E-ene-8,10-diynoic acid isobutylamide 
(UDA).  
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Extraction 
 
The preliminary studies presented here suggest that the alkylamides are sufficiently 
concentrated in extracts of E. purpurea to provide biological activity. Lower 
concentrations of alkylamides than those found in  the ethanolic extracts highlighted in 
Chapter 2, have proven in pharmacokinetic tests to result in blood levels in humans of 
alkylamides ranging from 17.4 ng/mL after a single oral dose of E. angustifolia tincture 
(Dietz et al., 2001) and 44 ng/mL after a single dose of E. purpurea tincture (Matthias et 
al., 2005a) to 336±131 ng/mL after ingestion of an ethanolic extract of E. purpurea and E. 
angustifolia in tablet form (Matthias et al., 2007a). Consequently, the ethanolic extracts 
were used in all steps in these series of experiments, generating data that is relevant to 
researchers, clinicians and consumers. Of interest to all of the before mentioned groups is 
that, depending on the ratio of plant to solvent and whether the extraction is fresh or dry, 
alkylamide groups are extracted differentially.  For example, the acetylene alkylamides 
under different conditions appear to extract at different concentrations than the olefinic 
alkylamides (Spelman et al., 2009b). Due to the fact that there has been different 
bioactivity shown for the acetylene versus the olefinc alkylamide (Chicca et al., 2009; 
Gertsch et al., 2004; Matthias et al., 2008; Matthias et al., 2007b; Matthias et al., 2005b; 
Raduner et al., 2007; Spelman et al., 2009a), this is of significance to many potential 
applications of echinacea products.   
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Metabolism 
 
The metabolism of the alkylamides has predominantly focused on one alkylamide, 
dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (Z-tetraene). This alkylamide is of 
significance to due to the elucidation of its CB2 activity (Matovic et al., 2007), but also 
because of the potential of drug-herb interactions (Freeman and Spelman, 2008). It is 
present in all 3 commercial species of echinacea (and most other Echinacea spp.) and 
occurs as a series of three isomers (tetraenes). The CB2 affinity is highest for the Z-
tetraene (≈57 nM), but the other isomers, dodeca-2E,4E,8E,10Z-tetraenoic acid 
isobutylamide and dodeca-2E,4E,8Z,10E-tetraenoic acid isobutylamide, also show CB2 
affinities that could be physiologically relevant (≈4.5 & 9.1 μM, respectively).  
Thus far, two independent labs have reported the hydroxylated metabolite of the 
tetraenes reported in chapter 3 of this document (Cech et al., 2006; Matthias et al., 2005b). 
In chapter 4 a carboxylated tetraene metabolite is reported. The carboxylated metabolite 
has, thus far, shown different immune activity than the native tetraenes. Specifically, the 
carboxylated metabolite appears to have diminished IL-2 inhibitory activity. This may 
prove to be of significance as the pharmacokinetics of these compounds becomes 
understood further.  
There has been data generated on other alkylamide metabolites, namely the 
alkylamide studied in the chapter 5 on PPARγ activity of undeca-2E-ene-8,10-diynoic acid 
isobutylamide (UDA). Cech et al. (2006) have shown that after exposure to human liver 
microsomes, UDA is metabolized to a hydroxylated structure (but not carboxylated). 
While this is interesting, there is still no data available for the physiological and 
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pharmacological effects of the hydroxylated metabolites. However, a potential target for 
hydroxylated metabolites will be suggested below.  
 
Degradation 
 
Considering that the extraction process was found to generate differential 
concentrations of alkylamide types, it should be no surprise that the degradation of 
alkylamides is also variable over time. The data presented here show that the tetraenes are 
stable over one year. In comparison, the acetylenic alkylamides appear to degrade at a 
much higher rate (over 50% loss) than the olefinic tetraenes in ethanolic extracts in the 
same time period. In addition, the alkylamides are found to degrade significantly in both 
cut/sift and powdered forms of echinacea root.  
This finding is key to researchers, clinicians and consumers. For researchers it 
suggests that the age of the plant material purchased and the processing of the plant 
material are key to generating full spectrum alkylamide extracts. Even if isolation of 
alkylamides is the goal, the quantity of alkylamides makes a difference on expense, time 
investment, energy investment and quantity of solvents. For clinicians and consumers, it 
suggest that all echinacea products are not created equal and that besides the expected 
expiration date, products should ideally have a harvest date, and a processing date. If the 
alkylamides (or the phenylpropanoids) are the dominant active constituents in echinacea, 
and this is still debatable, then the age of the material will potentially have a significant 
impact on efficacy. Moreover, due to differential effects of the alkylamides, an aged 
echinacea remedy may have different bioactivity than an extract made with newly 
harvested plant material. This is of course applicable to medicinal plant extracts generally 
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and is an impediment to rational clinical use and any regulatory efforts. There are many 
issues to be worked out regarding this issue and they include not only the data generated 
by analytical techniques, but also include politics, economics and special interest groups 
who have considerable resources to propose or oppose regulations.  
 
Bioactivity: alkylamides as PPARγ activators 
 
A number of fatty acid amides, a structurally diverse endogenous congener of 
molecules, are known to be bioactive (Table 6.1). Due to their role in cell signaling, these 
molecules, and their analogs, may prove to have diverse activity due to their interface with 
a number of receptor systems, including, but not limited to CB2 and PPARγ. Table 6.2  
 
Table 6.1. Bioactive Fatty Acid Amides 
Receptor Type Ligands 
CB1 
Anandamide; N-Dihomo-γ-linolenoylethanolamine;  
5Z,8 Z,11 Z –eicosatrienoylethanolamine; N-Acyldopamines;  
N-Arachidonoyldopamine 
CB2 
Anandamide; N-Dihomo-γ-linolenoylethanolamine;  
5Z,8 Z,11 Z -eicosatrienoylethanolamine 
GABAA Primary fatty acid amides; Oleamide 
Non-CB1/CB2 GPCR 
(aorta) 
N-Acyldopamines; N-Arachidonoyldopamine; 
GPR18 N-arachidonoylglycine 
GPR55 N-Palmitoylethanolamine 
GPR119 N-oleoylethanolamine 
PPARα 
Anandamide; N-oleoylethanolaminel; N-Palmitoylethanolamine;  
N-oleoyldopamine 
PPARγ Anandamide; N-oleoylethanolamine; ; N-oleoyldopamine 
TRPM8 Anandamide 
TRPV1 
Anandamide; N-oleoylethanolamine; N-linolenoylethanolamine; N-
linoleoylethanolamine; N-Acyldopamines; N-
arachidonoyldopamine; N-acylamino acids; N-arachidonoyltaurine 
TRPV4 N-acylamino acids; N-arachidonoyltaurine 
5HT2A, 5HT2C, 5HT7 Primary fatty acid amides; Oleamide 
From (Farrell and Merkler, 2008) 
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illustrates the endogenous ligands of CB2 and PPARγ and key alkylamides of echinacea 
that have shown PPARγ activity or CB2 activity. Table 6.2 includes UDA, the alkylamide 
found to activate PPARγ in Chapter 5. 
Besides the N-alkylamides found in a variety of plant families, the N-
acylethanolamines with their ethanolamide head group, are also worthy of mention. In 
addition, enzymes involved in these fatty acid derivatives biosynthesis and degradation, 
may also be a source of further insights in the activity of this class of molecules in 
mammalian systems. In particular, COX and LOX are relevant.  Considering the broad 
activity exhibited by the fatty acid amides, there is a wide range of activities including 
cancer, cardiovascular disease, inflammation, pain, drug addition, eating disorders, anxiety 
and depression (Farrell and Merkler, 2008). 
PPARγ plays a profound role in metabolic and immunological processes and as a 
result may play a role in many disease processes. Thus far this includes inflammation, 
cancer and autoimmune disorders and the list is growing (Desvergne et al., 2004; Khan and 
Vanden Heuvel, 2003; Rees et al., 2008; Vamecq and Latruffe, 1999; Yuan et al., 2004). 
PPAR  ligands inhibit the expression of proinflammatory
 
cytokines such as IL-1ß, IL-2, 
IL-6, IL-8, MCP-1,
 
TNF- , and MMPs in various cell types. This includes cell types such 
as monocyte/macrophages,
 
endothelial cells, smooth muscle cells, and adipocytes. These 
activities have been reported to be due to transcriptional regulation
 
and nontranscriptional 
interference with signaling pathways
 such as NFκB (p65, p50), NFAT, activator protein-1 
(AP-1 = fos·jun), MAPK cascade, and STAT-1/STAT-3 (Chinetti et al., 2000; Dubuquoy 
et al., 2002).   
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Table 6.2. Ligands of CB2 and PPARγ 
CB2 ligands PPARγ ligands 
1. 
O
NH
OH
Anandamide MW 347.3 (PPARγ)  
6. 
O
OH
O  
15-deoxy-Δ
12,14
-prostaglandin J2  
MW 316.4 (fibroblasts activity 7 μM) 
2. 
O
O
OH
OH
 
 
 
2-arachidonylglycerol MW 378.3 (PPARγ)  
7. 
O
OH
OH  
13-hydroxyoctadecadienoic acid MW 296.4 
3. 
N
H2
O
 
 
Dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide  
MW 247.3 (5 μM monocytes isomeric mix; PPARγ 
activation fibroblasts at 80 μM)) 
8. 
O
OH
O  
13- oxooctadecadienoic acid MW 294.4 
4. 
N
H2
O
 
 
Dodeca-2E,4E-dienoic acid isobutylamide 
MW 251.3 (PPARγ activation fibroblasts at 80 μM) 
9. 
N
H2
O
 
 
 
Undeca-2E-ene-8,10-diynoic acid isobutylamide 
MW 231.3 (fibroblast activity 22-44) μM;T cell 
activity 1.4 μM) 
5. 
N
H2
O
 
 
Dodeca-2E,4E,8Z-trienoic acid isobutylamide 
MW 249.3 (PPARγ activation fibroblasts at 80 μM) 
10. 
O
NH2
 
Hexadeca-2E,9Z,12Z,14E-tetraenoic acid 
isobutylamide MW 303.3(fibroblast activity 30 μM) 
a. When information was available concentrations found to be active are stated. 
b. Compounds 3 & 4 are also PPARγ activators. 
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As discussed in chapter 5, the endogenous cannabinoid ligands anandamide and 2-
AG, bind the PPARγ nuclear receptor. This has brought pause to cannabinoid researchers 
as the resolution of the signal transduction by CB2 has been obscured. For example, IL-2 
inhibition was thought to be a classic CB2 response (Kaplan et al., 2005). Most recently 
however, two independent groups have shown that IL-2 inhibition is due to endogenous 
and some synthetic cannabinoids binding to PPARγ (Clark et al., 2000; Kaplan et al., 
2005; Ouyang et al., 1998; Rockwell and Kaminski, 2004; Rockwell et al., 2006). In 
regard to echinacea, these results suggest the possibility of metabolic and immunogenic 
effects mediated by PPARγ. While the immunogenic effects of the alkylamides of 
echinacea are already well established, little to no work has been done on metabolic 
activity of echinacea. Thus far, two papers have suggested that the alkylamides of 
echinacea may have an influence on the physiological metabolism of fatty acids and blood 
glucose via PPARγ (Christensen et al., 2009; Spelman et al., 2009a). The Spelman (2009a) 
paper is a summation of Chapter 5. Christensen et al. (2009) suggested that the lipophilic 
fractions of E. purpurea could be useful in the management of insulin resistance and type 2 
diabetes. While this is possible, it is intriguing that one of the traditional uses of echinacea 
is listed as diabetes (Duke and Duke, 2002; Mills and Bone, 2000). 
 
Are there previous investigations suggesting PPAR activity? 
 
Gertsch et al. (2006) argues for the alkylamides being classified as 
cannabinomimetics due to an overall effect similar to cannabinoids; IL-2 inhibition and a 
Th biasing effect towards an increase of Th2 activity (Klein, 2005). However, the same 
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argument can be made for PPARγ which modulates immune function in a Th2 direction 
(Saubermann et al., 2002; Yang et al., 2002). Hence, in consideration of the results  
presented in chapter 5, in addition to CB2 activity, at least some of the alkylamides may 
mediate their immunomodulatory effects through PPARγ activity.    
Besides the investigations that show direct PPARγ involvement for the alkylamides 
of echinacea (Christensen et al., 2009; Spelman et al., 2009a), many of the previous 
investigations into echinacea and the alkylamides of echinacea can be extrapolated to 
suggest PPARγ activity. This includes the IL-2 activity, anti-neoplastic and life extension 
effects of echinacea extracts (Brousseau and Miller, 2005; Currier and Miller, 2001; 
Sasagawa et al., 2006). 
The IL-2 inhibition, previously discussed as due to PPARγ signaling (Rockwell and 
Kaminski, 2004; Rockwell et al., 2006), of other alkylamides besides UDA has been 
demonstrated (Sasagawa et al., 2006). Sasagawa et al. (2006) showed that dodeca-
2E,4E,8Z,10Z-tetraenoic acid and dodeca-2E,4E-dienoic acid isobutylamides also inhibited 
IL-2 activity. While both of these alkylamides have been reported to be CB2 ligands, this 
suggest the possibility of PPARγ activity as well. In unreported experiments, I found that 
both of these alkylamides at moderate to high concentrations (≈43 μM) induced 3T3-L1 
differentiation. Christensen et al. (2009) also reported that these alkylamides induced 
PPARγ activation although only weakly at high concentrations (40-100 μM).  
Besides these observations, more indirect extrapolations can be made. For example, 
a series of experiments have shown that the ingestion of a commercially prepared E. 
purpurea extract extends life in murine models. In one experiment, healthy mice were 
dosed daily (0.45 mg/mouse) from 7 weeks of age to 13 months. By 13 months, 46% of the 
control group was alive as opposed to 74% of the experimental group. In addition, NK cell 
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counts were elevated and stayed elevated throughout the experimental groups lifetime as 
compared to the controls (Brousseau and Miller, 2005). In another investigation, mice were 
injected with leukemic cells and started on the same dose and preparation of E. purpurea. 
By day 9, an elevation of NK cells was seen in the experimental group. By day 27 the 
untreated mice had died and by 3 months, 1/3 of the echinacea treated group were still 
alive and went on to live full life spans with 2 x the normal NK cell count as normal mice 
(Currier and Miller, 2001). Finally, mice that were immunized against leukemia 5 weeks 
prior to injection with live leukemic cells, exhibited a survival rate of about 30%. When 
echinacea was combined with the immunization, the survival rate went up to 60% group 
(same dose and preparation). In this case the echinacea treated group had NK levels 3 x the 
immunized mice. Intriguingly, past studies on structure activity relationships of 
alkylamides have suggested that some of these compounds promote terminal 
differentiation of leukemia to a benign state (Harpalani et al., 1993). However, these 
previously mentioned effects have not been shown for an echinacea preparation containing 
only alkylamides or isolated alkylamides. 
What is interesting about the results suggesting PPARγ activation by alkylamides is 
that activation of PPARγ is known to increase life span (Chung et al., 2008; Erol, 2007; 
Martin et al., 2006; Yamagishi et al., 2009; Zhang and Zheng, 2008)  and have a 
modulatory role on NK cells (Zhang et al., 2004; Zhang and Young, 2002). Notably, 
PPARγ ligands have a positive influence on leukemia models (Abe et al., 2002; Emi and 
Maeyama, 2004; Liu et al., 2009) and synergize with known leukemic cancer drugs (Bertz 
et al., 2009).  
Considering that select alkylamides may have PPARγ activity and CB2 activity, E. 
angustifolia and E. purpurea may differ in the degree of PPARγ and CB2 mediated 
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immunomodulation as suggested in Chapter 5. If the olefinic alkylamides do activate 
PPARγ, the fact that E. angustifolia has less of these olefins (< 45%), which are the 
primary alkylamides shown to target human CB2 (Raduner et al., 2006; Woelkart et al., 
2008), suggest that there may be differences in the physiological activity of echinacea 
species based on the concentration of the various alkylamide species.  
 
Other possible targets;  C/EBP, RXR, TRPV1      
 
The C/EBP protein  
 
There is also the possibility that CCAAT/enhancer binding proteins (C/EBP), and 
retinoic X receptor (RXR) proteins are involved in the immunomodulatory activity of 
echinacea alkylamides. The C/EBP protein (like PPAR) are synthesized in multiple 
isoforms and are involved in a broad range of physiological processes including as a 
mediator of IL-6 transcription and signaling (Poli et al., 1990). Due to their leucine zipper 
structure, they are able to form both homo- and heterodimers with other proteins.  
In the case of 3T3-L1 differentiation there has been controversy over which 
receptor is the “master” regulator. C/EBPα, which induces its own expression as well as 
the transactivation of PPARγ, is reported as the transcriptional master regulator of late 
adipocyte differentiation (Camp et al., 2002). Though, without C/EBPβ early stage 
differentiation would not proceed either (Lefterova et al., 2008). 
Besides a prominent role in adipocyte differentiation, C/EBP is known to play a 
role in IL-2 inhibition. C/EBPβ has been shown to suppress IL-2 and IFN expression and 
accordingly, plays a role in the commitment of Th0 cells to differentiate towards Th2 cells 
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(Berberich-Siebelt et al., 2000). Synthetic and endogenous PPARγ agonists have been 
demonstrated to block C/EBP transcriptional activity by forming PPARγ∙C/EBPβ 
complexes. 
Further support for the alkylamides of echinacea influencing C/EBP activity comes 
from gene microarrays. Altamirano-Dimas et al. (2007) reported that C/EBPβ was a likely 
upstream activation node for many of the pathways activated by echinacea after running 
their data through Ingenuity Pathways Analysis software.  
 
The RXR protein  
 
RXRs, occurring in 3 isoforms α, β, γ, are known as the major heterodimer partners 
of several nuclear receptors including the PPAR isoforms. The endogenous ligand is 9E 
retinoic acid, yet another fatty acid like molecule. RXR heterodimers bind to a variety of 
ligands derived for cholesterol, fatty acids, and glucose to regulated target genes that 
mediate metabolic homeostasis (Nohara et al., 2009).  
PPARγ is an obligate heterodimer with the RXR to transduce signals. As with other 
PPAR nuclear receptors, a ligand binding to PPARγ or RXR promotes dimerization, 
interaction with DNA and modulates transcription of several genes (Sun et al., 2007). The 
PPAR ∙RXR heterodimer is known to play a key role in mediating the inflammatory 
process and therapeutic applications
 
in inflammation-related diseases are underway 
(Desreumaux et al., 2001; Dubuquoy et al., 2002). 
Of interest, the PPAR ∙RXR heterodimer responds to ligands for either receptor 
and binding of both receptors is a synergic integration of two ligand-dependent pathways. 
Although the lipophiles that bind RXR appear to be more complex than the N-alkylamides, 
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the metabolized versions of alkylamides are remotely similar to the retinoids. Moreover, it 
may be possible that PPARγ binding of alkylamides may recruit endogenous retinoic acid 
to bind RXR, thereby synergizing the effect of the alkylamides. 
 
The Vanilloid Receptors  
 
The vanilloid family of receptors also known as the transient receptor potential 
cation channels are currently known to have 6 distinct receptor members in humans 
(Vennekens et al., 2008). The transient receptor potential cation channel, member 1 
(TRPV1), was the first vanilloid receptor identified and is also called the capsaicin receptor 
as it binds the alkylamide capsaicin from Capsicum annum (chili peppers). The TRPV1 
receptor is known to play a role in nociception resulting from inflammation and 
neuropathic pain (Tobin et al., 2002). Central to this discussion, the endogenous 
cannabinoids are known to bind this receptor.  
While Gertsch’s (2006) investigations have suggested that the alkylamides from 
echinacea did not bind TRPV1, others have shown that hydroxylated alkylamides may 
bind TRPV1 and another vanilloid receptor member, TRPA1 (Riera et al., 2009). The 
metabolites of the alkylamides need to be investigated for possible vanilloid receptor 
activation.  
 
Synergic activity? 
 
Synergy is often cited as a potential basis of action for many medicinal plant 
species (Kirakosyan et al., 2009; Spelman et al., 2006; Williamson, 2001). Considering the 
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number of compounds found in a medicinal plant extract, it seems highly likely that either 
pharmacokinetic potentiation or pharmacodynamic enhancement is likely for certain 
medicinal plant extract. For example, an Actea racemosa (black cohosh) product has been 
shown to modulate over 400 genes in MCF-7 cells (Gaube et al., 2007). In the case of 
echinacea, considering the activities that have been suggested, including antimicrobial, 
antioxidant, anti-inflammatory and immune upregulation, it is possible that synergic 
activity plays a role in echinacea’s activity on the immune system.     
Recent work by Chicca et al. (2009) has shown pharmacodynamic synergic activity 
by the alkylamides on the cannabinoid system. This includes inhibition of fatty acid amide 
hydrolase (FAAH), the enzyme the controls the half-life of the endogenous cannabinoids, 
direct binding to CB2 and facilitated transport of the endocannabinoids (Chicca et al., 
2009). 
Given that PPARγ binds the endogenous cannabinoids, it is also possible that an 
extended half-life of the endocannabinoids, a pharmacokinetic potentiation, prolongs 
signaling of the PPARγ and CB2 systems. In effect, this may lead to pharmacodynamic 
synergic activity due to alkylamide activation and extended half-life of the endogenous 
agonists of PPARγ and CB2. In addition, considering that the RXR∙PPARγ heterodimer 
responds to ligands for either receptor and binding of both receptors represents an 
integration of two ligand-dependent pathways, this generates further potential 
pharmacodynamic enhancement. Furthermore, due to the possibility of PPARγ receptor 
binding two ligands simultaneously, the likelihood of additive, synergic or antagonistic 
activity just within the PPARγ LBD domain is also possible.  
Besides the alkylamides there are other compounds that have recently shown 
PPARγ and CB2 activity in echinacea species. For example, kaempferol, a ubiquitous 
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flavonoid also found in echinacea, exhibits ligand and allosteric effector properties on 
PPARγ (Fang et al., 2008; Liang et al., 2001; Spelman and Burns, 2009). β-caryophyllene, 
occurring in echinacea and many other medicinal plant species is also a CB2 agonist 
(Gertsch et al., 2008). Such multi-pathway activation by diverse constituents as well as 
polyvalent activity by just the alkylamides generates a plethora of complexities that 
obscure the role of any one constituent in signaling pathways. With the existing data it 
does appear that multiple pathways, at least PPARγ and CB2 signal transduction pathways, 
converge for an immunomodulatory effect by the alkylamides, and possibly other 
constituents. 
 
Future work 
 
Considering the presented data on PPARγ activity by UDA, and the previous work 
by Christensen et al. (2009) and Spelman et al. (2009a), there is building evidence that 
PPARγ may be a key site in the alkylamide induced immunomodulation of echinacea. In 
light of the previous discussion, there are also other key sites to consider besides PPARγ 
and CB2 as discussed above. 
As we gain further insights into the interaction between cellular 
signaling/regulation and botanical compounds or food constituents, Shay et al. (2005) 
suggest a few principles are crystallizing. First, as with the alkylamides, it is increasingly 
obvious that one ingested dietary compound may interact with a number of systems such 
as PPAR regulation, antioxidative protection, and effects on cell signaling processes. 
Second, the inherent promiscuity of nuclear receptors permits the interface of multiple 
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phytochemicals with the lipid and immune regulating systems of the body (Shay and Banz, 
2005). 
The complexity of studying multicomponent remedies requires models that can 
assess multiple pathways simultaneously, since ingestion of a medicinal plant product (or 
food plant) likely activates multiple pathways. While the polyvalent nature of medicinal 
plant extracts adds to the potential of complex signal transduction, which is difficult to 
fully comprehend in current in vitro and in vivo models, recent technological 
breakthroughs such as gene microarrays and the “omics” platforms, in combination with 
new constructs such as network pharmacology, offer more realistic maps of real-time 
physiology.  
A common argument about medicinal plants is that they must be “assessed” in 
similar models as single chemical entities. While safety is of the utmost of importance and 
a rational requirement for the multicomponent products originating from medicinal plants, 
the current safety (and efficacy) model is based on the assessment of single molecules with 
steric factors and electronic forces that differ from the majority of the 
1
biosynthesized 
molecules. An evaluation of molecules generated from natural products shows that many 
do not conform to Lipinski’s rule of 5, a foundational principle used in drug development 
to guide the structural development of new chemical entities. This leads to the question, is 
it rational to evaluate the less complex new to nature molecules synthesized in laboratories 
by the same criteria as a series of molecules selected, through hundreds of millions of years 
of evolutionary high throughput screening, for different structural foundations? 
Intriguingly, the alkylamides do not conform to Lipinski’s rule of 5 (Basso et al., 2005; 
Gertsch et al., 2006) yet appear to offer a therapeutic option to modulate immune function.  
                                                          
1
 Biologically active allelochemicals/secondary metabolites from plants. 
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Future work may show that a diet rich in phytochemical content may result in 
complex signaling patterns, similar to what early humans were accustomed to, via a variety 
of promiscuous nuclear receptors, as well as other enzymes and receptors systems, that 
cannot be observed by following only one food or botanical constituent (Shay and Banz, 
2005). 
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A critical evaluation of drug interactionswith
Echinacea spp.
Camille Freeman1, 3 and Kevin Spelman2, 3
1 Department of Physiology and Biophysics (MS candidate), Georgetown University, Washington, DC, USA
2 Department of Chemistry and Biochemistry, University of North Carolina, Greensboro, NC, USA
3 Department of Herbal Medicine, Tai Sophia Institute, Laurel, MD, USA
Accurate information concerning drug–herb interactions is vital for both healthcare providers and
patients. Unfortunately, many of the reviews on drug–herb interactions contain overstated or inaccu-
rate information. To provide accurate information on drug–herb interactions healthcare providers
must account for product verification, dosage, medicinal plant species, and plant part used. This crit-
ical review assessed the occurrence of drug interactions with one of the top selling botanical rem-
edies, echinacea including Echinacea angustifolia, E. pallida, and E. purpurea. Only eight papers
containing primary data relating to drug interactions were identified. Herbal remedies made from
E. purpurea appear to have a low potential to generate cytochrome P450 (CYP 450) drug–herb inter-
actions including CYP 450 1A2 (CYP1A2) and CYP 450 3A4 (CYP3A4). Currently there are no ver-
ifiable reports of drug–herb interactions with any echinacea product. However, further pharmacoki-
netic testing is necessary before conclusive statements can be made about echinacea drug–herb inter-
actions. Given our findings, the estimated risk of taking echinacea products (1 in 100 000), the num-
ber of echinacea doses consumed yearly (A10 million), the number of adverse events (a100) and that
the majority of use is short term, E. purpurea products (roots and/or aerial parts) do not appear to be
a risk to consumers.
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1 Introduction
Medicinal plants, while necessarily part of healthcare in
developing regions, are becoming increasingly popular in
the industrial nations. Estimates suggest that up to 30% of
the North American population use herbal supplements [1].
Given that nearly 3.6 billion prescriptions were purchased
in 2005 [2] and 30% of Americans report using five or
more drugs in the sameweek [3] it comes as no surprise that
the incidence of consumers taking herbs in conjunction
with prescription medications is quite high. Eisenberg et al.
[4] found that up to 15 million adults were concurrently
using prescription medications and herbal supplements. A
nationwide telephone survey by Kaufman et al. [5] supports
this, finding that 16% of respondents had taken both pre-
scribed medications and supplements in the week preceding
the interview.
Echinacea is one of the most popular herbal supplements,
with a sales ranking of #2 in the mass market [6] and total
sales in 2006 (excluding Walmart sales), reaching more
than $36 million in the US [7]. Native Americans intro-
duced echinacea to European settlers, after which it became
one of the most popular remedies used by the Eclectic
physicians for a variety of conditions including septicemia,
typhoid fever, and catarrhal conditions of the respiratory
and reproductive tracts [8, 9]. Additionally, physicians prac-
ticing from the 19th century through the mid 20th century
used echinacea to treat other infections and counteract ven-
omous snakebites [10]. Echinacea was included in the
National Formulary from 1906 until 1950, eventually fall-
ing out of favor as pharmaceuticals came to dominate clini-
Correspondence: Kevin Spelman, Department of Chemistry and Bio-
chemistry, 435 Science Bldg, UNCG, Greensboro, NC, USA
E-mail: spelman123@earthlink.net
Fax: +1-336-334-5402
Abbreviations: CYP 450, cytochrome P450; CYP1A2, cytochrome
P450 1A2; CYP3A4, cytochrome P450 3A4; CYP2D6, cytochrome
P450 2D6; OATP-B, organic anion-transporting polypeptide; ROS, re-
active oxygen species
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cal therapeutics. Currently, the aerial portion of Echinacea
purpurea and the roots of E. pallida are approved for colds
and infection of the respiratory and urinary tracts by the
German Commission E [11].
The current body of scientific literature on echinacea can
be confusing not only due to the multiple species in use –
namely E. purpurea, E. pallida, and E. angustifolia – which
have phytochemical similarities, but also have notable dif-
ferences, particularly around the identity and concentration
of alkylamides and other key constituents [12–14]. Even
though 80% of the echinacea products sold to consumers
are made from purpurea [15], all three species are often
used interchangeably for the treatment of cold, flu, respira-
tory infection, and inflammation [16]. Multiple species,
plant parts, and preparations are also used, each of which
may have a different constituent profile [17]. “Echinacea”
may refer to the roots, aerial parts, whole plant, or a combi-
nation of the above; echinacea products can be made from
fresh or dried plant parts, and may be prepared by juicing,
alcohol extraction, infusion, decoction, or consumed as tab-
lets or capsules [18].
Many authors suggest that taking herbs such as echinacea
is potentially unsafe for those taking prescription medica-
tions, and statements of warnings/cautions about drug–
herb interactions are frequently found in the scientific and
medical literature [19–21]. In discussing ranking schemes
of medicinal plant efficacy and safety, Mills (Mills, S., sub-
mitted pers. comm.) points out that if safety statements
were graded to the same rigor as efficacy statements, most
of the papers citing poor safety records of herbal remedies
would fail the burden of proof. For example, Messina [19],
as well as Vickers and Zollman [21], citing an inaccurate
report that echinacea is hepatoxic due to pyrrolizidine alka-
loid content [22], contend that echinacea should not be used
with known hepatotoxic drugs. Other authors have noted
that the echinacea poses no risk of hepatoxicity [23–25].
The saturated pyrrolizidines found in echinacea lack any
toxicity, unlike unsaturated pyrrolizidines which are highly
susceptible to nucleophilic reactions [26].
To the detriment of the healthcare field, such misleading
information appears to be common in the literature, misin-
forming healthcare providers and unnecessarily frightening
patients. Brazier and Levine [27] found that of 240 articles
that pertained to drug–herb interactions, the majority of the
reports were anecdotal – less than 10% reported primary
data. Coon [28] reported that of 165 possible drug–herb
interactions, only 13% were supported by clinical data. Of
the 352 papers we found as relevant to drug interactions
with medicinal plant preparations in a MEDLINE search
limited to 2006, only 4.2% were actual case reports and
4.0% were clinical trials. It appears that the vast majority of
the data on drug–herb interactions are not based on primary
reports. Hence, the aim of this review is to provide a critical
evaluation of the primary literature on the evidence of drug
interactions with Echinacea spp.
2 Methods
We searched the MEDLINE, SciFinder Scholar, Web of
Science, Cochrane Library, CAPLUS, and EBSCO data-
bases using the terms echinacea, and “drug interaction,”
“herb–drug interaction,” or “P-glycoprotein” with a cutoff
date of 12-15-2006. A manual search of bibliographies
from published articles was also performed. Inclusion crite-
ria included the following research models: clinical trials,
in vivo, ex vivo, and in vitro investigations. The search was
limited to English-language papers; otherwise no limits
were placed on the search.
The authors independently assessed abstracts and titles
of each publication for evidence pertaining to drug–herb
interactions, and acquired full articles that made comments
on any Echinacea species and drug–herb interactions. Pub-
lications that referenced an interaction but did not contain
an original report were excluded; only primary literature
was assessed. Each interaction reported in the primary liter-
ature was evaluated by both authors and later reconciled.
Disagreements were resolved by discussion and consensus.
3 Results
Of the 49 articles located, only 8 contained primary evi-
dence of potential interactions between echinacea products
and drugs. All other articles either referenced these eight
primary studies or were based upon hypothetical interac-
tions (Table 1). Three of these primary articles did not con-
tain complete information about the dosing used [29–31];
only four indicated that the product used was verified
before the research was undertaken [31–34]. One of the
eight papers tested echinacea in combination with other
herbs [30], and therefore yielded little useful information
concerning interactions due to echinacea alone and was
eliminated from the review.
No documented case studies of echinacea–drug interac-
tions were found. Of the eight primary papers, only two
were conducted in a human model [32, 35]. No clinical
pharmacokinetic studies that tested coadministration of
echinacea products and pharmaceuticals were available.
Table 2 summarizes the cytochrome P450 (CYP 450) mod-
ulation reported in the eight primary papers.
3.1 Cytochrome P450 interactions
3.1.1 CYP 450 1A2 (CYP1A2)
Both Gurley et al. [35] and Gorski et al. [32] report human
pharmacokinetic results involving CYP1A2. In a study of
12 volunteers who took 1600 mg/day E. purpurea root for
8 day, Gorski et al. [32] found significant reduction in oral
caffeine clearance by 27%. The authors postulated that
inhibition at this level could affect CYP1A2 substrates with
narrow therapeutic index such as theophylline and cloza-
2
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pine. Gurley et al. [35] found no significant inhibition of
CYP1A2 in healthy volunteers after 28 day of 1600 mg/day
of whole-plant extract of E. purpurea, although a 13%
decrease in 6 h paraxanthine/caffeine values suggested a
possible inhibitory effect of E. purpurea whole-plant
extract on CYP1A2. This effect, however, was not statisti-
cally significant and was not considered clinically signifi-
cant by the authors.
3.1.2 CYP2C9
Yale and Glurich [31] using an unrevealed concentration of
a remarkably concentrated 50:1 E. purpurea aerial extract,
3
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Table 1. Primary research on drug interactions with Echinacea spp.
Author System tested Species and part used Model Comments
Budzinski et al.,
2000
CYP3A4 Tinctures of (ratio unknown),
55% EtOH of E. angustifolia
+ E. purpurea (1:1, part unknown);
E. angustifolia roots; E. purpurea roots;
E. purpurea tops
In vitro – fluorometric microtiter
plate assay
Ratio of plant material: menstruum was
not available. Thus dosing unclear the 1:1
ratio refers to proportion of E. angustifolia
to E. purpurea. Products used were not au-
thenticated.
Foster et al.,
2003
CYP3A4,
CYP2C9,
CYP2C19,
CYP2D6
Echinacea Plus – blend including
E. purpurea and angustifolia (plant
part not specified), extract of E.
purpurea root, and assorted other
herbs; Echinacea special – 210 mg
\(triple Echinacea\) root per cup, 18 mg
standardized E. purpurea root extract
per cup
In vitro – aliquots screened for
ability to affect in vitro metabolism
of marker substances
Teas were mixtures, dosing of echinacea
unclear, parts used unclear in some cases,
mixed teas were not inspected visually or
authenticated
Fuchikami et al.,
2006
OATP-B E. purpurea, aerial parts In vitro – uptake of estrone-3-
sulfate (an OATP-B substrate)
measured in human embryonic
kidney 293 cells
No human studies contextualize clinical
relevance of this info; paper does not indi-
cate if product was verified to actually be
E. purpurea
Gorski et al.,
2004
CYP1A2,
CYP2C9,
CYP2D6,
CYP3A
E. purpurea, root In vivo – 12 human volunteers
underwent a control phase to
test for metabolism of substrates
of these 4 enzymes; then they
took 400 mg E. purpurea root QID
for 8 day. Substrates were readmi-
nistered and blood/urine samples
taken
Formulation used was previously tested by
Consumer Labs and shown to have >1%
phenols. No adverse events reported by
volunteers or observed by researchers
Gurley, 2004 CYP3A4,
CYP1A2,
CYP2E1,
CYP2D6
Echinacea purpurea,
whole-plant extract
In vivo – 12 young adults partici-
pated in an open-label study
randomized for supplementation
sequence (three other herbs were
tested). Took 800 mg BID for
28 day. Phenotypic metabolic
ratios were used to determine
probe drug clearance before and
after supplementation periods
While mean levels were not affected, there
was interindividual varaion – some indi-
viduals appear to have significant inhibi-
tion or induction. One person had a minor
rash while taking Ech. Product used was
tested for marker compounds to confirm
identity of E. purpurea
Moulick and
Raner, 2003
CYP2E1,
CYP1A
E. purpurea, root In vitro – substrate p-nitrophenol
concentration monitored using
human liver microsomes and
expressed CYP450 2E1 and 1A2
Only abstract available. Direct communi-
cation with author provided information on
species, plant part, dose, etc.
Raner et al.,
2007
CYP2E1 E. purpurea, root; isolated
alkylamides; cichoric acid
In vitro – substrate p-nitrophenol
concentration monitored using
human liver microsomes and
expressed CYP450 2E1
Extract characterized by MS, individual al-
kylamides and cichoric acid also tested
Yale and Glurich,
2005
CYP2D6, 3A4, 2C9 E. purpurea, aerial portion, used cap
with 50 mg of 50:1 extract, 15%
pressed juice
In vitro – well plates with cDNA-
derived enzymes in microsomes
prepared from baculovirus-in-
fected insect cells
Product tested by Consumer Lab to ensure
identity of product and minimal lot-to-lot
variation
C. Freeman and K. Spelman Mol. Nutr. Food Res. 2008, 52, 000–0004
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Table 2. The Effect of Echinacea spp. on CYP 450
CYP 450
isoform
Species Plant part Preparation Concentration
(dose)
Model Results Author
1A purpurea Root 95% EtOH, 1:2
fresh
0.2–2% In vitro No effect on ethoxycoumarin
metabolism
(Moulick and Raner,
2003)
1A2 purpurea Root Capsule 1600 mg/
day68 day
In vivo 27% z in oral caffeine clear-
ance
(Gorski et al., 2004)
1A2 purpurea Whole plant Capsule 1600 mg/
day628 day
Clinical trial 13% z in paraxanthine/caffeine
serum ratios, not statistically
significant
(Gurley et al., 2004)
2C9 purpurea Aerial 50:1 extract (15%
pressed juice)
Unspecified In vitro Inhibition of 7-methoxy-4-tri-
fluoromethyl coumarin
[31] (Yale and Glurich,
2005)
2C9 purpurea Root Capsule 1600 mg/
day68 day
In vivo 11% – in oral tolbutamide
clearance
(Gorski et al., 2004)
2D6 purpurea Aerial 50 mg of 50:1 ex-
tract (15% pressed
juice)
Unspecified In vitro No effect on AMMC metabo-
lism
(Yale and Glurich,
2005)
2D6 purpurea Root Capsule 1600 mg/
day68 day
In vivo No effect on metabolism of
dextromethorphan
(Gorski et al., 2004)
2D6 purpurea Whole plant Capsule 1600 mg/
day628 day
Clinical trial No statistical significance in 4-
hydroxydebrisoquin/[debriso-
quin 4-hydroxydebrisoquin])
urinary ratios
(Gurley et al., 2004)
2E1 purpurea Root 95% EtOH 1:2
fresh
0.4% In vitro 29% inhibition of p-nitrophenol
metabolism
(Raner et al., 2007)
2E1 purpurea Whole plant Capsule 1600 mg/
day628 day
Clinical trial No statistical significance in 6-
hydroxychlorzoxazone/chlor-
zoxazone serum ratios
(Gurley et al., 2004)
3A4 angustifolia Root 55% EtOH ratio
unspecified
Unspecified IC50
1–2%
In vitro IC50 extrapolated, inhibition of
7-benzyloxyresorufin metabo-
lism
(Budzinski et al.,
2000)
3A4 angustifolia + -
purpurea 1:1
Part unknown 55% EtOH ext, ra-
tio unspecified
Unspecified IC50
A5% and a10%
In vitro Inhibition of 7-benzyloxyresor-
ufin metabolism
(Budzinski et al.,
2000)
3A4 purpurea Aerial 55% EtOH ratio
unspecified
Unspecified IC50
A5% and a10%
In vitro \)Moderately inhibitory\) (IC50
A5% and a10%), concentration
unlikely to be physiologically
relevant
(Budzinski et al.,
2000)
3A4 purpurea Aerial 50 mg of 50:1 ex-
tract, 15% pressed
juice
Unspecified In vitro No inhibition of resorufin benzyl
ether and \(mild inhibition\) of
7-benzyloxy-4-trifluoromethyl
coumarin
(Yale and Glurich,
2005)
3A4 purpurea Root 55% EtOH ratio
unspecified
Unspecified IC50
A1% and a5%
In vitro Inhibition of 7-benzyloxyresor-
ufin metabolism
(Budzinski et al.,
2000)
3A4 purpurea Root Capsule 1600 mg/
day68 day
Clinical trial No change in oral clearance of
midazolam; though FH and FG
affected differently volume of
distribution (AUC) not signifi-
cantly affected
(Gorski et al., 2004)
42% – systemic clearance;
18% z FH; FG – two-fold; 50%
– Foral of midazolam
3A4 purpurea Whole plant Capsule 1600 mg/
day628 day
Clinical trial No statistical significant differ-
ence in 1-hydroxymidazolam/
midazolam serum ratios
(Gurley et al., 2004)
HLM purpurea Root 95% EtOH 1:2
fresh
0.4% In vitro 27% inhibition of p-nitrophenol
metabolism
(Raner et al., 2007)
AMCC 3-[2-(N,N-diethyl-N methyl amino) ethyl]-7-methoxy-4-methylcoumarin; HLM, human liver microsomes; FH, hepatic availability;
FG, GI availability.
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reported mild in vitro inhibition. Gorski et al. [32] reported
an 11% reduction in clearance of tolbutamide, a substrate
of CPY2C9, after 8 day of E. purpurea root supplementa-
tion. Gorski et al. [32] suggest this interaction is not clini-
cally significant.
3.1.3 CYP 450 2D6 (CYP2D6)
Evidence from the Gurley et al. [35] and Gorski et al. [32]
studies presented above, as well as in vitro evidence from
Yale and Gurlich [31] have shown no interaction between E.
purpurea (aerial parts or root) and CYP2D6. Both human
studies concluded that no interactions were expected
between E. purpurea and substrates of CYP2D6.
3.1.4 CYP2E1
Gurley et al. [35] found no significant effects on CYP2E1
after 28 day of 1600 mg/day E. purpurea whole-plant
extract. In vitro data from Raner et al. [34], suggest inhibi-
tion of CYP2E1 by an ethanolic extract of E. purpurea root,
reporting a concentration of 2 lL/mL of a 95% EtOH
extract producing a 27–29% inhibition. Of particular inter-
est was the finding that the same concentration of a 33%
EtOH extract of E. purpurea root did not demonstrate
CYP2E1 inhibition.
3.1.5 CYP3A4
Conflicting data were reported for CYP3A4; in vitro
research, some at concentrations not obtainable with oral
dosing, suggested mild to strong inhibition on CYP3A4
while human trials show no overall CYP3A4 activity. Bud-
zinski et al., using benzyloxyresorufin as a substrate and
extract of (i) the E. purpurea aerial portion or (ii) a mixture
of E. purpurea aerial portions and E. angustifolia root (1:1),
observed moderate inhibition of CYP3A4 (unspecified
extract ratio, IC50 A5% and a10%). Using solely the roots
of both angustifolia and purpurea resulted in higher inhibi-
tion of CYP3A4 (unspecified extract ratio, IC50 A1% and
a5%) [29]. The concentrations of extracts used in these
assays, if typical of commercial extracts, are unobtainable
by oral dosing.
Further in vitro research by Budzinski et al. [29]
reported a significant difference in the effects of E. pur-
purea versus E. angustifolia roots on CYP3A4. While
E. angustifolia demonstrated a strong inhibitory effect on
CYP3A4 activity, E. purpurea was found to be a mild
inhibitor of CYP3A4 for 7-benzyloxy-4-trifluoromethyl-
coumarin metabolism and had no activity on resorufin
benzyl ether metabolism, except at nonrelevant physiolog-
ical concentrations (resulting in mild inhibition) [35].
Another in vitro investigation [29] demonstrated hydroe-
thanolic extracts of E. purpurea aerial portion and a com-
bination of E. purpurea and E. angustifolia (plant parts
unspecified) moderately inhibited CYP3A4-mediated
7-benzyloxyresorufin metabolism while root extracts of
E. purpurea and E. angustifolia demonstrated strong inhib-
ition. Unfortunately, not enough data were provided to cal-
culate the concentration of plant material that generated
these results.
Human investigations by Gorski et al. [32], found no
changes in the metabolism of midazolam, a CYP3A4 sub-
strate, after participants ingested 1600 mg of E. purpurea
root daily for 8 day. While the authors observed an 85%
increase in intestinal availability of midazolam, a 15%
reduction of hepatic availability (p a 0.003) was also noted.
The authors postulated that the induction of hepatic
CYP3A4 counteracted inhibition of intestinal CYP3A4,
leading to little to no effect in midazolam metabolism over-
all [32]. Using E. purpurea whole-plant extract (aerial and
root combined) in a human trial Gurley et al. [35] found no
statistically significant differences in CYP3A4 phenotypic
ratios [35]. CYP 450 phenotypic ratios have been shown to
provide a practical method for predicting CYP-mediated
drug interactions [35].
3.2 Organic anion-transporting polypeptide
(OATP-B)
Fuchikami et al. [36] found inhibition ofOATP-B by the aer-
ial parts of E. purpurea in vitro. The clinical significance of
this finding is unclear, as few drugs are metabolized via this
pathway and the findings have not been demonstrated in
vivo.
3.3 P-glycoprotein
No primary reports involving the constituents of any Echi-
nacea species could be found.
4 Discussion
The search for and appraisal of information relating to
drug–herb interactions are a challenge for researchers and
educators; accurate, readily accessible information for the
medical community is lacking. Unfortunately, reports on
drug–herb interactions have only recently been published
in the scientific literature. Perhaps due to the void in pri-
mary data, it appears that the majority of authors make rec-
ommendations without evaluating the quality of evidence
from which their conclusions are drawn.
A common shortcoming of many drug–herb interaction
reports is that investigators fail to report species, plant part
used, preparation type and concentrations assayed, and/or
dose, each of whichmay affect the accuracy of reporting and
the potential for drug–herb interactions. Additionally, a
recent study of echinacea products found that the relation-
ship between labeled milligrams and measured milligrams
was poor, suggesting that clinical and research studies may
be difficult to correlate with the products taken by consum-
ers [37].
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Our results demonstrate that although drug–herb inter-
actions related to echinacea products were cited in some 49
articles, only 16% (8) of these 49 papers contained primary
data relevant to interactions between echinacea products
and pharmaceuticals. Two studies were clinical trials [32,
35] and the remaining were in vitro assays, three of which
did not contain complete information about the concentra-
tion of extract used [29–31]; only half of the studies veri-
fied the authenticity of the echinacea [31–34]. One paper
was dropped because echinacea was used in combination
with other herbs [30].
The bulk of the available data on possible drug–echina-
cea interactions concerns the CYP 450s, a large family of
hepatic phase I detoxification enzymes that also are essen-
tial in a myriad of enzymatic reactions implicated in tissues
other than the liver [38]. CYP 450 genes code for enzymes
that play a role in the metabolism of drugs and foreign
chemicals as well as arachidonic acid metabolism and for-
mation of eicosanoids, cholesterol metabolism, bile acid
synthesis, steroid metabolism, vitamin D and vitamin A
metabolism [38]. CYP450s are crucial in understanding the
clinical pharmacology of drug interactions in addition to
interindividual variability in drug metabolism.
In vitro studies suggest that E. purpurea root may mildly
reduce clearance of substrates of CYP1A2 and CYP3A4.
Human trials by Gorski et al. [32] and Gurley et al. [35]
demonstrate wide interindividual variability of metabolism
of various echinacea preparations. Gurley et al. [35] con-
cludes that there is a minimal risk of drug interaction from
echinacea preparations. These data suggest that, as is the
case with pharmaceutical drugs, while the general effect of
echinacea products on consumers may be insignificant, rare
individuals within the group could possibly experience a
more significant induction or inhibition of these enzyme
systems or drug transporters. In general, further study of
interindividual variability is needed.
CYP1A2,whichmetabolizes theophylline and other phar-
maceuticals, may be particularly relevant for asthma
patients. It must be mentioned, however, that clinicians have
observed an improvement of asthma and bronchitis with
echinacea use, suggesting that echinacea may be useful to
asthmatics [39]. Supporting these observations, Sharma et
al. [40] found that preparations of root and aerial portions of
echinacea reversed the inflammatory response of human
bronchial epithelial cells to rhinovirus. Furthermore, partic-
ular alkylamides of Echinacea spp. are cyclooxygenase [41,
42] and lipoxygenase [41, 43] inhibitors, as well as antiviral
[14, 44] and cannabionomimetic [45–49]. Considering that
such activity may offer a significant reduction of spasm and
the inflammatory processes of asthma [50–52], possibly
protect against upper respiratory tract infections [53] and
that echinacea inhibition of CYP1A2 is insignificant to mild
as found in the human trials reviewed here, recommenda-
tions for individuals with asthma to halt echinacea should be
reserved for exceptional circumstances.
Echinacea may mildly inhibit the CYP 450 3A4 enzyme
system; this inhibition may be tissue specific. For example,
Mouly et al. [54] report that selected substrates can increase
hepatic CYP3A activity, yet have no effect on intestinal
CYP3A4 or, conversely, substrates may generate CYP
intestinal activity without inducing hepatic effects. Gorski
et al. [32] also report tissue specific activity, finding that E.
purpurea root extracts demonstrate inhibition of intestinal,
and induction of hepatic, CYP3A activity. The molecular
rationale behind these differential effects is still unclear.
Gorski's group suggests that echinacea root preparations
taken with high oral availability/low clearance drugs (e.g.,
alprazolam) may induce hepatic CYP3A4 resulting in
decreased serum concentrations. Conversely, they suggest
that low oral clearance/first-pass metabolism drugs (e.g.,
buspirone) taken with echinacea might result in increased
drug serum concentrations. More data are needed to support
this contention [32].
It has been suggested that CYP3A4 is the most important
enzyme for the metabolism of antineoplastic drugs [55].
Thus the information that echinacea may modulate, even
weakly, the activity of 3A4 may encourage healthcare pro-
viders to warn against the use of echinacea with patients
undergoing chemotherapy. However, such warnings could
be disadvantageous to the patient; in vivo studies of E. pur-
purea aerial parts demonstrate a reduction in chemotherapy
induced leucopenia [12, 56–59], while E. purpurea root
has demonstrated stimulation of natural killer cells [60–62]
and prolongation of life in leukemic mice [63]. Addition-
ally, a number of Echinacea species and constituents have
demonstrated direct antineoplastic activity in vitro [64–
66]. Thus again, case by case recommendations are needed
for cancer patients rather than a generalized recommenda-
tion to halt echinacea use.
Another isoform of the CYP 450 system, CYP2D6, is
known to play a primary role in the metabolism of pharma-
ceuticals used to treat psychiatric disorders (attention defi-
cit/hyperactivity disorders, bipolar disorder, depression,
schizophrenia) as well as cardiovascular disorders (b-block-
ers). E. purpurea products containing root or aerial parts in
both human [35] and in vitro models [31] has shown no
activity on CYP2D6. The current research suggests that no
interactions are expected between E. purpurea products and
substrates of CYP2D6.
The available data also suggest that extraction condi-
tions, the various species and botanical part of echinacea
have differing effects on the CYP 450 enzyme system [34].
For example, Raner et al. [34] found that the hydrophobic
constituents of E. purpurea (e.g., alkylamides) are much
more inhibitory to CYP450 than its hydrophilic constituents
(e.g., phenylpropanoids) and this work is in agreement with
other CYP 450 evaluations [67]. Recent work by Spelman
et al. (Spelman, K., Wetschler, M. H., Cech, N. B., submit-
ted.) demonstrated quantitative and qualitative differences
in alkylamide concentrations, including the alkylamides
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reported to modulate CYP activity, depending on the
extraction technique and the use of fresh or dry plant mate-
rial in ethanolic preparations of E. purpurea radix. Thus,
ethanolic extracts as well as other echinacea preparations
may differ in their activity on the CYP 450 system and
therefore generalizations about echinacea products and
drug–herb interactions may be misleading (Spelman, K.,
Wetschler, M. H., Cech, N. B., submitted.).
Although there are two human trials in this collection of
data, the remaining five studies attempt to extrapolate data
from in vitromodels. The fact that replicating relevant mod-
els of human physiology are difficult with in vitro methods
is widely acknowledged. Researchers are globally aware
that in vitro experimental models are often poorly represen-
tative of in vivomodels, especially in regard to gene expres-
sion, enzyme levels and metabolism [68]. One constraint
includes the absence of digestive and metabolic processing
of compounds within an extract by in vitro models
(although one study, Fuchikami et al. [36], attempted a
“digestion” in their model). Cech et al. [69] has demon-
strated that alkylamide metabolites of human liver micro-
somes have different immunological activity as compared
to their nonmetabolized counterparts, yet such significant
findings are frequently missed in vitro. Another limitation
concerns the experimental concentrations of echinacea
extracts utilized for in vitro models. Two of the studies
appear to have used concentrations of extract that are
impossible to achieve by oral dosing of echinacea extracts
[29, 31]. Central to the evaluation of these studies are the
previous investigations that have demonstrated that 0.4 ng/
mL (l0.31 ng/mL) are the maximum serum levels reached
by the dominant alkylamide, dodecatetraenoic acid isobuty-
lamide, in echinacea [70]. This particular alkylamide has
been previously shown, in vitro, to play a role in inhibition
of CYP 450 3A4 [67]. A more recent study has suggested
that the lowest obtainable IC50 for CYP 3A4 of dodecate-
traenoic acid isobutylamide to be 1.96 mg/mL, almost
5000-fold higher than the predicted concentration within
hepatocytes [71]. Thus, within the restraint of the available
data, it seems unlikely, even with chemical potentiation by
other echinacea constituents, that echinacea will generate
drug interactions, via CYP 450, of any consequence.
A more obscure and less considered complication of in
vitro research is the oxidative stress inherently generated by
in vitromodels. The increased exposure to oxygen due to in
vitro conditions leads to significant reactive oxygen species
(ROS) generation and may produce results that are not
reflective of in vivo conditions [68]. Key to this issue is that
many CYP 450 mechanisms are based in redox chemistry.
In considering in vitro research on the CYP 450 system,
increased ROS generation due to in vitro conditions may
skew the results of these assays. In the case of echinacea
extracts, increased ROS generation is particularly likely
due to the ease of oxidation of the polyphenols of echina-
cea. Accordingly, there is an obligatory caution that must
be observed in extrapolating data derived from in vitrowork
to clinical realities, especially in regard to CYP 450 assays.
A missing yet, crucial point in much of the drug metabo-
lism literature is that fruits, vegetables, grains, and legumes,
with their inherent phytochemical content, modulate
CYP450 enzyme expression, and activity [72]. Yet, except
for grapefruit, and tyramine-containing foods, the majority
of discussion on drug–herb interactions involves herbal
medicine and neglects the more frequently consumed plant-
based foods. Humans are routinely exposed to foods such as
the cruciferious vegetables with their indole-3-carbinols
that modulate phase I and phase II detoxification [38]. The
ubiquitous flavonoids found in most plant-based foods are
also known to modulate a number of isoforms of CYP 450
[73]. Other commonly consumed phytochemicals such as
caffeine are known to modulate CYP 450 function [73].
Hence, it is crucial that pharmacokinetic studies investigat-
ing the possibility of drug–herb interactions control for
diet. Fortunately, Gorski et al. [32], requested CYP 450
appropriate dietary restrictions of their subjects, as did Gur-
ley et al. [35]. However, in both trials dietary restrictions
depended on voluntary compliance as there is limited
opportunity for such trials to impose dietary restrictions
without significant burden. Nonetheless, to avoid ambigu-
ity and to provide optimal evaluation of drug–herb interac-
tions, it is crucial that clinical trials on drug–herb interac-
tions include measures to rule out dietary effects on drug
metabolism.
Ultimately, to generate clinically relevant data on the
CYP 450 enzyme system, multiple substrate concentrations
as well as multiple test inhibitor concentrations are required
[27, 28, 74]. Unfortunately, this is commonly neglected in
both in vitro and in vivo research and leaves much to the
unknown. In the meantime, it appears that many warnings
about the effects on Echinacea spp. on drug–herb interac-
tions and the CYP 450 system have been based on inad-
equate evidence leading to inaccuracies in the literature.
We suggest more objective and detailed methods for
reporting drug–herb interactions. Since many consumers
do not realize that herbs qualify as supplements, investiga-
tors, and clinicians must enquire about both “supplement”
and “herb” use when recording a proper medical history
[29]. Additionally, product verification, dosage, species,
and plant part used need to be documented. Occurrences of
potential drug–herb interactions need to be investigated
with greater accuracy and detail to identify what is clini-
cally relevant and what is not. Currently, 68–90% of data
on drug–herb interactions is based on unsubstantiated or
poor quality information [28] resulting in anecdotal report-
ing.
Of the three Echinacea species typically used in herbal
medicine, the available research predominantly focused on
E. purpurea, which accounts for 80% of commercial pro-
duction [15]. No case reports were found documenting an
echinacea–drug interaction, a finding supported by other
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reviewers [19, 74–77]. The fact that echinacea products
rank second in sales of herbal remedies in the US [6] and
the number of people using multiple pharmaceuticals (A75
million) [3], suggest that drug–herb interactions with echi-
nacea products are uncommon events. Barrett [78] con-
cludes that less than 100 serious adverse events have been
reported involving echinacea for an estimated A10 million
courses of treatment, leaving the risk estimate of less than 1
in 100000.
5 Conclusion
Currently there are no verifiable reports of actual drug–
herb interactions with any echinacea product. Both E. pur-
purea aerial parts and root appear to have a relatively low
potential to produce CYP-mediated drug–herb interac-
tions. However, further pharmacokinetic testing is required
before conclusive statements can be made. Further research
is also needed to confirm the potential for herb–drug inter-
actions involving other species of Echinacea. In order to
further clarify drug–herb interactions, healthcare providers
and researchers must account for product verification, dos-
age, species, and part used. Additionally, data obtained
from one product should not be extrapolated to other prod-
ucts, species, plant parts, or dosages.
Although there is not enough evidence to support the
need for precautions at this time, a prudent clinical
approach is to monitor patients taking echinacea products
concurrently with substrates of CYP3A4 or CYP1A2.
Given the data in this review, the number of echinacea doses
consumed yearly and that the majority of use is short term
for the treatment of upper respiratory tract infections,
E. purpurea products, consisting of roots and aerial parts,
do not appear to be a risk to consumers provided that the
preparations are authentic. Lastly, for proper public safety
measures, it is imperative that drug–herb reporting is done
methodically.
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a b s t r a c t
Echinacea purpurea (L.) Moench, a top selling botanical medicine, is currently of considerable interest due
to immunomodulatory, anti-inﬂammatory, antiviral and cannabinoid receptor 2 (CB2) binding activities
of its alkylamide constituents. The purpose of these studies was to comprehensively proﬁle the alky-
lamide (alkamide) content of E. purpurea root, and to compare yields of alkylamide constituents resulting
from various ethanolic extraction procedures commonly employed by the dietary supplements indus-
try. To accomplish this goal, a high performance liquid chromatography–electrospray ionization mass
spectrometry (HPLC–ESI-MS) method was validated for quantitative analysis of several E. purpurea alky-
lamides. Using this method, at least 15 alkylamides were identiﬁed and it was shown that fresh and dry
E. purpurea extracts prepared from equivalent amounts (dry weight) of roots, with exceptions, exhibited
similar yield of speciﬁc alkylamides. However, the amount of total dissolved solids in the dry extract
was higher (by 38%) than the fresh extract. Two extracts prepared from dried roots at different ratios
of root:solvent (1:5, w:v and 1:11, w:v) were similar in yield of total dissolved solids, but, there were
differences in quantities of speciﬁc alkylamides extracted using these two root:solvent ratios. In addition,
the important bioactive dodecatetraenoic acid isobutylamides are fully extracted from dry E. purpurea
root in 2 days, suggesting that the manufacturing practice of macerating Echinacea extracts for weeks
may be unnecessary for optimal alkylamide extraction. Finally, the identiﬁcation of a new alkylamide
has been proposed. These results demonstrate the differences of the described extractions and utility of
the analytical methods used to determine the wide-ranging individual alkylamide content of commonly
consumed Echinacea extracts.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
The investigations described herein employ high performance
liquid chromatography coupled to electrospray ionization mass
spectrometry (HPLC–ESI-MS) for the comprehensive characteriza-
tion of several extracts from themedicinal plant Echinacea purpurea
(L.) Moench. Echinacea is widely used for the treatment of upper
respiratory infections, and is a global top seller. Three main species
of echinacea are used clinically and available to consumers, Echi-
nacea pallida, E. purpurea and E. angustifolia. Of these, E. purpurea
represents 80% of commercial production [1]. E. purpurea prod-
ucts range from the injectables prepared to rigorous European
pharmaceutical manufacturing standards, to the low tech ethano-
Abbreviations: CB2, cannabinoid 2 receptor; HPLC–MS, high performance liquid
chromatography–mass spectrometry; ESI-MS, electrospray ionization mass spec-
trometry; MW, molecular weight; Tetraenes, isomers of dodeca-2,4,8,10-tetraenoic
acid isobutylamide.
∗ Corresponding author. Tel.: +1 336 334 3017; fax: +1 336 334 5402.
E-mail address: nadja cech@uncg.edu (N.B. Cech).
lic extractions or “tinctures” that follow general manufacturing
practices (GMPs) of the United States dietary supplements indus-
try. Although in Germany the aerial parts are preferred, ethanolic
extracts of echinacea root make up a large source of sales and
clinical use in the United States. Manufacturing practices gener-
ally dictate whether the starting plant material should be fresh or
dry, but in the case of echinacea species, both fresh and dry root
extracts are commercially available. To further complicate matters,
these extracts are prepared with varying ratios of plant:solvent
depending on the manufacturer. Currently, there are few investi-
gations comparing the efﬁciency of extracting active constituents
under these various extraction conditions. The few studies investi-
gating the extraction of alkylamides have generally utilized dried
root, while alkylamide extraction of fresh roots has scarcely been
studied [2]. There is currently a lack of information regarding differ-
ences in chemical compositionamongextracts preparedusing fresh
versus dried Echinacea. One of the goals of the studies conducted
herein was to provide such information.
Four constituent groups are currently believed to be the source
of activity in the echinacea genus; alkylamides (alkamides),
phenylpropanoids (caffeic acid derivatives), polysaccharides, and
0731-7085/$ – see front matter © 2009 Elsevier B.V. All rights reserved.
doi:10.1016/j.jpba.2009.02.011
Author's personal copy
1142 K. Spelman et al. / Journal of Pharmaceutical and Biomedical Analysis 49 (2009) 1141–1149
glycoproteins [3]. However, in extractions with ethanol concen-
trations above 40%, only very low levels of polysaccharides are
left in suspension, and denaturing of proteins is expected [4,5].
Thus, the major constituents of ethanolic echinacea extracts are
phenylpropanoids and alkylamides. To date, human pharmacoki-
netic studies of Echinacea spp. suggest that the alkylamides are the
major constituent group circulated in plasma [6].
Alkylamideshavebeenofpharmacological interest since the tin-
gling paresthesia from chewing plants rich in these compounds
were noted [7]. This anesthetic property was utilized by native
Americans [8] and eventually by physicians in the early 20th cen-
tury for a variety of purposes including as a sialogogue, antitussive
and for toothache. Alkylamides were later recognized as insectici-
dal [9] and oncolytic [10]. Recent investigations have demonstrated
immunomodulatory activity of alkylamides in vitro [11] and in vivo
[12], as well as direct antiviral activity [13]. Most recently, these
compounds have become a subject of interest due to their elucida-
tion as agonists of the cannabinoid receptor 2 (CB2) receptor [14].
Given that the alkylamides appear to be one of the key con-
stituent groups responsible for pharmacological activity of E.
purpurea, the studies described herein focused on this class of con-
stituents. A number of analytical studies, the bulk by Bauer et al.,
have relied on liquid chromatographywith UV detection (LC-UV) to
analyze echinacea alkylamides [15–18]. However, comprehensive
proﬁling of echinacea alkylamide content using LC-UV alone has
been challenging. These compounds are present at widely differ-
ent concentrations, and many of them are isomeric. Consequently,
co-elution of structurally similar alkylamides is common, and UV
detectorsmay not detectminor alkylamide constituents because of
low concentrations and/or co-elutionwith other compounds. Mass
spectrometry (MS) provides a distinct advantage over UV detec-
tors due to its sensitivity and the ability to select by mass the ions
corresponding to the compounds of interest [19]. As the data pre-
sented here will demonstrate, this advantage makes HPLC–ESI-MS
an ideal technique for the comprehensive analysis of the isomeric
alkylamide content in E. purpurea. Although several investigators
have previously employed HPLC–ESI-MS to the analysis of alky-
lamides in Echinacea [20–22], none of the previous methods have
been validated for quantitative purposes. Furthermore, because of
the abundance of isomeric alkylamides in E. purpurea, even with
the use of MS detectors, misidentiﬁcation or incomplete identiﬁ-
cation of alkylamides has been common [22–24]. With this study,
we present the ﬁrst validated HPLC–ESI-MS method for the analy-
sis of alkylamides in E. purpurea. This method enables quantitative
comparison of alkylamide content in various E. purpurea extracts.
In addition, by relying on MS–MS fragmentation patterns to dis-
tinguish isomeric alkylamides, we report a more comprehensive
proﬁle of alkylamide content in E. purpurea than has previously
been published.
2. Experimental
2.1. Reagents
The following chemicals and reagents were used:
Acetonitrile (high performance liquid chromatography (HPLC)
grade) (Honeywell Burdick and Jackson, Muskegon, MI), acetic acid
(Fisher Chemical, Fairlawn, NJ), alkylamide standards (Chromadex
Inc., Santa Anna, CA), ethanol (AAPER, Shelbyville, KY), nanopure
water (Nanopure Diamond D11931, Barnstead International, Ther-
molyne, Dubuque, IA).
2.2. Plant material
Cultivation of E. purpurea took place in Grants Pass, OR at Paciﬁc
Botanicals. Fresh, dormant roots of E. purpurea were harvested in
March 2007. Species was veriﬁed by Richard Cech (Horizon Herbs,
Williams, OR) and voucher specimens were submitted to the Uni-
versity of North Carolina Herbarium in Chapel Hill, NC (accession
numbers 583416 and 583417). The rootswere two years-old at time
of harvest.
2.3. Plant extractions
A typical protocol [25] for themanufacture of ethanolic extracts
was followed in all extractions, except that post washing, the roots
were brieﬂy soaked (5min) in 70% ethanol as a disinfectant, and
blown partially dry with compressed air. A loss of the isomeric
dodeca-2,4,8,10-tetraenoic acid isobutylamides (tetraenes) of 1.4%
(against ﬁnal fresh root concentrations) was calculated from the
initial rinse. The roots were then cut into small pieces (≤1 cmwide)
andextractedusing threedifferent extraction techniques, fresh root
extraction (1:2, w:v) and dry root extraction at two different root to
solvent ratios, 1:11 and 1:5 (w:v). All ratios are expressed as mass
rawplantmaterial (E. purpurea roots) inweight (g) per volume (mL)
of extraction solvent.
To prepare fresh root extracts, samples of the cut roots (65g)
were blended using a Waring Blender (Tarrington, CT) in a solvent
of 95% ethanol (AAPER, Shelbyville, KY) at a ratio of 1 g roots:2mL
solvent. Samples of root from the same batchwere dried in an oven
at 50 ◦C and water content was determined to be 74.5%. Dry root
extractions were carried out with the same method as the fresh
except that the solvent consisted of 74.5% ethanol and 25.5% water
(to account for the plant water removed upon drying). To make
these dry root extracts, 16.6 g of dried root was added to 179mL of
solvent (74.5% ethanol) for a ratio of 1:11 and 16.6 g of dried root
was added to 83mL of solvent (74.5% ethanol) for a ratio of 1:5. Four
replicate extracts were prepared at each extraction ratio (fresh 1:2,
dry 1:11 and dry 1:5).
Aliquots (dry root 1:11, 200L) for the extraction as a function
of time study were taken on a daily basis (days 2–33) during the
process ofmaceration and stored at−70 ◦Cuntil the timeof analysis
for alkylamide content. Aftermaceration for onemonth, the solvent
was removed from all of the extracts using a hydraulic press. The
extracts were then aliquoted into 1mL portions in polypropylene
microcentrifuge tubes and kept in the dark at room temperature
until needed for analysis. Previous investigations have established
stability of alkylamides under these conditions [26]. All extractions
were macerated at 24 ◦C.
2.4. Preparation of samples and standards
Prior to analysis, samples were removed from storage and
allowed to reach room temperature. Aliquots (500L) from all
extractionswerecentrifugedat14,000 rpm(SavantSpeedvacSc110,
Farmingdale, NY) for 5min. Supernatant was then diluted in the
same solvent used for extraction (70% ethanol), and pipetted
(300L) into autosampler vials (Agilent Technologies, Santa Clara,
CA) for LC-MS analysis. Several dilutions were prepared from each
extract to adjust alkylamide content to within the linear dynamic
range of the method. Neat samples were used for determination
of dodeca-2E-ene-8,10-diynoic acid and1000-fold dilutions were
used for analysis of the isomers of dodeda-2,4,8,10-tetraenoic acid
isobutylamide.
Alkylamide primary standards were purchased from Chro-
madex (Santa Anna, CA) with certiﬁcates of analysis verifying
identity by NMR and HPLC, and purity of ≥99% by HPLC.
Concentrated stock solutions of dodeca-2E-ene-8,10-diynoic acid
isobutylamide (molecular weight 245.37, lot # 04950-601) and
dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (molecular
weight 247.38, lot # 04953-102) were prepared at 5mg/mL in
ethanol and stored at 4 ◦C. The stock solutions were diluted in
Author's personal copy
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ethanol to produce ﬁnal concentrations of 0.1, 10, 50, 100 and
500M.
2.5. HPLC–ESI-MS analysis
An ion trap mass spectrometer with electrospray ionization
source (LCQ Advantage, ThermoFisher, San Jose, CA)was employed.
The solvent gradient, which was a minor variation on that previ-
ously published [21], was as follows, where solvent A is aqueous
acetic acid (17mM, original pH 2.74) and solvent B is neat HPLC
grade acetonitrile. For t=0–4min, a constant composition of A–B
(90:10, v/v); for t=4–15min, a linear gradient from A–B (90:10,
v/v) to A–B (60:40, v/v); for t=15–30min, a linear gradient from
A–B (60:40, v/v) to A–B (40:60, v/v); for t=30.1–35min, a con-
stant compositionofA–B (0:100, v/v); for t=35.1–43min, a constant
composition of A–B (90:10, v/v). The mass spectrometer was oper-
ated in the positive ion mode with a scan range of 50.00–2000.00.
Spray, capillary, and tube lens offset voltages were 4.5 kV, 3V and
−60V, respectively.
2.6. Quantitative and qualitative analysis of alkylamides
Constituents in the extracts were identiﬁed according to
their molecular weights, HPLC retention times, and previously
established MS–MS fragmentation patterns [27]. For quantitative
determination of alkylamide content, calibration curves were plot-
ted as the log of the area of the selected ion chromatogram for
the protonated alkylamide of interest versus the log of concentra-
tion. Extract samples were analyzed neat and at 1000-fold dilution
within the same run as the calibration standards. The concen-
trations of dodeca-2E-ene-8,10-diynoic acid isobutlyamide and of
the isomers of dodeda-2,4,8,10-tetraenoic acid isobutylamidewere
determined by plugging the relevant peak area into the linear
regression equation for the corresponding calibration curve. All
samples for which quantitative comparisons were made were ana-
lyzed within a single run.
2.7. Method validation
Method validation was conducted according to International
Committee of Harmonization (ICH) guideline [28]. Alkylamide
standards prepared as described in Section 2.4 were analyzed in
triplicate on three separate days (for a total of 9 analyses of each
standard). To assess accuracy, a “measured concentration” for each
standard was back-calculated from the corresponding calibration
curve. The measured concentration reported was an average of
the measured concentrations calculated on three separated days.
This measured concentration was then compared to the theoret-
ical concentration of each standard, and the % relative difference
was reported as the “residual”. Repeatability was determined as
the relative standard deviation among the back-calculated concen-
trations for the triplicate analyses of each standard within a single
run. Intermediate precision was calculated as the relative standard
deviation among the back-calculated concentrations for three runs
conducted on three separate days. The limit of detection (a mea-
sure of the sensitivity of themethod) was determined based on the
concentration required to give a signal to noise ratio (S:N) of 3:1 in
the relevant selected ion chromatogram. Limit of quantitation was
based on the signal necessary to achieve a S:N of 10:1.
2.8. Statistical analysis
The standard error of the mean (SEM) was determined for
each set of concentrations or peak areas. Data are expressed as
the mean± SEM and comparison of means was conducted using
a two tailed t-test for paired data when differences were observed.
The mean values were considered signiﬁcantly different if p<0.05.
Where appropriate, outlying data points were rejected on the basis
of the Q-test. Statistical analyses were performed with Microsoft
Excel (2003).
2.9. Determination of yield of dissolved solids
Polypropylene microcentrifuge tubes (1.5mL) were weighed
before addition of 500L aliquots of centrifuged extracts. After
dehydration in the speedvac for 39h at 24 ◦C, the mass of dissolved
solids for each sample was determined. The ratio of the mass of
dissolved solids to the amount of dry root used in the equivalent
volume of extract was then calculated, providing a measure of the
quantity of dissolved solids extracted per mass of Echinacea root
(extract yield). For the fresh extract, the dryweight of the root used
for the extract was calculated by subtracting the mass of the water
contained in the roots from the total mass of the fresh roots.
3. Results and discussion
In this section, a comprehensive proﬁle of alkylamide con-
stituents in E. purpurea is listed, with a description of how these
compounds can be identiﬁed using HPLC–ESI-MS. In addition,
quantities of dissolved solids and speciﬁc alkylamides present in
various E. purpurea extracts are compared. The extracts analyzed
here were prepared using several different procedures commonly
employed in the dietary supplement industry. Analysis of these
extracts provides insight into the similarities and differences in
extract composition that result from these variations in extraction
technique.
3.1. Identiﬁcation of alkylamides
Table 1 lists alkylamides identiﬁed from E. purpurea, with refer-
ences that refer to publications in which these identiﬁcations were
made. This is the most comprehensive listing of alkylamides of E.
purpurea root to date. Most reports and reviews list some, but not
all, of thealkylamidespresent in this species [16,24,29,30]. Past esti-
mates suggest the presence of eleven alkylamides in the roots of E.
purpurea [31,32]. Table 1, lists a total of 17 compounds, although,
as described later on, some of these identiﬁcations are only tenta-
tive and one compound (C) was not detected in our samples of E.
purpurea.
Many of these compounds were present in the E. purpurea
extracts investigated here, as demonstrated in Fig. 1. This ﬁgure
shows a base peak chromatogram (Fig. 1A) obtained from analy-
sis of the 1:5 dry root E. purpurea extract. Peak labels correspond
to alkylamide designations in Table 1, and were conﬁrmed based
on comparison of retention time with previous investigations [21]
and MS–MS spectra (Table 2, Fig. 2). A few of the minor alky-
lamides in the extract were obscured by co-elution with major
alkylamides, but can be visualized through the use of selected ion
chromatograms (Fig. 1B–D).
The isomeric compounds D, E, F and G all demonstrateMH+ ions
at m/z 244 and compounds P and Q both have MH+ ions with m/z
258. Nonetheless, these alkylamides are distinguishable based on
an MS–MS spectra. Table 2 illustrates the primary fragments that
result from collisionally induced dissociation of several isomeric
alkylamides. Structurally similar fragments have been grouped
with designations of i, ii, iii, iv and v for ease of reference.
One of the major groups of fragments formed by collision-
ally induced dissociation is the acyllium ion (fragment group i
in Table 2), as previously reported by Hiserodt et al. [27]. These
ions form due to a charge-remote hemolytic cleavage that yields
a resonant distonic radical cation, which subsequently undergoes
hydrogen rearrangement. Alkylamides F and G (Fig. 2D and E) show
Author's personal copy
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Table 1
Alkylamides from Echinacea purpurea.
Designation Alkylamide MW Reference
A Undeca-2E,4Z-diene-8,10-diynoic acid isobutylamide 229.32 [32]
B Undeca-2Z,4E-diene-8,10-diynoic acid isobutylamide 229.32 [42]
C Undeca-2E-ene-8,10-diynoic acid isobutylamide 231.34 [35]
D Undeca-2E,4Z-diene-8,10-diynoic acid 2-methylbutylamide 243.35 [32]
E Undeca-2Z,4E-diene-8,10-diynoic acid 2-methylbutylamidea 243.35
F Dodeca-2Z,4E-diene-8,10-diynoic acid isobutylamide 243.35 [42]
G Dodeca-2E,4Z-diene-8,10-diynoic acid isobutylamide 243.35 [32]
H Dodeca-2E,4E,10E-triene-8-ynoic acid isobutylamide 245.37 [32]
J Dodeca-2E-ene-8,10-diynoic acid isobutylamideb 245.37 [35]
K Dodeca-2E,4E,8Z,10E-tetraenoic acid isobutylamide 247.38 [32]
L Dodeca-2E,4E, 8Z,10Z-tetraenoic acid isobutylamideb 247.38 [32]
M Dodeca-2E,4E, 8E,10Z-tetraenoic acid isobutylamide 247.38 [38]
N Dodeca-2E,4E,8Z-trienoic acid isobutylamide 249.40 [32]
O Dodeca-2E,4E-dienoic acid isobutylamide 251 41 [31]
P Trideca-2E,7Z-diene-8,10-diynoic acid isobutylamide 257.38 [31]
Q Dodeca-2E,4Z-diene-8,10-diynoic acid 2-methylbutylamide 257.38 [40]
R Dodeca-2,4,8,10-tetraenoic acid 2-methylbutylamide 261.41 [36]
a Proposed structure of newly identiﬁed alkylamide.
b Compounds J and L were utilized as standards.
Fig. 1. Characteristic chromatograms obtained by liquid chromatography–mass
spectrometry analysis of an E. purpurea root extract (1:5). Panel A shows a base peak
chromatogram (plot of the most abundant ion in the mass spectrum versus time),
with peak labels that correspond to the designations in Table 1. Several minor alky-
lamides that coelute with the compounds shown in the base peak chromatogram
can be distinguished with selected ion chromatograms, as shown in panels B (mass
range 245.5–246.5), C (mass range 249.5–250.5) and D (mass range 257.5–258.5).
an acyllium ion at m/z 171, while alkylamides D and E (Fig. 2A and
B) result in the acyllium ion at m/z 157.
Two additional fragments useful for elucidation of alkylamide
structure are the group ii and group iii fragments (Table 2). The
group ii fragments result from the loss of the amide portion alky-
lamide, and correspond to the remaining alkyl chain. The group iii
fragments are observed at an m/z value 2 amu above the group ii
fragments. Recent work utilizing deuterated alkylamides suggests
that in the diene alkylamides, group iii fragments are formedwhen
an unsaturated bond is lost and the remaining double bond shifts
to the 3 position (in 2,4-dienes), with a subsequent gain of two
hydrogens [27].
In combination, thegroup ii and iii ions canbeused todetermine
(1) whether the alkylamide is a diene; (2) how many carbons are
present in the alkyl chain; and (3) the identity of the amide moiety
(isobutyl versus 2-methylbutyl). Isobutylamideswill have two frag-
ments corresponding to a loss of 101 (group ii) and 99 (group iii)
from the MH+ precursor ion (Fig. 2D–F). For 2-methylbutylamides,
the fragmentswill reﬂect theadditional carbon in theamidemoiety,
and fragment ions corresponding to a loss of 115 (group ii) and 113
(group iii) from theMH+ precursor ionwill be observed (Fig. 2A–C).
The group iv fragments (Table 2) correspond to the MH+ ion of
the protonated alkylamide that remains after loss of the N-alkyl
group. Loss of the N-isobutyl group results in a signiﬁcant fragment
(relative intensity 26–60%) at m/z 188 for compounds F and G and
185 for compound Q, while loss of the N-(2-methylbutyl) group
Table 2
Fragments formed by collisionally induced dissociation (MS–MS) of the MH+ ion of various E. purpurea alkylamides.
Designation, name, m/z Group id,
RIc 30–90%
Group iie,
RI 30–90%
Group iiif ,
RI 60–100%
Group ivg,
RI 26–100%
Group vh,
RI < 3–20%
D 244a Undeca-2E,4Z-diene-8,10-diynoic acid 2-metylbutyl amide 157 129 131 174 188, 202, 216
E 244 Undeca-2Z,4E-diene-8,10-diynoic acid 2-methylbutylamideb 157 129 131 174 188, 202, 216
F 244 Dodeca-2Z,4E-diene-8,10-diynoic acid isobutylamide 171 143 145 188 202, 216
G 244 Dodeca-2E,4Z-diene-8,10-diynoic acid isobutylamide 171 143 145 188 202, 216
P 258 Trideca-2Z,7E-diene-8,10-diynoic acid isobutylamide 185 157 159 202 216,230
Q 258 Dodeca-2E,4Z-diene-8,10-diynoic acid 2-methylbutylamide 171 143 145 188 202, 216
a The number beneath the letter designation indicates the m/z value for the MH+ ion.
b Proposed structure for compound E based on retention time and MS/MS fragmentation.
c RI corresponds to relative intensity.
d The group i fragments correspond to acyllium ions as shown in Fig. 2.
e The group ii fragments are carbocations that correspond to the alkyl chain of the alkylamide and are formed by loss of the amide portion (isobutylamide or 2-
methylbutylamide).
f The group iii fragments correspond to the alkyl chain of the alkylamide and are formed by the loss of the amide portion of the molecule and saturation of one of the
double bonds on the alkyl chain.
g The group iv fragments correspond to the protonated alkylamide minus the N-alkyl group.
h The group v fragments correspond to the protonated alkylamide minus various portions of the N-alkyl group (see Fig. 2).
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Fig. 2. MS/MS spectra of isomeric alkylamides. This ﬁgure compares fragments that result from collisionally induced dissociation precursor ions that represent the protonated
molecular ion (MH+) of a number of isomeric alkylamides. Even ions with the same MH+ ion have different fragmentation patterns, facilitating structural assignment.
results in a fragment with m/z 174 for compounds D and E (relative
intensity 56–100%) and a fragment with m/z 202 for compound
P. The mass that is lost to form the group iv fragment serves as
an additional conﬁrmation to distinguish isobutylamides from 2-
methylbutylamides.
The ﬁnal fragments that result from collisionally induced disso-
ciation of alkylamides are group v in Table 2. They are formed by
cleavage of various C C bonds on the N-alkyl substituent (Fig. 2).
The group v fragments are useful for verifying whether the N-alkyl
substituent is a 2-methylbutylamide or isobutylamide.
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Table 3
Calibration parameters, limits of quantiﬁcation (LOQ) and limits of detection (LOD) for E. purpurea alkylamides.
Slope (±SDa) Intercept (±SDa) R2 Linearity (M) LOD (M) LOQ (M)
Dodeca-2E-ene-8,10-diynoic acid isobutylamide (J) 0.757 (±0.013) 8.00 (±0.023) 0.999 1.0–500 0.051 1.7
Dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (L) 0.813 (±0.040) 6.95 (±0.070) 0.993 1.0–100 0.99 3.3
a SD: Standard deviation.
An example of the utility of MS–MS for structural elucidation
of alkylamides can be demonstrated for the speciﬁc case of alky-
lamide P, trideca-2E,7Z-diene-8,10-diynoic acid isobutylamide. The
MS–MS spectrumof the precursor ion atm/z 258 for this compound
is shown in Fig. 2F. An acyllium ion (group i) is present at m/z 185.
This suggests a thirteen carbon alkyl chain. This chain length is fur-
ther conﬁrmed by the group ii fragment at m/z 157. The presence
of the group iii fragment (m/z 159) indicates that the compound
is indeed a diene alkylamide, and, the characteristic loss of 99 to
formthis fragment (258–159=99) suggests that thecompound is an
isobutylamide rather than a 2-methylbutylamide. The high inten-
sity group iv fragment at m/z 202 further conﬁrms that the N-alkyl
group is an isobutylamide. The low intensity group v fragments
also conﬁrm an N-isobutyl group rather than an N-2-methylbutyl
group; additional group v fragments would be observed for a 2-
methylbutylamide. Thus, the identity of the compound is proposed
to be trideca-2E,7Z-diene-8,10-diynoic acid isobutylamide, which
has previously been shown to occur in E. pallida, but rarely is
reported as occurring in E. purpurea [33]. The E/Z assignments
for trideca-2E,7Z-diene-8,10-diynoic acid isobutylamide have been
made based on comparison of the relative retention times observed
in this study with those reported previously [33], and are only ten-
tative without NMR conﬁrmation.
With HPLC–ESI-MS and MS–MS data such as those shown
in Figs. 1 and 2, all of the previously identiﬁed alkylamides
from E. purpurea in Table 1 except undeca-2E-ene-8,10-diynoic
acid isobutylamide (compound C) were identiﬁed in the extracts
prepared in this study. Although past work cites the presence
of undeca-2E-ene-8,10-diynoic acid isobutylamide in E. purpurea
root [34,35], this compound was not detected in the echinacea
extracts used for these studies. A commercially available standard
of this compound was readily detectable with limit of detection
of 0.15M, therefore, it can be concluded that undeca-2E-ene-
8,10-diynoic acid isobutylamide was not present in the extracts
at concentrations above 0.15M. Binns et al. [36], using solely UV
spectra and retention time, previously identiﬁed undeca-2E-ene-
8,10-diynoic acid isobutylamide compound in E. purpurea roots
of wild plants but not cultivated germlings. Hence, it is possible
that some genetic strains of E. purpurea contain undeca-2E-ene-
8,10-diynoic acid isobutylamide while others do not. However,
our laboratory has investigated over 20 different US sources of E.
purpurea (data not included) and thus far not detected this com-
pound. Another possibility is that previous reports of the presence
of undeca-2E-ene-8,10-diynoic acid isobutylamide in E. purpurea
weredue to improperly identiﬁedplantmaterial. AnotherEchinacea
species, E. angustifolia, does produce signiﬁcant levels of undeca-
2E-ene-8,10-diynoic acid isobutylamide, and the misidentiﬁcation
of echinacea species has often been documented [15,37,38].
In addition to aiding in structural elucidation of known alky-
lamides, with HPLC–ESI-MS it was possible to tentatively identify
a new alkylamide, the structure of which has not been previously
published. This compound is undeca-2Z,4E-diene-8,10-diynoic acid
2-methylbutylamide (compound E in Table 1). Identiﬁcation of
this compound was based on retention time and the correlation
between MS–MS fragmentation pattern and alkylamide structure.
The mass and fragmentation pattern for compound E (Fig. 2) con-
ﬁrms that it is a 2-methylbutylamide, and indicates the level of
saturation and length of the carbon chain. The mass spectral data
do not indicate stereochemistry or bond position; however, relative
retention time does suggest that this compound is the 2Z/4E isomer
of compound D. For the previously identiﬁed alkylamide isomers
that vary by the 2E/4Z and 2Z/4E stereochemistry, such as com-
pounds A/B and F/G, we have demonstrated (Fig. 1) that the 2E/4Z
isomer elutes before the 2Z/4E isomer. Thus, it is logical to assume
a similar relationship in stereochemistry between compounds D
and E. However, as noted earlier, without NMR conﬁrmation, the
reported stereochemistry of this new alkylamide is only tentative.
Bauer and Remiger previously demonstrated that with reversed
phase HPLC, alkylamides with terminal alkynes elute early in the
separation followed by tetraene alkylamides [33]. For the purposes
of this discussion, compounds A–G, J, P and Q are designated as
polyacetylene amides, while the term “tetraenes” refers to isobuty-
lamides with four double bonds in the alkyl chain. Consistent with
the Bauer study, our results (Fig. 1) indicate that the polyacetylene
amides (A, B, C, D/E, F/G, H, J, P, Q) elute early in the separation,
between 25 and 31min, followed by the tetraenes and dienes (K, L,
M, N and O). These ﬁndings are signiﬁcant in that alkynes, speciﬁ-
cally 8,10 terminal alkynes, have been shown to modulate CYP 450
function [34], while tetraene isomer L and alkylamides N and O
are ligands of the CB2 receptor [14]. The results in Fig. 1 suggest
preparatory scale HPLC could be used to separate groups of alky-
lamides with differing physiological and pharmacological activity.
3.2. Calibration results and method validation
Table 3 illustrates the linear regression equations and statistical
data for thealkylamide standards. The linear rangeof thecalibration
curves was from 1 to 500M for dodeca-2E-ene-8,10-diynoic acid
isobutylamide (J), and from 1 to 100M for dodeca-2E,4E,8Z,10Z-
tetraenoic acid isobutylamide (L). Correlation coefﬁcients (R2) of
the alkylamide standards were 0.999 (J) and 0.993 (L). The limit of
detection (concentration required to give a signal to noise ratio,
S:N, of 3:1) for isobutylamides dodeca-2E-ene-8,10-diynoic acid
and dodeca-2,4,8,10-tetraenoic acid were 0.051 and 0.99, respec-
tively. Limits of quantitation (based on S:N of 10:1) were 1.7 and
3.3, respectively.
Table 4 shows the results of method validation for the quantita-
tive analysis of alkylamide content, which was accomplished using
International Committee ofHarmonization (ICH) guidelines [28], as
described in Section 2.7. The values for the residuals, repeatability,
and intermediate precision conform to the parameters for method
validation according to the ICH.
3.3. Comparison of alkylamide yield in various E. purpurea
extracts
Three extracts were chosen for comparison of alkylamide con-
tent. One of these (fresh 1:2) was prepared from fresh E. purpurea
roots using 1g roots for every 2mL of solvent. The other two were
prepared from dry E. purpurea roots, one using 1g dried roots per
11mL solvent (1:11) and the other1 g dried roots per 5mL sol-
vent (1:5). All of the three extracts contain the same percentage
of ethanol (69%). The extracts differ only in the nature of starting
material (fresh or dry root) and the ratio of root:solvent. Once the
mass of the fresh roots is adjusted to account for water content, the
fresh 1:2 and dry 1:11 extract have equivalent ratios of dry weight
Author's personal copy
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Table 4
Validation parameters for quantitative analysis of E. purpurea alkylamides.
Dodeca-2E-ene-8,10-diynoic acid isobutylamide (J)
Theoretical concentration (M)a Measured concentration (M)b Residues (%)c Repeatability (%)d Intermediate precision (%)e
1.0 1.1 14 3 2
10 8.8 −12 2 2
50 44 −11 1 3
100 99.6 −0.3 1 4
500 568 13 0.5 0.7
Dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (L)f
1.0 0.99 −.5 3 6
10 9.7 −3 3 2
50 49 −3 0.5 4
100 105 5 3 0.6
a Theoretical concentration based on the mass of standard per volume of solution.
b Measured concentration for a given standard is the average of the back-calculated concentration (from the calibration curve) for three analyses conducted on three
separate days.
c The residuals (Res) are calculated by ﬁrst determining the difference between the measured concentration (CM) and the theoretical concentration (CT) and then dividing
this value by the measured concentration: Res = (CM −CT)/CM ×100.
d Repeatability corresponds to the relative standard deviation of the back-calculated concentration for triplicate analyses of the same standard on the same day.
e Intermediate precision corresponds to the relative standard deviation of the back-calculated concentration for triplicate analyses of the same standard on three different
days.
f Validation results are reported for dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide up to 100M, the upper limit of the linear range.
Table 5
Quantities of the isomeric alkylamides K, L and M and alkylamide J in ethanolic extracts of E. purpurea root.
Type of extract Alkylamides K, L and M Alkylamide J
Fresh 1:2 Dry 1:11 Dry 1:5 Fresh 1:2 Dry 1:11 Dry 1:5
Mean concentration (mg/mL)a 1.4 1.6 7.2 0.0047 .0072 0.013
Mean concentration (mM)a 5.7 6.4 29 0.019 0.029 0.054
SEb 0.5 0.2 3 0.001 0.0004 0.002
a The mean concentration was calculated for four replicate extractions (n=4).
b SE represents the standard error of the concentrations in mM.
plant material:mL solvent. Therefore, by comparing the composition
of the fresh 1:2 and dry 1:11 extracts, it should be possible to determine
how extract composition differs depending on whether fresh or dried
roots are used for extraction. The two extracts prepared from dried
E. purpurea differ only in the ratio of g root:mL solvent (1:11 versus
1:5), therefore, by comparing the composition of the dry 1:11 and dry
1:5 extracts, it should be possible to determine whether changing the
root:solvent ratio has an effect on extract composition.
Utilizing available alkylamide standards, the quantities of alky-
lamides in the fresh and dry E. purpurea root extracts were
determined. Table 5 displays these results in terms of concen-
trations of the isomeric tetraenes (compounds K, L and M) and
dodeca-2E-ene-8,10-diynoic acid isobutylamide (compound J) per
millilitre of solvent. The threedifferentEchinacea extracts, fresh1:2,
dry 1:11 and dry 1:5, all contained these alkylamides. However, as
shown in Table 5, the dry 1:5 extract contained the greatest amount
of these compounds. This is to be expected given the lower ratio of
g roots:mL solvent used in the preparation of the 1:5 extract.
In order to easily compare how efﬁciently alkylamides were
extracted in the three different E. purpurea extracts, the quantity
of each alkylamide (mg) was divided by the dry weight of E. pur-
purea root (g) used to prepare an equivalent volume of extract. The
resulting value is referred to as “alkylamide yield” (Fig. 3). The only
difference in the fresh 1:2 versus the dry 1:11 extracts is whether
fresh or dry root was used in their preparation. Therefore, assum-
ing no loss of alkylamide during the drying process, alkylamide
yield would be expected to be very similar for these two extracts.
Indeed, the alkylamide yield for the fresh 1:2 versus the 1:11 were
comparable for the tetraenes K, L, M (Fig. 3A), 15.3±2.5 versus
17.1±1.3mg/g, respectively. For alkylamide J, the yieldwas lower in
the 1:2 extract as compared to the 1:11 extract (0.0506±00.0053
versus 0.0775±0.0024mg/g, respectively). This difference could be
Fig. 3. Comparison of alkylamide yield in fresh 1:2, dry 1:11 and dry 1:5 E. purpurea
root ethanolic extracts. All concentrations represent the mean from four replicate
extractions at room temperature. Error bars denote standard error of the mean
(SEM). Comparisonsweremadebetween fresh1:2, dry 1:11 and1:5 extracts,with (*)
indicating p<0.005; (**) indicating p<0.001. Alkylamide yield is similar in the fresh
1:2 and dry 1:11 extracts, indicating no loss of alkylamides in the drying process.
Better yield of alkylamide J was obtained for the fresh 1:2 versus dry 1:11 extract.
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due to differences in particle size between the extracts, which may
have given rise to more efﬁcient extraction in the dry as compared
to the fresh extract. Importantly, comparison of alkylamide yield for
the 1:2 and 1:11 extracts does not indicate any signiﬁcant degrada-
tion of alkylamides due to drying. The extracts in this study were
prepared from roots immediately after completion of oven drying.
Kabganian et al. [39] came to the same conclusion ﬁnding no degra-
dation of alkylamides in roots thatwere oven dried.Whether or not
there is a loss in alkylamide content in E. purpurea roots stored for
long periods of time would be a worthy subject of a future investi-
gation.
In comparing the extraction yield of the alkylamides between
the 1:11 versus 1:5 dry root extracts, a logical prediction, provided
a 1:5 extract is not saturated, would be that the alkylamide yield
would be the same in the two extracts. As can be seen in Fig. 3,
however, this is not the case. While alkylamide yield is similar in
the two extracts, there are statistically signiﬁcant differences. For
alkylamides K, L, M (Fig. 3A), extraction is more efﬁcient in the 1:5
as compared to the 1:11 extract. This is the opposite of what would
be expected if the solution were saturated in the case of the 1:5
extract; therefore, saturation is not the cause of the differences.
Conversely, for alkylamide J, extraction is more efﬁcient in the 1:11
extract than the 1:5 extract (Fig. 3B). Previous studies have estab-
lished that solvent interactions of N-alkylamides differ depending
on molecular structure and the surrounding phytochemical matrix
[40]. Therefore, it is plausible that extraction of certain alkylamides
is favored inmore dilute extracts, while concentrated extracts favor
the extraction of structurally different species.
3.4. Comparison of yield of dissolved solids in various E. purpurea
extracts
The amount of total dissolved solids in the three extracts
described in Section 3.3 was compared. Total dissolved solids are a
measure of howmuchmaterial overall (alkylamides aswell as other
compounds) was dissolved in the original extract. When the mass
of dissolved solids is divided by the dry weight of the plant mate-
rial used to produce an equivalent volume of extract, the resulting
value is referred to as “extract yield,” which is a measure of how
much of the initial starting material was converted into extract.
Fig. 4 displays the extract yield (mg dissolved solids/g dry root)
for the three E. purpurea extracts under investigation. Overall, the
extract yield was similar for all three extracts. However, the yield
for the fresh root extract (196.6±2.7mg/g) was slightly lower than
Fig. 4. Yield of dissolved solids in ethanolic extracts of Echinacea purpurea roots.
Mass of dissolved solidswasdeterminedbyevaporationof the ethanol/water solvent
from aliquots of extracts, and this value was ratioed to the quantity of root (dry
weight) used to prepare an equivalent volume of extract to calculate dissolved solids
yield. Yield of dissolved solids in the 1:11 extraction does not statistically differ
from 1:5 extraction. The fresh root extraction (1:2) differs from the 1:11 and the
1:5 extraction by 26.8% and 32.4% respectively. (*) indicates p<0.005;(**) indicates
p<0.001.
Fig. 5. Relative concentration of dodecatetraenoic acid isobutylamides (alkylamides
K, L and M) in an E. purpurea root extraction over time. Relative concentrations (CR)
were calculated by dividing the concentration of each sample (CS) by the concen-
tration at day 2 (Cday2) and converting to percent: CR =CS/Cday2 ×100. Samples were
taken daily over 28 days from dry root (1:11) ethanolic maceration of E. purpurea.
Results show that maximal extraction of dodecatetraenoic acid isobutylamide is
achieved by day 2.
the two dry root extracts (269±12 and 290±24mg/g for the 1:11
and 1:5 extracts, respectively, p<0.001). As mentioned previously,
a similar effect was observed for alkylamide J. This difference could
possibly be attributed to differences in particle size in fresh ver-
sus dry extractions. Between the two dried extracts, there was no
statistically signiﬁcant difference in extract yield. This similarity
between 1:11 and 1:5 extracts indicates that it is possible, by dou-
bling the quantity of root used for the extraction, to double the
amount of material dissolved in the solvent, at least up to a ratio
of 1:5. It should be pointed out that because of the greater amount
of root used to prepare the 1:5 extract, this extract does, overall,
contain a greater concentration of dissolved solids then the 1:11
extract. However, there is no signiﬁcant difference between the two
extracts when the amount of dissolved solids is expressed relative
to the mass of root used in the extract.
3.5. Extraction of the tetraene isomers as a function of
maceration time
Lastly, the quantity of the isomeric dodeca-2,4,8,10-tetraenoic
acid isobutylamides present in a macerating E. purpurea extract
against time was measured (Fig. 5). The results are all displayed
relative to that achieved on the ﬁrst day when concentration
was measured (day 2). These tetraene isobutylamides are sig-
niﬁcant because they typically compose from 30 to 70% of the
total alkylamides in echinacea products [41]. The results in Fig. 5
demonstrate that the extraction of dodeca-2,4,8,10-tetraenoic acid
isobutylamides is completebyday2. Thus, in termsof theextraction
of speciﬁcally these compounds, maceration beyond day 2 should
not be necessary. This ﬁnding is particularly interesting given that
many dietary supplements manufacturers currently suggest that
the appropriate time for amaceration is 2weeks or longer, depend-
ing on the part of the plant used [25]. While commonly used long
maceration times seem to have little effect on alkylamide con-
tent, long maceration times could actually be detrimental if some
compounds (for example caffeic acid derivatives) degrade during
maceration. Future investigations of the optimal maceration time
for producing an extract with maximal concentrations of all desir-
able constituents are warranted.
4. Conclusion
With these investigations, it has been demonstrated that
HPLC–ESI-MS is an excellent technique for comprehensive analysis
of the alkylamide content of E. purpurea extracts. Using HPLC–ESI-
MS, a more comprehensive alkylamide proﬁle was obtained than
is typically possible with other analytical approaches. By relying
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on collisionally induced dissociation, it was possible to distinguish
between isomeric alkylamides, and to tentatively identify a new
E. purpurea alkylamide, undeca-2Z,4E-diene-8,10-diynoic acid 2-
methylbutylamide. In addition, the validated method facilitated
quantitative comparison of alkylamide content among extracts
prepared with different extraction procedures. All three extrac-
tion techniques investigated here (fresh 1:2, dry 1:5 and dry 1:11)
resulted in very similar alkylamide proﬁle, and gave similar yields
of alkylamides and of total dissolved solids. The similarity in alky-
lamide content in fresh 1:2 and dry 1:11 extracts indicates that
drying of root material at 50 ◦C does not result in a loss of alky-
lamides. It appears that either fresh or dried roots can be used to
prepare extractswith high alkylamide content, although the overall
yield was slightly lower for fresh extracts. Lastly, the analysis of a
1:2 fresh root ethanolic extract suggest that themaximum concen-
tration of the tetraenes (dodecatetraenoic acid isobutylamides) is
achieved by day 2 in an ethanolic extraction.
Although alkylamide yields were, overall, similar with the
three extraction techniques, there were some statistically signif-
icant differences in quantities of alkylamides extracted. Notably
the isomeric tetraenes were extracted more efﬁciently with a
root to solvent ratio of 1:5 (w:v) as compared to a ratio of
1:11, while dodeca-2E-ene-8,10-diynoic acid isobutylamide was
extracted more efﬁciently with a ratio of 1:11. Given that the bio-
logical activity of alkylamides differs depending on structure, these
suggest that pharmacological activity of E. purpurea extracts could
differ depending on the ratio of root:solvent used in extraction.
Ultimately, in vitro and in vivo studies are needed to elucidate the
differences in pharmacokinetic and pharmacodynamic activity of
extracts of variousEchinacea spp. The resultspresented in thispaper
do, however, suggest that it would be erroneous to assume that all
ethanolic extracts of E. purpurea result in equivalent phytochemical
proﬁles.
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Certain fatty acid amides from Echinacea spp. have demonstrated moderate to high cannabinoid activity. As a
result, CB2 activation is currently hypothesized to be the basis of activity for immunomodulation by Echi-
nacea spp. PPARγ, an orphan nuclear receptor and lipid sensor, is known to inhibit IL-2 production and be
activated by fatty acid derivatives such as the endocannabinoids. In these investigations, we demonstrate
that undeca-2E-ene-8,10-diynoic acid, an Echinacea angustifolia-derived alkylamide lacking afﬁnity for the
CB2 receptor, inhibits IL-2 secretion in Jurkat T cells through PPARγ activity at low micromolar
concentrations (330 ng/mL). The IL-2 inhibition is reversed by the addition of the selective PPARγ
antagonist T0070907. Additionally, we show that that undeca-2-ene-8,10-diynoic acid stimulates 3T3-L1
differentiation, a process dependent on PPARγ activity. These experiments demonstrate that PPARγ is
involved in T cell IL-2 inhibition by undeca-2-ene-8,10-diynoic acid and suggest that cytokine modulation by
the alkylamides is due to polyvalent activity.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
Peroxisome proliferator activated receptor gamma (PPARγ) is an
orphan nuclear receptor that regulates transcription of target genes in
response to the binding of small lipophilic ligands [1]. It was originally
described as a compulsory target in differentiating adipocytes [2].
Later it was identiﬁed in other tissues [3] and a role inmacrophage [4],
dendritic cell [5] and T cell [6] activity was observed. Intriguingly,
recent results suggest that endogenous cannabinoids such as ananda-
mide and 2-arachidonoylglycerol are agonists of PPARγ [7,8].
Recent work has demonstrated that several of the unsaturated
alkylamides of Echinacea spp. exhibit signiﬁcant afﬁnity for the
cannabinoid-2-receptor (CB2) [9] and that in the presence of these
alkylamides, LPS-induced TNF secretion is down-regulated, a function
of alkylamides targeting CB2 in macrophages [10]. Raduner et al., [11]
conﬁrmed the high CB2 afﬁnity of the 2,4-diene unsaturated
isobutylamides (oleﬁnic alkylamides). Moreover, this group also
reported that the selective CB2 antagonist SR144528 is incapable of
fully inhibiting increases in total cellular concentrations of Ca2+ in
HL60 cells induced by 2-arachidonoylglycerol (2-AG) and alkylamides,
suggesting the possibility of the involvement of a second receptor.
Echinacea spp.-derived alkylamides have been shown to inhibit IL-2
secretion by humanT cells [12], but the basis of alkylamide-induced IL-
2 inhibition has not yet been reported.
PPARγ activation has recently been found to be responsible for IL-2
inhibition induced by the endocannabinoids [7,8]. In addition, Chris-
tensen et al. [13] recently demonstrated that various fatty acids and
alkylamides from the ﬂowers of E. purpurea activated PPARγ at high
concentrations (40–100 μM). Considering the structural similarity
between 2-AG and alkylamides, we investigated the possibility of
induction of PPARγ activity by the alkylamide undeca-2E-ene-8,10-
diynoic acid isobutylamide (hitherto referred to as undecaenediynoic
acid isobutylamide) found in E. angustifolia and Spilanthes acmella
(Fig. 1) [14]. This 2-ene alkylamide, containing a diacetylinic tail, has
previously been found to have negligible afﬁnity for CB2 [11]. Utilizing
the previously established models of IL-2 inhibition and 3T3-L1
adipogenesis, we investigated the possibility that PPARγ is a target of
undecaenediynoic acid isobutylamide, and that interaction of this
alkylamide with PPARγ contributes to alkylamide-induced IL-2 inhibi-
tion and adipocyte differentiation.
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2. Materials and methods
2.1. Reagents
The following materials, chemicals and reagents were used. All
reagents were from Sigma-Aldrich (St. Louis, MO) except the follow-
ing: undeca-2E-ene-8,10-diynoic acid isobutylamide (MW 231.34;
certiﬁcate of analysis veriﬁed identity by NMR and HPLC, and purity
of ≥99% by HPLC lot #21235-501; (Chromadex Inc., Santa Anna,
CA); troglitazone (MW 441.5; Rezulin, abbreviated as TZD, gift from
Ron Morrison, UNCG, Department of Nutrition); T0070907 (MW
277.7; Cayman Chemicals, Ann Arbor, MI); ethanol (AAPER, Shelby-
ville, KY); nanopure water (Nanopure Diamond D11931, Barnstead
International, Thermolyne, Dubuque, IA); calf serum (Colorado
Serum Co., Denver, CO); human IL-2 Duo Set ELISA Kit-DY202 (R&D
Systems, Minneapolis, MN); Jurkat E6.1 cells (ATCC, Manassas, VA);
3T3-L1 preadipocytes (a gift from Ron Morrison); nitro-cellulose
membranes (Bio-Rad, Hercules, CA); anti-human PPAR γ primary
antibody (Aviva Systems Biology, San Diego, CA); and goat anti-rabbit
conjugated to horse radish peroxidase (US Biological, Swampscott,
MA).
2.2. Immunodectection of PPARγ protein in Jurkat cells by Western
blotting
Cells were harvested (2×106 cells) and lysed by boiling for 5min.
Nuclear extracts were analyzed in a denaturing 10% polyacrylamide
gel, electrotransferred to a supported nitro-cellulose membrane, and
immunoblotted with the PPAR γ primary antibody (Aviva Systems
ARP32880_T100). The membranes were soaked in blocking buffer [5%
nonfat dry milk diluted in Tris-buffered saline— 0.1% Tween-20 (TBS-
T)] for 1 h at room temperature with the indicated primary antibody
(1:10,000). After washing, membranes were developed with horse-
radish peroxidase-conjugated secondary antibodies and visualized
with a chemiluminescent detection system (GE Healthcare/Amer-
sham Biosciences, Buckinghamshire, England). A double band is the
expected image resulting from this antibody.
2.3. Fibroblast cell culture and differentiation
3T3-L1 cells were cultured in DMEM plus 10% calf serum, 4 mM
L-glutamine and 1 mM Na pyruvate. Cells were plated in 6 well plates
in a total of 1.5 mL of medium and grown to conﬂuence over 4–
5 days. 48h after conﬂuence was achieved (day 0), insulin (10 μg/mL)
was added to all wells except the insulin free control. On day 2, media
was changed to contain FBS and the following treatment conditions,
which were added to separate triplicate wells: undecaenediynoic acid
isobutylamide (5.0 μg/mL, 7.5 μg/mL and 10 μg/mL); TZD positive
control (10 μM); insulin negative control (10 μg/mL); and vehicle
control (EtOH:DMSO 0.4%:0.1%) were added. Every 2 days, medium
and all reagents, including treatments, were replenished after a PBS
wash. Experiment was halted on day 5, at which time adipogenesis
was determined by photomicroscopy by morphology and the pre-
sence of the obvious prominent lipid vacuoles. Images were taken
with a SPOT digital camera mounted on an Olympus BX60 ﬂuore-
scence microscope.
2.4. Jurkat cell culture and IL-2 ELISA
Human E6.1 Jurkat T cells were cultured in RPMI 1640with 10% FBS,
2 mM L-glutamine and 1 mM Na pyruvate. After serum starvation for
7h, Jurkat cells were plated in 96 well culture plates at 1.25×105cells/
mL in RPMI 1640 (without phenol red)with 10% FBS. Cells were treated
with PMA (1.25 ng/mL) and PHA (0.25 μg/mL) and the selective
antagonist T0070907 or DMSO vehicle was added to appropriate wells
and incubated at room temperature for 15min after which alkylamides
and TZD were added. Plates were then incubated for 18 h. Cell
supernatants were collected (100 µL) and assayed for IL-2 by ELISA
(Human IL-2 Duo Set ELISA Kit). All test conditions were assayed in
triplicate and veriﬁed with repeated experiments three times.
2.5. Cell survival by XTT assay
The cytotoxicity of undecaenediynoic acid isobutylamide was
measured by the XTT colorimetric assay [15], which was performed
on the same plated cells cultured for the IL-2 cytokine testing in dual
ELISA/XTT assays. For the cell viability standard curve, unstimulated
cells were plated in triplicate at 2.5×104, 2×104, 1.5×104, 7.5×103,
5.0×103, and 2.5×103cells/well. After removal of 100 µL supernatant
from all wells, 100 μL of 1 mg/mL of 2,3-bis(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) plus 0.02 mM
phenazine methosulfate (PMS), in medium was added. After 5 h
incubation, ODs at 450 nm (Teacan Sunrise plate reader, Grödig,
Austria) were measured and cell concentrations extrapolated from
known cell concentrations in standard curve. Test conditions were
assayed in triplicate and repeated in two experiments.
2.6. Statistical analysis
All data are expressed as means±SE of experiments conducted in
triplicate. Statistical analysis was performed using Student's t-test and
analysis of variance (one-way ANOVA). The accepted level of sig-
niﬁcance was p<0.05.
3. Results
3.1. Presence of PPARγ receptor in Jurkat cells
Jurkat cells have previously been demonstrated to express the
PPARγ nuclear hormone receptor [16]. The presence of the PPARγ
protein in the Jurkat E6.1 strain of cells used for these experimentswas
conﬁrmed by Western blot (see supplemental information). Nuclear
extracts of untreated Jurkats were incubated with polycolonal PPARγ
antibodies from 1 μg/mL to 4 μg/mL following standard Western blot
procedures. Analysis of Jurkat cell nuclear extracts conﬁrmed the
expression of PPARγ receptor in Jurkat E6.1 cells. A signal of 56 kDa is
seen at 1 μg/mL that grows in intensity with increasing PPARγ
antibody concentration. These results demonstrate that PPARγprotein
is expressed in the E6.1 strain of Jurkat cells used in this study.
3.2. The PPARγ selective antagonist T0070907 attenuates the IL-2
inhibition induced by undecaenediynoic acid isobutylamide at
suboptimal Jurkat stimulation
To assess the response of T cells to undecaenediynoic acid
isobutylamide (Fig. 1), suboptimal IL-2 stimulation of Jurkats by PMA/
PHA (PMA 1.25 ng/mL & PHA 0.25 μg/mL) was used. Previous work has
used this model system to demonstrate that PPARγ mediates IL-2
inhibition in T cells [7,8,16]. Cells were serum starved for 7h, plated
and then exposed to vehicle control (EtOH/DMSO), positive control
(TZD-a selective PPARγ agonist), positive control with antagonist (TZD/
T0070907), undecaenediynoic acid isobutylamide or undecaenediynoic
acid isobutylamide with antagonist (UDA/T0070907) at increasing
Fig. 1. Undeca-2E-ene-8,10-diynoic acid isobutylamide (undecaenediynoic acid
isobutylamide).
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concentrations. T0070907 was held at constant concentration (2.5 μM).
After 18 h incubation, ELISA of the supernatants collected from wells
treatedwith the various conditionswas performed. Results demonstrate
that undecaenediynoic acid isobutylamide dose-dependently inhibits IL-
2 production beginning at 0.33 μg/mL (1.4 μM) (Fig. 2). When the
selective PPARγ antagonist T0070907 is added with undecaenediynoic
acid isobutylamide, a dose-dependent attenuation of the IL-2 inhibition
is seen starting at 0.33 μg/mL. At this concentration, the IL-2 level returns
to baseline in thewells treatedwith T0070907.However, at higher levels
of undecaenediynoic acid isobutylamide treatment, the antagonistic
effect of T0070907 on IL-2 secretion is lost, as would be expected in
increasing concentrations of a competitive agonist and a ﬁxed con-
centration of antagonist.
3.3. Cell survival of Jurkats after treatment with undecaenediynoic acid
isobutylamide and undecaenediynoic acid isobutylamide/T0070907
does not account for IL-2 modulation
Wenext determined if the IL-2 changes seen in Jurkats treated in the
experimental conditions were due to the effects of undecaenediynoic
acid isobutylamide and undecaenediynoic acid isobutylamide/
T0070907 and not due to signiﬁcant changes in cell number under
these treatment conditions. Cells from the same treatment conditions in
the same experiment in which supernatants were harvested for IL-2
ELISA were assayed for cell viability by the XTT assay. A statistically
signiﬁcant (p<0.05) proliferative effect of undecaenediynoic acid
isobutylamide on the Jurkat E6.1 cells was observed (Fig. 3). Thus, the
IL-2 inhibition induced by undecaenediynoic acid isobutylamide is not
due to cell death, as IL-2 inhibition occurs despite the increase in cell
number. In addition, these data demonstrate that the increase in IL-2
concentration observed in wells of Jurkat cells treated with the PPARγ
selective antagonist T0070907 are not due to an increase in cell number. 3.4. Treatment of 3T3-L1 preadipocytes with undecaenediynoic acid
isobutylamide indicates PPARγ involvement
The 3T3-L1 cell line, which is PPARγ dependent for differentiation
into adipocytes, has been widely established as a model to probe for
PPARγ activity [17,18]. To verify PPARγ involvement in the inhibition
of IL-2 by undecadiynoic acid in T cells, 3T3-L1 differentiation in the
presence of controls or undecaenediynoic acid isobutylamide was
analyzed to conﬁrm that this alkylamide is able to induce PPARγ-
dependent preadipocyte differentiation.
3T3-L1 cells were grown to conﬂuence and then exposed to
experimental conditions including the TZD positive control (10 μM),
insulin negative control (10 μg/mL), vehicle control, or treatmentwith
undecaenediynoic acid isobutylamide (+insulin 10 μg/mL) at in-
creasing concentrations (5.0 μg/mL, 7.5 μg/mL and 10 μg/mL).
Differentiation was assessed morphologically by the relatively
round shape of the adipocytes and by the presence of the obvious
prominent lipid vacuoles seen bymicroscopy. The vehicle control (VC)
and the insulin control exhibit no differentiation, while undecaene-
diynoic acid isobutylamide induced a dose dependent adipogenesis in
3T3-L1 cells that was morphologically indistinguishable from that
induced by the selective PPARγ agonist positive control (TZD) (Fig. 4).
4. Discussion
PPARγ plays a role in a variety of diseases including diabetes,
atherosclerosis, inﬂammation, cancer and autoimmune disorders [19–
23]. Thus, novel PPARγ ligands may offer further therapeutic options
for a wide array of diseases. PPARγ ligands include fatty acid
derivatives, as well as the selective PPARγ agonists known as the
thiazolidinediones (TZDs). Both classes of compounds have been
shown to reduce IL-2 levels in T cells [6,16,24–26]. This effect has been
shown via reporter assays to be due to the PPARγ nuclear receptor [8].
Moreover, endocannabinoids, which share common structure with
Fig. 2. PPAR-γ antagonist T0070907 attenuated the undecaenediynoic acid isobutyla-
mide (UDA) induced inhibition of IL-2 secretion by suboptimally stimulated Jurkat E6.1
cells. Cells were subjected to suboptimal mitogenic stimulation (PMA 1.25 ng/mL, PHA
0.25 μg/mL) after serum starvation, for induction of IL-2 in all cases except in the no
treatment group (No Tx). The selective agonist troglitazone (TZD) represents a positive
control (black bar). Stripped bars represents the combination of 2.5 μM of T0070907
with the matched treatments (vehicle-VC, undecaenediynoic acid isobutylamide, TZD)
shown in the left bar of each pair. Results show a dose dependent response of IL-2 by
undecaenediynoic acid isobutylamide and the positive control TZD. The T0070907
treatments dose-dependently attenuate the IL-2 inhibition (up to 1 μg/mL undecaene-
diynoic acid isobutylamide) that occurs upon treatment of Jurkat cells with increasing
doses of undecaenediynoic acid isobutylamide (grey bars). The positive control (TZD
black bar), also shows signiﬁcant inhibition of IL-2 which is blocked by T0070907.
Values are mean+S.E. of experiments performed in triplicate. One-way ANOVA was
used to determine statistical signiﬁcance between the vehicle (VC) versus the various
treatments (undecaenediynoic acid isobutylamide or TZD) treated groups (*p<0.05)
and the undecaenediynoic acid isobutylamide versus the undecaenediynoic acid
isobutylamide/T0070907 treated groups (†p<0.05).
Fig. 3. Cell survival assay (XTT assay) of Jurkat E6.1 cells treated with undecaenediynoic
acid isobutylamide (UDA) and T0070907. Cells were subjected to identical conditions
as the IL-2 assays. The selective agonist troglitazone (TZD) represents a positive
control (black bar). Stripped bars represent the combination of 2.5 μM of T0070907
with the matched treatments (vehicle-VC; undecaenediynoic acid isobutylamide; or
TZD) shown in the left bar of each pair. A proliferative effect by undecaenediynoic acid
isobutylamide (grey bars) on Jurkat cells is observed. A trend showing inhibition of
proliferative effects is observed with the addition of the selective PPARγ antagonist
T0070907. The positive control, selective PPARγ agonist TZD combined with
T0070907, shows a statistically signiﬁcant inhibition of proliferation as compared to
TZD alone (black bar). One-way ANOVA was used to determine statistical signiﬁcance
between the vehicle (VC) versus the undecaenediynoic acid isobutylamide — or TZD-
treated groups (*p<0.05), and the undecaenediynoic acid isobutylamide versus the
undecaenediynoic acid isobutylamide/T0070907 treated groups (†p<0.05).
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some of the unsaturated alkylamides, have been shown to reduce IL-2
levels via PPARγ [7,8].
While cannabinoid 2 receptor (CB2) activity has been shown for
the 2,4-diene oleﬁnic alkylamides, the 2-ene alkylamide undecaene-
diynoic acid isobutylamide (Fig. 1) has shown relatively no afﬁnity for
CB2 [11]. With this in mind, we probed for PPARγ activity with
undecaenediynoic acid isobutylamide. The effect of undecaenediynoic
acid isobutylamide treatment on PPARγ activation was assessed using
two well established PPARγ mediated biological responses, IL-2
production and PPARγ-dependent adipogenesis in 3T3-L1 cells.
As shown in Fig. 2, the selective PPARγ antagonist T0070907 at
2.5 μM is effective in attenuating the IL-2 inhibitory effects of
undecaenediynoic acid isobutylamide at alkylamide concentrations
between 330 ng/mL and 1 μg/mL. This is in range of relevant
physiological alkylamide concentrations based on in vivo human
pharmacokinetic data [27]. T0070907 appears to lose its ability to
attenuate the IL-2 inhibition at higher concentrations of undecaenediy-
noic acid isobutylamide. This apparent loss of antagonist activity is an
expected observation of competitive agonism. The ﬁxed dose of
T0070907 (2.5 μM) appears to be overwhelmed by increasing concen-
trations of undecaenediynoic acid isobutylamide ranging two orders of
magnitude. It is also possible that at high undecaenediynoic acid
isobutylamide concentrations, IL-2 inhibition occurs independently of
PPARγ activity. Alternatively, recent data suggests that the PPARγ
receptor,whichpresents a particularly large binding cavity as compared
to other nuclear receptors,may bindmore than one ligand at a time[26].
For example, rosiglitazone, a selective PPARγ agonist structurally similar
to the agonist used in these studies, occupies only about 40% of the
ligand-binding site in the ternary complex of PPARγ, leaving adequate
room for other ligands [28]. Crystal structures of PPARγ demonstrate
that PPARγ can bind two 9-(S)-hydroxyoctadecadienoic acidmolecules
concurrently [29]. Thus a more involved explanation of the loss of the
antagonism by T0070907 at higher undecaenediynoic acid isobutyla-
mide concentrations may be that PPARγ is binding both T0070907 and
undecaenediynoic acid isobutylamide at the same time and this may
result in an overall IL-2 inhibitory effect. It is also possible these results
could be explained by undecaenediynoic acid isobutylamide acting as a
partial agonist, asmost recently suggested for the alkylamide hexadeca-
2E,9Z,12Z,14E-tetraenoic acid isobutylamide in a ﬁbroblast in vitro
model [13].
Undecaenediynoic acid isobutylamide, is considered a 2-ene
alkylamide, which commonly contain diacetylinic tails, and are more
characteristic of the alkylamides found in E. angustifolia. This is
opposed to the 2,4-diene alkylamides, more commonly found in E.
purpurea, which are more commonly oleﬁnic alkylamides. However,
both Echinacea species contain oleﬁnic and acetylinic classes of
alkylamides [30]. The oleﬁnic 2,4-dienes have demonstratedmoderate
to high CB2 afﬁnity, while the diacetylinic 2-enes have thus far, with
few exceptions, demonstrated negligible CB2 afﬁnity [11]. Considering
Christensen's et al. [13] recent work demonstrating activation of
PPARγ in ﬁbroblasts with oleﬁnic alkylamides at high concentrations
(40–100 μM) and our results showing PPARγ activation atmuch lower
concentrations (1.4–14 μM) with a diacetylinic alkylamide, it is
possible that other diacetylinic alkylamides which have lower
afﬁnities for CB2 than the oleﬁnic alkylamides, may activate PPARγ.
Accordingly, it may be that E. angustifolia and E. purpurea differ in the
degree of PPARγ and CB2 mediated immunomodulation. Previous
studies report that the alkylamide investigated here, undecaenediynoic
Fig. 4. Dose-dependent response of 3T3-L1 cell differentiation by undeca-2E-ene-8,10-diynoic acid (UDA). Increasing concentrations of UDA enhance 3T3-L1 differentiation, as
observed by microscopy. 3T3-L1 cells were plated in 6 well plates with 1.5 mL of medium and grown to conﬂuence over 5 days. After conﬂuence was achieved, UDA, insulin positive
control (10 μg/mL), TZD (10 μM), or vehicle control (EtOH/DMSO) were added. Medium and treatment conditions were replenished every 2 days after PBS wash. Photomicrographs
were taken using an Olympus inverted microscope at day 5. Results shown are representative of triplicate experiments.
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acid isobutylamide, comprises 5% of the alkylamide content of E.
angustifolia root [31]. Furthermore, up to 55%ofE. angustifolia alkylamides
possess a diacetylenic tail like that of undecaenediynoic acid isobutyla-
mide [32]. This is in contrast to E. purpurea root, which does not contain
undecaenediynoic acid isobutylamide in detectable concentrations [30],
and contains less than 45% diacetylenic alkylamides overall [31]. Of
interest, previous reports by the eclectic physicians of the early-mid 19th
to mid 20th century, who brought Echinacea into clinical practice,
suggested that the two species differed in effect [33]. Further research is
needed to evaluate howE. angustifolia andE. purpureavary in their effects,
possibly due to differential actions on pathways such as PPARγ and CB2.
Our results should be interpreted carefully. There are other
proteins known to directly inﬂuence adipocyte differentiation other
than PPARγ. This includes CCAAT/enhancer binding proteins (C/EBP),
and the basic helix-loop-helix-leucine zipper transcription factor
sterol regulator element-binding-protein-1c [29]. Furthermore, acti-
vation of C/EBP is known to engage the PPARγ pathways in both 3T3-
L1 cells [34] and T cells [35]. Of particular relevance, a recent gene
expression study using microarrays suggested C/EBPβ is an upstream
activation node for many of the pathways activated by Echinacea [29].
It remains to be determined whether C/EBPβ plays a role in the PPARγ
dependent alkylamide interactions reported here.
In summary, these experiments illustrate the involvement of
PPARγ in the inhibition of IL-2 secretion by T cells in response to
undeca-2-ene-8,10-diynoic acid isobutylamide. We demonstrate a
decrease in IL-2 levels in this model system starting at 330 ng/mL of
undeca-2E-ene-8,10-diynoic acid isobutylamide, which is reversed by
the addition of a PPARγ selective antagonist. However, the possibility
that other targets are involved in this effect is not ruled out by these
data. Thus, it is possible that there is a combination of effects due to
PPARγ and other targets that inhibit IL-2 production and induce
adipocyte differentiation. These results, coupled with previous results
demonstrating cannabinoid activity of the alkylamides, suggest that
the immunomodulatory potential of the alkylamides is likely due to
polyvalent actions. Further investigations are needed to elucidate the
role of PPARγ and other potential alkylamide targets in the IL-2
inhibitory response of T cells to undecaenediynoic acid isobutylamide.
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